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ABSTRACT 
THE SPHINGOLIPID SYNTHASES OF 
 TOXOPLASMA GONDII AND OTHER ORGANISMS 
Nilu Kumari Wansadhipathi-Kannangara 
 
Toxoplasma gondii is an obligate intracellular protozoan parasite of the phylum 
Apicomplexa, and toxoplasmosis is an important disease in immuno-compromised 
individuals - especially AIDS patients, organ transplant recipients and patients receiving 
anti-cancer chemotherapy. Toxoplasmosis also has economic importance as it results in 
spontaneous abortion in economically important animals. Due to emerging drug resistance 
and the possible side effects of the existing therapeutics there is a necessity to explore new 
drug targets. Sphingolipids are essential components of eukaryotic cell membranes and 
signal transduction pathways. Mammals produce sphingomyelin (SM) via a SM synthase, 
whereas yeast, plants and some protozoa utilise an inositol phosphorylceramide (IPC) 
synthase to produce IPC. IPC synthases have no mammalian equivalent and have been 
proposed as targets for anti-fungals and anti-protozoals. In this study sphingolipid 
scavenging from the host was shown to be non-essential for Toxoplasma proliferation 
indicating de novo synthesis is key. To investigate this pathway in the parasite an 
orthologue of the SM synthase from the related apicomplexan Plasmodium falciparum was 
identified in the genome database as being encoded by a single copy gene. Subsequently it 
was characterized as a functional orthologue of the yeast AUR1p (IPC synthase), with 
mass spectrometry identifying this lipid species in parasite extracts for the first time. Like 
AUR1p and the human SM synthase, the Toxoplasma sphingolipid synthase (Tg SLS) is 
Golgi localized. However, unlike AUR1p Tg SLS is resistant to the inhibitor aureobasidin 
A and also facilitates production of a minor complex sphingolipid suggested to be SM. 
Further study characterized the sphingolipid synthases from the Trypanosoma species 
(protozoan Kinetoplastida) and the plant Arabidopsis. Bioinformatic and phylogenetic 
analyses of these and previously characterized SM and IPC synthases, indicate them to be 
a family of evolutionarily related, but functionally diverse, enzymes. Many of these may 
prove to be targets for pharmaceutical or herbicidal intervention. 
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1 INTRODUCTION 
1.1 TOXOPLASMA GONDII 
Toxoplasma gondii is an obligate intracellular protozoan parasite belonging to phylum 
Apicomplexa (Cortex et al., 2007). It is also a highly ubiquitous and prevalent parasite 
with a widespread distribution both in terms of geographical and host range (Hide et al., 
2009; Hide et al., 2007). Toxoplasma gondii is an opportunistic pathogen causing 
toxoplasmosis, which is an important disease in immuno-compromised individuals such as 
patients receiving anti-cancer chemotherapy, organ transplant recipients and AIDS patients 
(Chowdhury, 1986). It causes congenital defects in humans and spontaneous abortion in 
economically important and domestic animals (Huong and Dubey, 2007).  
 
The significance of Toxoplasma as a model system for other disease-causing apicomplexan 
parasites including Plasmodium, the causative agent of malaria; Eimeria, which is the 
cause of poultry coccidiosis; and Cryptosporidium, which is another important 
opportunistic infection in AIDS patients, is emerging (Blader and Saeij, 2009). 
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1.2 TAXONOMY OF TOXOPLASMA 
According to NCBI Entrez taxonomy (ncbi.nlm.nih.gov/),  
Domain  : Eukarya 
Super Kingdom : Eukaryota 
Kingdom  : Chromalveolata 
Super Phylum : Alveolata 
Phylum  : Apicomplexa 
Class   : Coccidia 
Order   : Eucoccidiorida 
Sub Order  : Eimeriorina 
Family  : Sarcocystidae 
Genus   : Toxoplasma 
Species  : Toxoplasma gondii  
 
There are 7 species recognized in this genus: Toxoplasma gondii from about 200 species of 
mammals and birds; Toxoplasma alencari from the frog Leptodactylus ocellatus; 
Toxoplasma brumpti from the iguana Iguana tuberculata; Toxoplasma colubri from the 
snakes Coluber melanoleucus and Coluber viridiflavus; Toxoplasma hammondi (a new 
name for Hammondia hammondi) from the house mouse; Toxoplasma ranae from the 
leopard frog Rana pipiens; and Toxoplasma serpai from the toad Bufo marinus (Levine, 
2008). 
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1.3 HISTORY OF THE ORGANISM 
This organism was first described by Charles Nicolle and Louis Manceaux in the rodent 
Ctenodactylus gundi and by Alfonso Splendore in rabbits in 1908, and named a year later 
(Black and Boothroyd, 2000; Dubey, 2008).  By 1937 very little was known about the 
nature of this organism and it was grouped with parasites of doubtful nature by Sabin and 
Olitsky (Manwell, 1941). Its medical importance remained unknown until 1939 when it 
was identified in tissues of a congenitally infected infant, and its veterinary importance 
became known when it was found to cause abortion storms in sheep in 1957 (Dubey, 
2008).   
 
Toxoplasma gondii was identified as small and usually crescent-shaped parasite and named 
based on its morphology. The species designation originated from the name of the North 
African rodent (Ctenodactylus gundi), and the genus name was derived from the Greek 
word toxon meaning “bow” and referring to the crescent shape of the organism (Black and 
Boothroyd, 2000).  T. gondii occur in various types of leucocytes, body fluids and 
endothelial cells (Manwell, 1941) and can be found in large numbers in various organs 
such as liver, spleen, bone marrow, lungs, kidneys and brain.  It was also identified as 
infecting a variety of hosts, including mammals and birds (Manwell, 1941). 
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1.4 POSITION OF TOXOPLASMA IN APICOMPLEXAN PHYLOGENY 
The Apicomplexa are a group of phylogenetically related parasitic protists. Based upon the 
genome sequences from seven apicomplexan species and a ciliate outgroup it has been 
found that the piroplasms Theileria and Babesia form the sister group to the Plasmodium 
species, the coccidian Eimeria and Toxoplasma are monophyletic and are the sister group 
to the Plasmodium species and piroplasms. Cryptosporidium forms the sister group to the 
above (Figure 1-1; Kuo, Wares and Kissinger, 2008).  
 
Figure 1-1: An inferred apicomplexan species tree. The Maximum Likelihood (ML) tree is 
generated from the concatenated alignment of 268 single-copy genes. Labels above 
branches indicate the level of consensus support (%) based on ML, Maximum Parsimony 
(MP) and Neighbour Joining (NJ) (Kuo, Wares and Kissinger, 2008). 
 
 
 
  
 
CHAPTER 01: INTRODUCTION 
 
33 
 
1.5 LIFE CYCLE AND TRANSMISSION 
The life cycle of Toxoplasma gondii was not discovered until 1970 when it was found that 
felids are its definitive host and an environmentally resistant stage i.e. oocyst is excreted in 
faeces of infected cats (Dubey, 2008). 
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Figure 1-2: Routes of transmission and life cycle of the parasite (adapted from 
http://www.dpd.cdc.gov/dpdx/HTML/Toxoplasmosis.htm) 
 
 
CHAPTER 01: INTRODUCTION 
 
35 
 
The life cycle can be explained by sexual phase and asexual phase (Figure 1-2). The 
asexual component consists of two distinct stages called tachyzoites and bradyzoites.  
 
The tachyzoite stage defines the rapidly growing form of the parasite found during the 
acute phase of toxoplasmosis (Black and Boothroyd, 2000).  Tachyzoites are 
approximately 6 x 2 μm and these infect and multiply within nucleated host cells (Weiss 
and Kim 2007), with a generation time of 6 to 8 hours, until lysis (after 6 or 7 generations 
by endodyogeny) releases progeny to infect neighbouring cells (Black and Boothroyd, 
2000).  
 
In the infected animal, tachyzoites differentiate into bradyzoites and form tissue cysts 
(Figure 1-2), which begin to appear 7 to 10 days post-infection (Black and Boothroyd, 
2000). These bradyzoite bearing cysts are predominantly found in the central nervous 
system and muscle tissue, and they can stay for the normal life span of the host (Black and 
Boothroyd, 2000). This development of tissue cysts throughout the body of the host 
characterises the chronic stage of the asexual cycle, and ingestion of these through 
consumption of infected meat leads to rupture in the digestive tract and the release of the 
gastric peptidase resistant bradyzoites within (Blader and Saeij, 2009). These bradyzoites 
then infect the epithelium of the intestinal lumen, where they differentiate back to the 
rapidly dividing tachyzoite stage for rapid dissemination throughout the body via 
secondary lymphoid tissues, thereby completing the asexual cycle (Black and Boothroyd, 
2000; Blader and Saeij, 2009).  
 
Toxoplasma sexually reproduces only in felids (cats). In this definitive host, parasites 
infecting the intestinal epithelium undergo sexual reproduction producing oocysts which 
are shed in the faeces. Mature oocysts are approximately 12 μm in diameter and contain 
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eight infective sporozoites (Weiss and Kim, 2007). The sexual life cycle ends when 
oocysts are excreted by the cats in their faeces 3 to 10 days after infection (Black and 
Boothroyd, 2000). Unsporulated oocysts are shed in the cat‟s faeces for 1 to 2 weeks, in 
this time large numbers may be shed.  These take between 1 and 5 days to sporulate in the 
environment and become infective, oocysts can then persist in the environment for several 
months and are extremely resistant to disinfectants, freezing, and drying (Alfonso, Thulliez 
and Gilot-Fromont, 2006).  
 
In nature, intermediate hosts (including birds and rodents) become infected after ingesting 
soil, water or plant material contaminated with oocysts shed from the felid reservoirs. Cats 
themselves become infected after consuming intermediate hosts (e.g. birds and rodents) 
harbouring T. gondii tissue cysts, although they may also become infected directly 
following the ingestion of sporulated oocysts.  Notably, animals bred for human 
consumption and wild game may also become infected after ingestion of sporulated 
oocysts from the environment leading to the presence of contaminating cysts in their 
tissues (dpd.cdc.gov/dpdx).  
 
On ingestion cysts in contaminated meat disintegrate within the stomach and small 
intestine and the released sporozoites transform rapidly into tachyzoites (Alfonso, Thulliez 
and Gilot-Fromont, 2006). In cats, the multiplication and reproduction of T. gondii within 
the walls of the intestines leads to the shedding of oocysts as described. In intermediate 
hosts these tachyzoites disperse, as described above, primarily to muscle and nervous 
tissue, and to a lesser extent in lungs, liver and kidney, where they transform into 
bradyzoites and form tissue cysts which may persist for many years (Hill and Dubey, 
2002). Humans enter this cycle either by consuming meat contaminated with cysts (raw or 
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undercooked) or through ingestion of oocyst contaminated food or water (Figure 1-2) (Hill 
and Dubey, 2002; Alfonso, Thulliez and Gilot-Fromont, 2006).  
 
1.6 BIOLOGY OF TOXOPLASMA GONDII 
As outlined above Toxoplasma exists in intermediate hosts, in two inter-convertible stages: 
bradyzoites and tachyzoites (Blader and Saeij, 2009). The crescent-shaped, disease causing 
tachyzoites possess a pellicle, subpellicular microtubules, a polar ring, a conoid, rhoptries, 
micronemes, mitochondria, a single stack of Golgi apparatus, ribosomes, rough surface 
endoplasmatic reticulum, micropores and a well-deﬁned nucleus (Figure 1-3) (Petersen and 
Dubey, 2005; Joiner and Roos, 2002; de Graffenried, Ho and Warren, 2008).     
 
Figure 1-3: A schematic representation of ultra-structure of a T. gondii tachyzoite  
(adapted from 
http://journals.cambridge.org/fulltext_content/ERM/ERM3_01/S1462399401002204sup01
3.gif). 
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Subpellicular microtubules run longitudinally for almost the entire length of the parasite 
and give Toxoplasma its distinctive shape. The polar ring located anteriorly encircles the 
conoid, a cylindrical cone consisting of 6 to 8 ﬁbrillar elements. Here the club-shaped 
rhoptries abut; these structures have a secretory function associated with host cell 
penetration (Petersen and Dubey, 2005). Close by are the grain-like micronemes also 
thought to participate in host cell invasion (Petersen and Dubey, 2005).  
 
Tachyzoites activate a potent host immune response that eliminates most of the parasites. 
Some tachyzoites, however, escape destruction and convert into bradyzoites (Blader and 
Saeij, 2009).  These forms then divide slowly by endodyogeny within tissue cysts (Figure 
1-4) (Petersen and Dubey, 2005). A tissue cyst is a collection of bradyzoites surrounded by 
a well-deﬁned host cell membrane, they develop in the host cell cytoplasm where its wall 
becomes tightly associated with the host endoplasmic reticulum (ER). Cysts are sized from 
5 µm to 60 µm in the brain and up to 100 µm in other tissues (Petersen and Dubey, 2005). 
The formation of bradyzoites within cysts is required for the establishment of chronic 
infection. The process is driven by the host response to rapidly dividing tachyzoites and is 
marked by changes in the parasite expression profile (Blader and Saeij, 2009).   
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Figure 1-4: Intracellular T. gondii tissue cyst (arrow) in a section of mouse cerebellum 
(adapted Petersen and Dubey, 2005). 
 
 
 
Notably, T. gondii can infect and replicate within any nucleated mammalian or avian cell. 
Within these the parasites replicate within a parasitophorous vacuole (PV) before egress 
and infection of neighbouring cells (Black and Boothroyd, 2000; Blader and Saeij, 2009). 
The PV is formed after invasion and is delineated by a parasitophorous vacuole membrane 
(PVM) which contains numerous intravacuolar tubules apparently connected to the parasite 
plasma membrane (Petersen and Dubey, 2005).  
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1.6.1 Host cell invasion process 
Host cell invasion by T. gondii is a complex process with multiple, regulated stages. 
Firstly, the parasites attach to the host cell surface via a low affinity interaction largely 
mediated by GPI-anchored pathogen SAG proteins (surface antigens) (Blader and Saeij, 
2009).  
 
Subsequently, an unknown signal triggers an increase in cytosolic calcium stimulating 
microneme discharge (Blader and Saeij, 2009). More than 20 micronemal proteins have 
been identified and many are either transmembrane adhesins or adhesin accessory proteins 
(Blader and Saeij, 2009). Adhesin binding to host cells tightens the attachment of T. 
gondii, the parasite then utilises actin-myosin powered gliding motility for invasion 
(Blader and Saeij, 2009).  
 
A second unknown trigger then stimulates the T. gondii to release the contents of the 
rhoptry bodies (Blader and Saeij, 2009). These rhoptry proteins function in the formation 
of a complex on the host cell plasma membrane known as the moving junction, this 
migrates down the entire length of the parasite as invasion proceeds (Blader and Saeij, 
2009).  
 
During penetration the PV is formed, largely from lipids derived from the host plasma 
membrane (Blader and Saeij, 2009). However, T. gondii regulated the protein composition 
of the PV by blocking the accumulation of most host transmembrane, but not GPI-linked, 
proteins (Blader and Saeij, 2009). The parasite forms a parasitophorous vacuole (PV) 
(Figure 1-5) immediately after invasion and resides within it while depending on the host 
for nutrients (Stedman et al., 2003).  
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Figure 1-5: Electron microscopy image of Toxoplasma gondii within parasitophorus 
vacuoles (PV) within the host cell cytoplasm. 
(adapted from http://vmbmod10.msu.montana.edu/vmb/white-lab/photos.htm) 
 
 
 
1.6.2 Interaction between the host and parasite 
Within the PV the interactions between the parasite and host remain largely unknown. The 
PV does not fuse with host organelles, however it is closely associated with the host ER 
and mitochondrion (Martin et al., 2007). In addition, small soluble molecules (less than 
1300-1900 Da) are able to cross PVM and enter the PV by diffusion (Schwab, Beckers and 
Joiner, 1994). The parasite also actively scavenges a variety of fatty acids and lipids from 
the host, some of which are further metabolised by the parasite (Coppens, 2006). 
Furthermore, recent evidence suggests that the relationship of T. gondii with its host cell 
extends beyond a simple parasitic relationship (i.e. scavenging and survival) and involves 
the manipulation of host metabolism (Weiss and Kim, 2007).   
 
 
 
PV 
Toxoplasma 
Host cell cytoplasm 
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Importantly, T. gondii is unable to synthesize a number of essential nutrients de novo and 
therefore must be able to scavenge for these efficiently (Blader and Saeij, 2009). As 
mentioned above, small molecules (e.g. ions, amino acids, sugars, nucleosides, nucleotides 
and polyamines of less 1300-1900 Da) diffuse passively across the PVM. However, T. 
gondii must also scavenge the macromolecule cholesterol, and many studies have 
demonstrated that parasite replication is hindered in the absence of exogenous lipoprotein 
(Coppens et al., 2000).  
 
During invasion host cholesterol from the plasma membrane is incorporated into the PVM 
through a caveolae independent mechanism, and depleting plasma membrane cholesterol 
blocks parasite internalization (Bansall, Bhatti and Sehgal, 2005). However, post invasion 
T. gondii exploits host low density lipoprotein receptor-mediated endocytosis to acquire 
essential cholesterol (Bansall, Bhatti and Sehgal, 2005). Similarly, host-derived lipoic acid 
is scavenged, although the reasons for this are unclear given that lipoic acid is synthesized 
and used in the vestigal apicomplexan plastid organelle, the apicoplast (Crawford et al., 
2006). 
 
1.7 TOXOPLASMOSIS 
1.7.1 Toxoplasmosis is caused by Toxoplasma gondii 
Toxoplasmosis, the resulting disease from T. gondii infection, is a frequent cause of lethal 
cerebral pathology in immuno-compromised individuals and can also induce severe 
congenital anomalies (Figure 1-6) (Georgiev, 1994).  In the past two decades, there has 
been a dramatic increase in the number of immuno-compromised individuals and thus a 
concomitant increase in severe toxoplasmosis (Black and Boothryod, 2000). Therefore, 
this disease represents an important concern in the AIDS community.  
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Figure 1-6: Congenital defects (hydrocephalus, liver enlargement and growth retardation) 
in infants (adapted from :http://gsbs.utmb.edu/microbook/ch084.htm) 
 
 
 
 
 
 
 
 
 
The most damaging form of toxoplasmosis is congenital toxoplasmosis which results 
hydrocephalus, intracranial calcification, and chorioretinitis in foetus (Holland, 2003).  
Acute infections in pregnant women (and animals) can be vertically transmitted to the 
foetus and cause severe illness (toxoplasmosis.org). Notably, recent research suggested 
that congenital transmission may be much more important than previously thought in the 
spread of T. gondii, at least in animal populations (Hide et al., 2009).  
 
Toxoplasmosis is the most widespread zoonosis in felines, and economically important 
agricultural and domestic animals such as dogs, pigs, cattle, poultry, sheep, goats and 
horses (Dubey and Jones, 2008). T. gondii has also been recorded in wild animal species, 
including game and captive zoo animals including endangered species and marine 
mammals (Dubey and Jones, 2008). 
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1.7.2 Geographical distribution of Toxoplasma in humans 
T. gondii is a common parasite and toxoplasmosis is one of the most common infections 
throughout the world (dpd.cdc.gov/dpdx). Although the burden of this disease varies 
greatly from country to country, it remains a global public health problem which affects 
about one billion individuals. The recent discovery of its common infection in certain 
marine wildlife such as sea otters indicates contamination of seas with T. gondii oocysts 
washed from land (Dubey, 2008). 
 
T. gondii varies in the severity of disease caused (benign to fatal) and the mode of 
transmission. Whilst investigating the role of genetic-variation in this it was demonstrated 
that whilst most T. gondii genotypes restricted to certain regions, some closely related 
types are found across continents. This indicated a recent radiation of a pandemic genotype 
(Lehmann et al., 2006). Evidence suggested that South American and Eurasian populations 
have evolved separately until recently, when ships populated by rats, mice, and cats 
provided T. gondii with unprecedented migration opportunities, probably during the 
transatlantic slave trade (Lehmann et al., 2006). 
 
1.7.3 Disease burden 
It is estimated 400-4,000 cases of congenital toxoplasmosis occur each year in the United 
States. These are primarily caused by the consumption of contaminated meat, making 
toxoplasmosis the third leading cause of food-borne deaths in USA (toxoplasmosis.org). A 
high prevalence of infection in France has been related to a preference for eating raw or 
undercooked meat, while a high prevalence in Central America has been related to the 
frequency of stray cats in a climate favouring survival of oocysts and soil exposure 
(toxoplasmosis.org).  
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1.7.4 Diagnosis 
Toxoplasma infection can be diagnosed through the use of serological tests on blood or 
body fluids, amniocentesis (via PCR), isolation of the parasite and the characteristic 
microscopic appearance of tissues such as bronchoalveolar lavage material from immuno-
compromised patients, or lymph node biopsy (toxoplasmosis.org; dpd.cdc.gov/dpdx). 
 
1.7.5 Pathogenesis 
Clinical disease is normally limited either to immuno-compromised individuals or to 
congenital disease resulting from an acute infection of the expectant mother. The severity 
of congenital infection depends upon the stage of pregnancy when the acute infection 
occurred, and spontaneous abortions or neurological disorders such as blindness and 
mental retardation may result (Black and Boothroyd, 2000). In immuno-compromised 
individuals (typically those with an untreated HIV infection) Toxoplasma is a frequent 
cause of intracerebral focal lesions resulting in toxoplasmic encephalitis, which can be 
fatal (Black and Boothroyd, 2000).  
 
In immuno-competent humans, postnataly acquired toxoplasmosis is either unapparent, or 
accompanied by cervical lymphadenopathy with fever, joint pain, headache and tiredness 
(Kankova and Flegr, 2007). In addition, some congenitally infected infants are 
asymptomatic at birth, but can develop clinical signs in the later years, i.e. slower 
neurological and mental development and late chorioretinitis (Kankova and Flegr, 2007). 
Evidence suggests that most individuals with ocular toxoplasmosis were infected 
postnataly where ocular lesions may first develop many years after the infection. The risk 
of recurrent ocular disease appears to be greater during the first year after an episode of 
toxoplasmic retinochoroiditis than during subsequent years (Holland, 2003). 
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Within the host there is an apparent low rate of spontaneous reactivation whereby 
Toxoplasma bradyzoites differentiate back to tachyzoites (Black and Boothroyd, 2000). 
Normally, the immune response efficiently prevents the dissemination of these tachyzoites 
(Black and Boothroyd, 2000), but in immuno-compromised hosts this reactivation may go 
unchecked and / or more frequent. This lead to the suggestion that the parasites may 
actively detect a lowered immunity against them resulting in the massive and potentially 
fatal recrudescences observed (Black and Boothroyd, 2000).  
 
1.7.6 Transmission and etiologic factors 
T. gondii utilises both horizontal and vertical transmission (Hide, 2009). Generally, 
horizontal transmission occurs from individual to individual and is mediated by alternative 
hosts (cats and mice in the case of T. gondii). However, vertical transmission leads to 
transmission of T. gondii from one generation of host to the next by, for example, 
controlling the physiology of the host to promote transmission (Hide, 2009). Therefore, T. 
gondii must have evolved mechanisms to exploit both of these transmission routes to 
ensure its survival.  
 
Transmission to humans can occur by three principal routes: i. ingestion of oocysts shed by 
cats; ii. ingestion of raw or inadequately cooked infected meat; and iii. congenital 
transmission (a newly infected pregnant woman passing the infection to her unborn foetus; 
Hide et al., 2009). 
 
In addition to undercooked meat, drinking water and unwashed vegetables contaminated 
with oocysts may be an important source of infection (Hide et al., 2009). Ingestion of cat 
faeces through hand-to-mouth contact following gardening, cleaning cat litter box and 
contact with children‟s sand pits may also lead to infection (Hill and Dubey, 2002; 
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Alfonso, Thulliez and Gilot-Fromont, 2006). In addition, blood transfusion and organ 
transplantation have been recognised as another source of transmission 
(dpd.cdc.gov/dpdx). 
 
1.7.7 Recommendations for prevention 
Hygiene remains the best preventive measure because currently there is no vaccine to 
prevent toxoplasmosis in humans (Dubey, 2008). Cooking meat to a safe temperature (i.e. 
one sufficient to kill Toxoplasma), peeling or thoroughly washing fruits and vegetables 
before eating, cleaning cooking surfaces and utensils after they have contacted raw meat, 
poultry, seafood, or unwashed fruits and vegetables are some of the preventive measures 
recommended (toxoplasmosis.org). 
By recognising the risks many cases of congenital toxoplasmosis could be prevented. 
Specific measures that can be taken by women to decrease the infection risk during 
pregnancy include those mentioned above plus, for cat owners, avoiding changing the litter 
tray and / or limiting the risk of the cat becoming infected by not feeding it raw or 
undercooked meat and keeping it indoors to prevent it eating infected prey 
(toxoplasmosis.org). 
 
1.7.8 Potential therapeutics for toxoplasmosis 
Immuno-compromised or AIDS patients are given sulfadiazine and pyrimethamine 
(Kankova and Flegr, 2007). Folinic acid (leucovorin) is administered in all cases to reduce 
the bone marrow suppression caused by pyrimethamine. Spiramycin is given to pregnant 
women with acute toxoplasmosis (Kankova and Flegr, 2007). Although the current drug 
therapy will effectively kill the tachyzoite stage, such treatment does not remove the 
chronic bradyzoite stage, and thus long-term therapy is needed (Black and Boothroyd, 
2000).  A live tachyzoite vaccine, Toxovax is the only commercially available vaccine 
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worldwide to protect against congenital toxoplasmosis in ewes (Innes et al., 2009 and 
Buxton et al., 2007). This suggests that it may also reduce or prevent tissue cyst 
development in muscle. However, the question of whether the vaccine could be used to 
make meat safer for human consumption is still unanswered (Buxton et al., 2007). 
 
While chemotherapy is the major control strategy for these parasites, drugs to treat these 
parasites are limited by their inability to eliminate the infection, emerging resistance and 
poor patient tolerance (Derouin, 2005). Since resistance is often due to mutations within 
drug target sites, there is a genuine need not only for new drugs, but also for the 
identification of novel chemotherapeutic targets (Aspinal et al., 2002). 
 
1.8 LIPIDOMICS AND DRUG TARGETS 
Investigations of lipids and their biosynthesis can increase understanding of the lipid-
regulated physiopathological events and perhaps indicate new therapeutic strategies (Singh 
and Del Poeta, 2011). Identifying cellular processes that are unique and essential to the 
parasite is therefore a crucial step towards defining appropriate drug targets. Recent 
achievements in this field are promising and suggest that the elucidation of lipid pathways 
will provide new opportunities for designing potent anti-parasitic strategies (Denny et al., 
2006). One essential apicomplexan metabolic process that may be exploited for the 
development of anti-parasitic drugs is the fatty acid biosynthetic pathway (Goodman and 
McFadden, 2007). Another potential pathway for intervention is sphingolipid metabolism; 
here the parasites possess several novel enzymes that could be exploited for the 
development of new drugs for toxoplasmosis (Sonda et al., 2005).  
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1.8.1 Structure and diversity of sphingolipids 
Sphingolipids were first discovered by J. L.W. Thudichum in 1876 and are ubiquitous 
constituents of membranes in eukaryotic organisms. They fall into 3 major categories: 
ceramides (the simplest or „base‟ sphingolipid), phosphosphingolipids (e.g. 
sphingomyelin) and glycosphingolipids. They are a structurally diverse family of lipids 
consisting of a sphingosine backbone with a long chain fatty acid with, in the case of 
complex sphingolipids, a polar head group (Figure 1-7) (Landoni et al., 2007; Koeller and 
Heise, 2011). 
 
Figure 1-7: Chemical structure of a complex sphingolipid representing the sphingosine 
backbone and the long chain fatty acid. R is the head group, H in the case of ceramide. 
 
The polar head groups of complex sphingolipids show a striking structural diversity among 
phylogenetically separate organisms (Hanada, 2003). In mammalian cells, choline 
phosphoceramide (sphingomyelin) accounts for approximately 10% of membrane 
phospholipids, while various lower animal cells have ethanolamine phosphoceramide and 
its N-mono or dimethyl derivatives in place of sphingomyelin (Hanada, 2003). In contrast, 
plants and fungi produce phosphoinositol-containing sphingolipids (inositol phosphoryl 
ceramide) (Hanada, 2003). With respect to glycosphingolipids, numerous variations in the 
glycosyl head structure exist even within in the same organism (Hanada, 2003). 
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1.8.2 Sphingolipid functions and roles in pathogenicity 
For a long time these species were considered to primarily play a structural role in 
membrane formation (Bartke and Hannun, 2008). However, intensive studies of 
sphingolipid metabolism and function has revealed ceramide, sphingosine, sphingosine-1-
phosphate (S1P) and ceramide-1-phosphate (C1P), as bioactive molecules playing roles 
from regulation of signal transduction pathways, through direction of protein sorting to the 
mediation of cell-to-cell interactions and recognition (Bartke and Hannun, 2008; Singh and 
Del Poeta, 2011).  
 
Sphingolipids also play important roles through their abundance and involvement in 
membrane microdomain or raft formation, as well as serving as the lipid anchor for many 
of these molecules which function as in signal transduction and protein sorting (Zhang et 
al., 2010; Bartke and Hannun, 2008). In these ways sphingolipids and their metabolites 
modulate proliferation, differentiation, growth suppression, apoptosis and also, pathogen 
infection and host defense (Landoni et al., 2007; Hullin-Mastuda and Kobayashi, 2007). 
For example, microbial sphingolipids and their metabolizing enzymes have a pivotal role 
in the regulation of fungal pathogenicity, notably in Cryptococcus neoformans. In this case 
sphingolipids mediate cellular processes such as cell growth, proliferation, apoptosis and 
senescence (Landoni et al., 2007).  
 
In addition sphingolipid synthesis and signaling renders the pathogenic fungi hypervirulent 
by making them resistant environmental stresses and killing by the host immune responses 
(Singh and Del Poeta, 2011). With respect to protozoan pathogens, the interactions of 
parasite sphingolipid metabolism with that of the host may be important in parasite 
survival and / or host defence (Zhang et al., 2010). 
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1.8.3 Ceramide 
The simplest sphingolipid, ceramide is a precursor of complex sphingolipids and a major 
player in cell signalling (Block et al., 2007). This lipid is a key signalling molecule in 
processes including apoptosis, growth arrest, senescence, differentiation, the immune 
response and cell cycle arrest (Baier and Barrantes, 2007).  
 
Cellular ceramide can be generated by hydrolysis of sphingomyelin via an acid or neutral 
sphingomyelinase (Baier and Barrantes, 2007; Holthuis et al., 2001). Another important 
source of ceramide is from the breakdown of glycosphingolipids through the removal of 
their terminal hydrophilic groups by a series of specific hydrolases (Hannun and Obeid, 
2008). In all cases the released ceramide can be either recycled into sphingolipid synthesis 
or degraded to sphingosine by ceramidases (Merrill et al., 2002). Sphingosine can then be 
phosphorylated by sphingosine kinases to generate sphingosine-1-phosphate (S1P), an 
intracellular second messenger and extracellular ligand for specific receptors (Holthuis et 
al., 2001).  
 
Ceramide can also be synthesized de novo in the ER through the action of ceramide 
synthase, subsequently this lipid can be translocated to the Golgi apparatus where it is 
modified to complex phospho- or glyco-sphingolipid (Cremetsi, Goni and Kolesnick, 
2002). It has been suggested that transport of proteins through the secretory pathway is 
coupled to sphingolipid biosynthesis (Holthuis et al., 2001). 
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1.8.4 De novo synthesis of sphingolipids 
Despite the diversity evident in eukaryotic sphingolipids, serine palmitoyltransferase (SPT) 
is the enzyme ubiquitously responsible for the initial synthetic step (Figure 1-8). This 
limiting step is the condensation of L-serine and palmitoyl CoA to produce 3-
ketodihydrosphingosine (KDS) (Hanada, 2003; Merrill, 2002). In mammals and yeast at 
least two gene products (termed LCB 1 and LCB 2, or sometimes SPT 1 and SPT 2) 
responsible for this activity have been identified (Cheng et al., 2010).   
 
In the second step, KDS is reduced to form dihydrosphingosine (Figure 1-8). In 
mammalian cells this is N-acylated by ceramide synthase to form dihydroceramide, which 
is then de-saturated to form ceramide, which is primarily used for the synthesis of 
sphingomyelin (Figure 1-8 SM; Hanada, 2003). SM synthase transfers a phosphocholine 
head group from phosphatidylcholine (PC), generating SM and also diacylglycerol (DAG) 
and water as by-products (Hannun and Obeid, 2008). Ceramide can also be phosphorylated 
by ceramide kinase, which in turn can be recycled by a ceramide-1-phosphatase (C1P); or 
glycosylated by glucosyl or galactosyl ceramide synthases (Figure 1-8) (Hannun and 
Obeid, 2008). 
 
In contrast, in fungal (and plant) cells, dihydrosphingosine is hydroxylated to generate 
phytosphingosine, which is N-acylated to produce hydroxyceramide (Figure 1-8 
phytoceramide; Hanada, 2003). The prevalent acyl chain of fungal phytoceramide is C26 
hydroxy fatty acid, whereas typical acyl chains of mammalian ceramide are saturated C16 
and C24 fatty acids (Hanada, 2003). In both plant and fungal cells phytoceramide is 
converted to inositol phosphorylceramide (IPC), a species absent from mammalian cells, 
whose formation is catalysed by IPC synthase (Figure 1-8; Hanada, 2003). This enzyme 
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catalyses the transfer of phosphoinositol from phosphatidylinositol to phytoceramide to 
produce IPC which is then used to produce more complex phosphosphingolipids, such as 
glycosylated phosphosphingolipids in plants and mannose-inositol phosphoryl ceramide in 
yeast (Merrill and Sandhoff, 2002).   
 
 
 
 
 
 
 
 
  
 
 
 
 
CHAPTER 01: INTRODUCTION 
 
54 
 
Figure 1-8: Sphingolipid biosynthetic pathway of mammalian and fungal cells (adapted from Hanada, 2003)  
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Therefore, there is evolutionary divergence in the pathway, with the ﬁnal products of the 
sphingolipid biosynthetic pathways being diﬀerent in mammals, fungi and plants (Figure 
1-8). Thus, certain steps of this pathway are potential targets for chemotherapy against 
fungal pathogens (Koeller and Heise, 2011). 
 
1.8.5 Sphingomyelin (SM) and SM synthase 
Sphingomyelin (SM) is the primary phosphosphingolipid of animal cell membranes and 
mammalian cells (Koeller and Heise, 2011). Plants, fungi and yeast do not produce SM 
(Rosenwald, Machamer and Pagano, 1992). This lipid is composed of phosphocholine and 
ceramide (Figure 1-9).   
Figure 1-9: Chemical structure of sphingomyelin. Sphingomyelin is composed of a 
ceramide backbone with a phosphocholine head group attached to the C-1 free alcohol 
group of ceramide. The fatty acid (R) is attached to the second carbon of sphingosine via 
an amide linkage. 
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This molecule is formed by the transfer of the phosphocholine head group from 
phosphatidylcholine (PC) to ceramide (Figure 1-10) (Koeller and Heise, 2011). This 
process is mediated by SM synthase (SMS) in the lumen of the Golgi apparatus and on the 
cell surface (Rosenwald, Machamer and Pagano, 1992). SMS also catalyses the reverse 
reaction as it is in equilibrium with substrates (PC and ceramide) and products (SM and 
diacylglycerol) (Melendez, 2008). 
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Figure 1-10: A schematic representation of chemical reaction in the formation of 
sphingomyelin from phosphatidylcholine and ceramide. In this reaction, phosphocholine 
head group of phosphatidylcholine is transferred on to ceramide, resulting in 
sphingomyelin, diacylglycerol (DAG) and water. This reaction is catalysed by 
sphingomyelin synthase (SMS). 
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In the human genome there are two genes encoding sphingomyelin synthase denoted as Hs 
SMS 1, Hs SMS 2 whose products are localized in Golgi and on the plasma membrane 
respectively (Huitema et al., 2004).  It is predicted that other animal genomes also contain 
at least 2 SMS genes (Huitema et al., 2004; Koeller and Heise, 2011).   
 
The catalytic mechanism employed by the SM synthase requires a catalytic triad consisting 
of two histidines and an aspartate residue. The transmembrane arrangement of the enzyme 
means that this triad is presented towards the lumen of the Golgi in the case of Hs SMS 1 
and the extracellular environment in the case of Hs SMS 2 (Figure 1-11) (Huitema et al., 
2004). In this the SM synthases resemble the lipophosphotransferases (LPPs). In the case 
of SMS the choline phosphate residue is proposed to be transferred from 
phosphatidylcholine to an activated histidine, this is then subjected to nucleophilic attack 
by the oxygen of the ceramide primary hydroxyl group, resulting in transfer to the 
sphingoid base (Figure 1-11; Huitema et al, 2004). This triad lies within domains 3 and 4 
(D3 and D4) of the SMS proteins, 2 other domains of unknown function are also conserved 
(D1 and D2; Huitema et al., 2004). 
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Figure 1-11: Membrane topology of Hs SMS 1/2 proteins showing the 6 transmembrane 
domains and the conserved catalytic triad incorporating two histidines (H) and one 
aspartate (D) residues in domains 3 and 4 (adapted from Huitema et al., 2004). 
 
 
1.8.6 Inositol phosphorylceramide (IPC) and IPC synthase 
Plants, fungi, and some protozoa synthesize inositol phosphorylceramide (IPC) rather than 
SM as their primary phosphosphingolipid (Koeller and Heise, 2011). Inositol 
phosphorylceramide (IPC) synthase is an enzyme common to both fungi (where it is 
known as the AUR1, Aureobasidin resistance, protein) and plants (Sugimoto, Sakoh and 
Yamada, 2004). Its product, like SM in mammalian cells, is known to be a major 
component of the plasma membrane. However, yeast, plants and certain protozoa also 
incorporate IPC into GPI-anchors for plasma membrane proteins (Koeller and Heise, 
2011).   
 
IPC synthase (AUR1) catalyses the transfer of inositol phosphate (phosphoinositol head 
group) from phosphatidylinositol (PI) to C-1 hydroxy of ceramide to produce IPC (Figure 
1-12) (Koeller and Heise, 2011; Sugimoto, Sakoh and Yamada, 2004; Denny et al., 2006). 
AUR1 is localized to the Golgi of yeasts and possess the same catalytic triad as the animal 
SM synthases (Levine et al., 2000), however it lacks regions corresponding to D1 and 2 
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(Huitema et al., 2000). Notably, mutation of His-294, part of catalytic triad in the yeast 
AUR1p, results in nonviable haploid cells (Levine et al., 2000). Recently an accessory 
protein involved in IPC synthase activity (KEI1p) has been identified (Sato et al., 2009).  
 
AUR1 has been shown to have a role in hyphae formation in Aspergillus nidulans though 
regulation actin cytoskeleton (Singh and Del Poeta, 2011).  In addition, AUR1 regulates 
the level of (phyto) ceramide (Figure 1-8; the acceptor substrate of the AUR1 reaction) and 
this is a substrate for ceramidases for the production of the apoptotic inducers phyto- and 
dihydrosphingosine (Cerbón et al., 2005; Singh and Del Poeta, 2011). This enzyme also 
controls the levels of diacylglycerol (DAG; Figure 1-8) which acts as a mitogenic signal 
(Cerbón et al., 2005). Thus AUR1, and by extension SM synthase, regulates the balance 
between apoptosis (cell death) and mitogenesis (cell growth) (Mina et al., 2011). 
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Figure 1-12: A schematic representation of chemical reaction in the formation of inositol 
phosphorylceramide from phosphatidylinositol and ceramide. In this reaction, 
phospholinositol head group of phosphatidylinositol is transferred on to ceramide, resulting 
in inositol phosphorylceramide, diacylglycerol (DAG) and water. This reaction is catalysed 
by inositol phosphorylceramide synthase (IPCS). 
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The Saccharomyces cerivisiae AUR1 protein is, therefore, essential (Nagiec et al., 1997). 
Given that IPC synthases have no functional mammalian equivalent, the enzyme is well 
established as a target for antifungals (Georgopapadakou, 2000) and inhibition of this 
essential biosynthetic step leads to the accumulation of phytoceramide in growing cells and 
cell death (Fischl et al., 1986). The cyclic depsipeptide aureobasidin A (Ab A) is the „gold 
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standard‟ AUR1 inhibitor and is widely used as a selectable marker for various plasmids 
(e.g. Clontech, Matchmaker Gold). 
 
1.9 PROTOZOAN AND PLANT SPHINGOLIPIDS AND THEIR SYNTHESIS      
Notably, many protozoan parasites also synthesize IPC as their primary 
phosphosphingolipid (Smith and Denny, 2004). For example, T. gondii has been indicated 
to synthesize IPC and possess an IPC synthase activity that can be inhibited by Ab A 
(Sonda et al., 2005). IPC is also the predominant phosphosphingolipid in the related 
kinetoplastid Leishmania species (Denny et al., 2004). The first protozoan IPC synthase to 
be identified and characterised was from L. major (Denny et al., 2006). Notably, the 
Leishmania enzyme Lmj IPCS, and its orthologues in the kinetoplastid pathogens, possess 
a conserved catalytic triad in the same conformation as the yeast and mammalian enzymes. 
However, unlike AUR1 they also have the D1 and D2 regions found in the animal SM 
synthases (Zhang, Bangs and Beverley, 2010).  
 
This work has led to much interest as to whether IPC synthase could be a novel drug target 
for leishmaniasis, a neglected tropical disease affecting 12 million of the world‟s poorest 
people (Mina et al., 2010 b). The same argument could be made for the functionally 
equivalent enzymes in other kinetoplastid pathogens such as T. cruzi (Chaga‟s disease) and 
T. brucei (the cause of African Sleeping Sickness) or, for example, T. gondii. However, at 
the beginning of this work these enzymes remained undiscovered, as did the plant IPC 
synthase. 
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1.10 THE APICOMPLEXA 
1.10.1 Toxoplasma gondii 
De novo synthesis of ceramide, glycosphingolipids and SM in T. gondii has been 
demonstrated by metabolic labelling with tritiated serine and galactose, followed by 
analyses using thin layer chromatography (Azzouz et al., 2002). The incorporation of 
serine into sphingolipids indicated the presence of an active serine palmitoyltransferase 
(SPT) and the two well-documented SPT inhibitor, L-cycloserine, strongly inhibited the 
synthesis of these sphingolipids (Azzouz et al., 2002). In addition, lipidomic analyses 
using mass spectrometry has shown ethanolamine phosphorylceramide (EPC) to be 
relatively abundant in T. gondii compared to host cells (Welti et al., 2007). These studies 
did not identify IPC, however Ab A treatment inhibits T. gondii replication irreversibly and 
induces morphological changes in the parasite cell shape and integrity, with increased cell 
vacuolization (Sonda et al., 2005). In addition, analyses of parasite lipids revealed an 
inositol-containing species that was resistant to alkaline treatment which suggested the 
presence of IPC (Sonda et al., 2005). However, it is not yet clear whether IPC synthesis is 
required for parasite replication and more definitive characterizations of T. gondii 
sphingolipids and the enzymes involved in their synthesis is of paramount importance. 
 
1.10.2 Plasmodium falciparum 
Plasmodium species are, like T. gondii, apicomplexan parasites. They are the causative 
agents of malaria residing in mammalian red blood cells, hepatocytes, or in mosquito 
midgut epithelial cells. Biosynthesis of SM and glycosphingolipids by P. falciparum intra-
erythrocytic stage of parasite has been demonstrated using radio-labelled and fluorescent 
ceramides (Haldar et al., 1991; Gerold and Schwarz, 2001). More recently, a putative SM 
synthase has been identified (Huitema et al., 2004). An active glucosylceramide synthase 
has also been identified and sulphated glycosphingolipids are evident in P. falciparum 
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however, there is no evidence for the presence of IPC or other inositol-sphingolipids 
(Zhang, Bangs and Beverley, 2010).  
 
P. falciparum sphingolipid biosynthesis and parasite development can be inhibited with 
threo-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) or its threo-phenyl-2-
decanoylamino-3-morpholino-1-propanol (PDMP) derivative, both of which are potent 
inhibitors of glucosylceramide synthase and sphingomyelin synthase (Couto et al., 2004).  
Although, the precise mechanism of action of PPMP and PDMP with respect to P. 
falciparum is unknown their potent activity in vitro suggests that sphingolipid biosynthesis 
could provide a target for new antimalarials. 
 
1.11 THE KINETOPLASTIDAE  
The Kinetoplastidae cause a range of neglected human diseases (WHO.int), including the 
leishmaniases (a broad spectrum of infections caused by Leishmania species), Chaga‟s 
disease (Trypanosoma cruzi) and African sleeping sickness (Trypanosoma brucei) (Stuart 
et al., 2008). Together these affect 20-30 million people, largely in the developing world. 
Currently there are no effective vaccines and many of the drugs available to treat these 
diseases are expensive, difficult to administer or toxic, compromised by low efficacy and 
resistance is rising (Cobb and Denny, 2010). Therefore the discovery of new anti-
kinetoplastid therapeutic targets and compounds is of great importance. Recently, 
functional orthologues of the AUR1p have been identified in the Kinetoplastida and these 
may represent novel drug targets (Denny et al., 2006; Koeller and Heise, 2011). 
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1.11.1 Trypanosoma species 
The trypanosome species cause two major and distinct human diseases: African 
Trypanosomiasis (Sleeping Sickness, T. brucei spp); and South American Trypanosomiasis 
or (Chaga‟s Disease, T. cruzi) (Stuart et al., 2008). However, there are marked differences 
within the genus with respect to life cycle, biochemistry, geographical distribution, and 
disease pathology. This is reflected in significant differences in sphingolipid composition 
and metabolism between T. brucei and T. cruzi (Zhang, Bangs and Beverley, 2010). 
 
1.11.2 Trypanosoma cruzi 
Trypanosoma cruzi (South American trypanosome) is the causative agent of human 
Chaga‟s disease, a neglected tropical disease affecting an estimated 10 million people 
mostly in Latin America (WHO.int). T. cruzi has a complex lifecycle complex with 
multiple morphological forms, including an extracellular phase in the triatomine insect 
(„kissing bug‟) vector and an intracellular stage inside the vertebrate host (Koeller and 
Heise, 2011). These lifecycle stages possess neutral glycosphingolipids such as gluco-, 
galacto-, and lactosylceramides (Koeller and Heise, 2011). In addition, they depend upon a 
variety of parasite synthesized GPI-anchored surface glycoconjugates, and therefore the 
biosynthetic pathways of GPI anchor biosynthesis have been proposed as attractive targets 
for new therapies for Chaga‟s disease (Koeller and Heise, 2011).  
 
Unlike in Leishmania species and T. brucei, many of these anchors incorporate IPC 
(Sugimoto, Sakoh and Yamada, 2004). However, like Leishmania species T. cruzi are 
known to synthesize this non-mammalian phosphosphingolipid using an IPC synthase 
(Denny et al., 2006; Figueiredo et al., 2005). SM has also been reported in insect stage 
epimastigotes (Quinones et al., 2004), however radio-labeling with [
3
H] palmitate only 
showed the presence of synthesized IPC in epimastigotes and mammalian stage 
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amastigotes (Salto et al., 2003). Unlike yeast and plant IPC in which phytoceramide 
predominates, the T. cruzi species contains a mixture of dihydroceramide and ceramide 
(Berello et al., 1995), in this it resembles L. major (Hsu et al., 2007). But like fungi and 
plants, and unlike Leishmania species, T. cruzi IPC can be modified in vivo by glycosyl 
groups to form free glycoinositolphospholipids (GIPLs) which are present on the parasite 
cell surface in all lifecycle stages (Salto et al., 2003).  
 
Ab A has been proposed to inhibit the T. cruzi IPC synthase, with 10-20 μM impeding the 
differentiation of insect stage forms to amastigotes in vitro (Salto et al., 2003). However, it 
had no effect on the growth of epimastigotes at high concentrations, and was completely 
ineffective against IPC synthase in a direct enzymatic assay with epimastigote membranes 
(Figueiredo et al., 2005). Similarly, the L. major IPC synthase has been demonstrated to be 
Ab A resistant (Denny et al., 2006). Therefore, the inhibition of T. cruzi differentiation is 
likely to have been due to off-target effects (Figueiredo et al., 2005). However, the T. cruzi 
IPC synthase remains a promising drug target (Koeller and Heise, 2011). 
 
1.11.3 Trypanosoma brucei  
Trypanosoma brucei species are the causative agents of another neglected tropical disease, 
human African trypanosomiasis (HAT or African Sleeping Sickness) which affects many 
of the most under-developed regions of Africa. It kills in excess of 50,000 people annually 
and many of the drugs available are expensive and have severe toxicity (Barrett and 
Burchmore, 2003). Like Leishmania species and T. cruzi, T. brucei is an insect vector 
borne kinetoplastid, with the Tstse fly harbouring insect stage procyclic forms (PCFs) 
before differentiation to bloodstream forms (BSFs) on inoculation into a mammalian host. 
In both stages T. brucei is an extracellular parasites never residing within a host cell 
(Simarro, Jannin and Cattand, 2008). 
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Analyses of extracts from PCFs and BSFs by mass spectroscopy has confirmed the 
presence of both SM and IPC, as well EPC (Guther et al., 2006; Sutterwala et al., 2008). In 
addition, neutral glycosphingolipids have been identified in BSFs (Uemura et al., 2006). 
Interestingly, whilst IPC is dominant in PCF T. brucei, SM is present in both lifecycle 
stages and EPC is only found in BSFs (Sutterwala et al., 2008). Like T. cruzi, the 
phosphosphingolipids contain a mixture of dihydroceramide and ceramide, however for 
unknown reasons the first is favoured in PCFs and the other in BSFs (Sutterwala et al., 
2008). 
 
Inhibition of the T. brucei SPT, either pharmacologically (Sutterwala et al., 2007) or 
genetically (Fridberg, 2008), is lethal but can be rescued with 3-ketodihydrosphingosine 
the product of SPT (Sutterwala et al., 2007).  This contrasts with Leishmania species 
where loss of SPT is tolerated (Denny et al., 2004; Zhang et al., 2003; Mullin et al., 2001).  
This indicated that sphingolipid biosynthesis is essential for T. brucei and therefore a drug 
target. Like T. cruzi, T. brucei encodes orthologues of the L. major IPC synthase (Denny et 
al., 2006). These 4 isoforms may represent promising drug targets but at the start of this 
project they were uncharacterised. 
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1.12 ARABIDOPSIS THALIANA 
In the model plant Arabidopsis thaliana, the major sphingolipid types are 
glycosylinositolphosphoceramides, glucosylceramides, hydroxyceramides 
(phytoceramides) and ceramides (Markham and Jaworski, 2007). Several enzymes 
involved in plant sphingolipid metabolism have characterized (Pata, Hannun and Nq, 2010; 
Dunn et al., 2004). However, at the start of this project the key IPC synthase remained 
unidentified despite the availability of the complete genome sequence, although the 
enzyme activity has been measured in bean microsomal extracts and shown to be acutely 
sensitive to Ab A (Bromley et al., 2003). 
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2 OBJECTIVES OF THE STUDY 
The apicomplexan protozoan parasite Plasmodium falciparum encodes two sequence 
orthologues of the human sphingomyelin synthases (Pf SMS 1 and 2; Huitema et al., 2004) 
and is known to synthesize SM (Haldar et al., 1991; Gerold and Schwarz, 2001). However, 
the Pf SMS proteins have not been functionally characterised. Furthermore, orthologues in 
other apicomplexans were yet to be identified. For example Toxoplasma gondii is known 
to synthesize SM (Azzouz et al., 2002) and is believed to make IPC and EPC (Welti et al., 
2007; Sonda et al., 2005), but the enzymes responsible remained unknown. Similarly, IPC 
synthase activity is known to exist in plants but no sequence orthologues of the well 
studied fungal enzyme AUR1 were apparent in the genome databases (Bromley et al., 
2003). 
 
A functional orthologue of the fungal IPC synthase (AUR1) has been identified and 
characterised in the kinetoplastid, protozoan parasite Leishmania major (Lmj IPCS; Denny 
et al., 2006). This study also identified orthologues in the related parasites Trypanosoma 
brucei (Tb SLS 1-4) and Trypanosoma cruzi (Tc IPCS 1 and 2). However, again these 
enzymes remained uncharacterised despite the evidently important roles of sphingolipids in 
anchoring surface proteins (Sugimoto, Sakoh and Yamada, 2004), in differentiation and, 
perhaps, in pathogenicity (Sutterwala et al., 2008). 
 
Given the fact that these enzymes represent promising drug targets, further study of the 
kinetoplastid and apicomplexan is essential (Denny et al., 2006). Such work is vital in 
moving towards the ultimate goal of identifying compounds with the potential for 
development into much needed, pharmacologically active anti-protozoals. 
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To move towards these goals the following objectives were set: 
 
1. Establish the role of host sphingolipid biosynthesis in Toxoplasma gondii 
proliferation using a mutant CHO host cell line. 
 
2. Identify and isolate the sphingolipd synthase from T. gondii (Tg SLS) using a 
bioinformatic approach. 
 
3. Functionally characterize this enzyme (and those from the Trypanosma species) 
using an established complementation approach in yeast and various biochemical 
techniques. 
 
4. Localise Tg SLS in the T. gondii parasite 
 
5. Establish the evolutionary relationship of the apicomplexan, kinetoplastid, plant, 
fungal and animal sphingolipid synthases using bioinformatic and phylogenetic 
approaches. 
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3 MATERIALS AND METHODOLOGY 
3.1 MATERIALS 
Chloroform ACS reagent 99.8%, methanol ACS reagent 99.8%, isopropyl alcohol, ethanol, 
butanol, formaldehyde, propanol, lithium chloride (LiCl2), lithium acetate (LiAc), alkaline 
phosphatase, 50% polyethylene glycol (PEG), potassium chloride (KCl), hydrochloric acid 
(HCl), acetic acid, sodium acetate, sodium dodecyl sulphate, sodium hydroxide (NaOH), 
sodium phosphate dibasic anhydrous, sodium chloride (NaCl), ammonium chloride 
(NH4Cl), ammonium sulphate, magnesium chloride (MgCl2), HEPES, pryimethamine, N, 
N Dimethyl acrylamide, N, N  Dimethyl formamide, fuschin,  Thiourea, Triton X-100, 
Tween 200, urea, Xanthine, EDTA, EGTA, DMSO, CHAPS, PBS, β- mercaptoethanol, 
80% glycerol, agarose, agar, raffinose, glucose, sucrose,  galactose, Trisma base, fatty acid 
free BSA, oleic acid, adenine, lycine, leucine, tryptophan, glycine, histidine amino acids, 
Hs SMS 2 primers, cyclohexamide, myriocin, amplicillin, ethidium bromide, Dulbecco‟s 
modified Eagle‟s medium (DMEM) and acid washed glass beads (425-600 µm, 30-40 U S 
sieve) were from Sigma-Aldrich
®
. 
 
Protein assay kit was from BIO-RAD
®
 with Coomassie
®
 Brilliant Blue G-250.  
 
Complete
® 
EDTA-free Protease inhibitor cocktail tablets were from Roche
®
 Applied 
Science. 
 
Yeast nitrogen base, yeast extract, peptone and BODIPY
®
 FL C5 ceramide and NBD C6 
ceramide were from Invitrogen
®
. 
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Tryptone and yeast extract were from Melford
®
. 
 
Amino acid drop-out (DO) supplement -HIS-URA-TRP was from Clontech
®
. 
 
Hs SMS 1 primers, restriction enzymes and buffers were from Promega
®
. 
 
Tg SLS primers, Pfu polymerase and buffer were from Stratagene
®
. 
 
Phosphatidylinositol (PI), Phosphatidylcholine (PC), Phosphatidylethanolamine (PE) were 
from Avanti
®
 Polar Lipids. 
 
Aureobasidin A was from TaKaRa
®
 Bio Inc. 
 
DMEM, Ham‟s F12, penicillin, streptomycin, fetal bovine serum and L-glutamine were 
from GIBCO
®
 BRL. 
 
Nutridoma-SP was from Boehringer Mannheim
®
. 
 
FideliTaq DNA Ploymerase, T4 DNA Ligase and buffers were from GE Healthcare
®
. 
 
[5,6-
3
H]uracil (specific radioactivity 40–50 Ci/ mmol) was from New England® Nuclear 
Research Products. 
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Plasmid MiniPrep and Midi Prep, and PCR Prep kits were from QIAGEN
®
.  
 
Tissue culture flasks, multiwell plates and petri dishes were from Nunc
®
. 
 
Glass fibre filters were from Whatman
®
. 
 
Sampling manifold for transfer of material to filters was from Millipore
®
. 
 
Scintillation cocktail was BudgetSolve
®
 from Research Products International. 
 
Toxoplasma gondii laboratory strain RHΔHX, host VERO cells and the expression vector 
the pT8mycTy were a kind gift from Prof Dominique Soldati, University of Geneva. 
 
Toxoplasma gondii genomic DNA was a kind gift from Dr Barbara Clough, MRC NIMR, 
London. 
 
Trypanosoma cruzi genomic DNA was a kind gift from Dr Martin Taylor, LSHTM, 
London. 
 
Trypanosoma brucei genomic DNA was a kind gift from Dr Helen Price, University of 
York. 
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Hs SMS 1 and 2 cloned cDNA was a kind gift from Dr Joost Holthuis, Utrecht University. 
 
HFF was from the United Kingdom National Culture Collection. 
 
SPB-1 mutants and parent CHO cells from Riken BioResource Center, Japan with the kind 
permission of Prof Kentaro Hanada. 
 
YPH499 and YPH499-HIS-GAL-AURI yeast, and the pRS426MET25 yeast expression 
vector were kind gifts from Dr Hosam Shams-Eldin and Prof Ralph Schwarz, Phillips 
University, Marburg. 
 
Arabidopsis thaliana cDNA from total flower RNA was kindly provided by Dr Tony 
Fawcett, Durham University. 
 
3.2 INSTRUMENTS AND EQUIPMENT 
1.5ml LoBind
®
 tubes from Eppendorf
®
 were used in solvent extraction steps.  Eppendorf
® 
1.5ml centrifuge tubes were used in all other activities. 
 
Beckman
®
 Coulter Avanti J-20 XPI high-speed and Optima L-90K ultra-centrifuge 
machines were used for preparative processes. Boeco
®
 U-320R benchtop and M-240R 
mirco centrifuge were used for routine centrifugation steps.  
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Boeco
®
 S-32 Spectrophotometer was used in protein bioassays and culture density 
measurements.  
 
MT20 Chiltern
®
 Vortex mixture was used in mixing and cell disruption techniques.  
 
Perkin Elmer
®
 DNA Thermal Cycler and PCR programmer machines were used PCR 
amplification and programmed vector-insert ligation.  
 
Fusion TM, Packard
®
 Bioscience plate reader and OptiPlate-96 F from Perkin Elmer
®
 were 
used in fluorescence and radiolabel quantification.  
 
HPTLC plates were from Merck
®
. Visualisation and quantification of TLC were done 
using Fuji
®
 FLA-3000 plate reader and interpretation was by AIDA Image Analyser 
software 3.52 version. 
 
BTX
®
 ECM630 electroporator and 2 mm gap electroporation tubes were both from 
Harvard Instruments.  
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3.3 BUFFERS, SOLUTIONS AND CULTURE MEDIA  
Table 3.3.1 Buffers 
Buffer Stock solution Volume/weight Final concentration 
STE Buffer (50 ml) 1 M Tris/ HCl pH 7.4 1.25 ml 25 mM 
1 M Sucrose 12.5 ml 250 mM 
0.5 M EDTA 100 µl 1 mM 
Complete
® 
protease inhibitor 1 tablet  
 Add 50 ml water  
Storage Buffer (50 ml) 1 M Tris/ HCl pH 7.4 2.5 ml 50 mM 
80% (w/v) Glycerol 6.25 ml 10% (w/v) 
1 M MgCl2 0.25 ml 5 mM 
Complete
®
 protease inhibitor 1 tablet  
 Add 50 ml water  
Tris/EDTA/BSA or Assay Buffer (50 ml) 1 M Tris/ HCl pH 7.4 12.5 ml 250 mM 
0.5 M EDTA 2.5 ml 25 mM 
Fatty acid free BSA 750 mg 15 mg/ ml 
 Add 50 ml water  
PBS (100 ml) PBS from Sigma-Aldrich
®
 1 tablet  
 Add 100 ml water  
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Table 3.3.1 Buffers (Contd) 
Buffer Stock solution Volume/weight Final concentration 
10X TE Buffer (1 L) 1 M Tris/ HCl (pH 7.4) 
0.5 M EDTA (pH 8.0)  
100 ml  
20 ml 
Add 880 ml ultra-pure water 
Tris/ MgCl2 / Triton X-100 buffer  
(Sphingomyelinase assay buffer) 
1 M Tris/ HCl (pH 7.4) 1 ml 20 mM 
1 M MgCl2 0.5 ml 10 mM 
Triton X-100 0.025 g 0.05% (w/v) 
 Add water up to 50 ml  
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Table 3.3.2 Solutions and reagents 
Solution/ reagent Stock solution Volume/weight 
10X TE/ LiAc (50 ml) 1 M Lithium Acetate 5 ml 
10 X TE Buffer 5 ml 
 Add 50 ml ultra-pure water 
10X PEG/ LiAc (50 ml) 1 M Lithium Acetate 5 ml 
10X TE Buffer 5 ml 
50% PEG 3350 50 ml 
Cytomix 120 mM KCl 
0.15 mM CaCl2 
10 mM K2HPO4 (pH 7.6) 
25 mM HEPES (pH 7.6) 
2 mM EGTA 
5 mM MgCl2   
 
 
 
 
Filter sterilized 
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Table 3.3.3 Culture media 
Media Stock  Volume/weight 
SD-HIS-URA (1 L) 
 
Solution I Glucose 20 g 
 Add 820 ml of water and autoclaved 
Add 20 g of Agar for SDA-HIS-URA solid medium  
Solution II A Yeast Nitrogen base 1.7 g 
NH4SO4 5 g 
 Add 80 ml of water and autoclaved 
Solution II B 
 
 
Amino acid Drop out supplement (no Histidine, Uracil or 
Tryptophane) 
0.7 g  
Tryptophane  4 mg  
Solution II A and II B were mixed and added to solution I  
(When temperature falls below 45C, immediately poured over the plates under aseptic conditions for solid medium) 
SD-HIS-URA-MET (1 L) 
 
Solution I Glucose 20 g 
 Add 820 ml of water and autoclaved 
Add 20 g of Agar for SDA-HIS-URA solid medium 
Solution II A Yeast Nitrogen base 1.7 g 
NH4SO4 5 g 
 Add 90 ml of water and autoclaved 
Solution II B 2 mg/ ml Adenine   
10 mg/ ml Lysine 
10 mg/ ml Leucine    
10 mg/ ml Tryptophane 
2 ml 
3 ml 
3 ml 
2 ml 
Filter sterilized 
Solution II A and II B were mixed and added to solution I  
(When temperature falls below 45C, immediately poured over the plates under aseptic conditions for solid medium) 
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Table 3.3.3 Culture media (contd)   
Media Stock  Volume/weight 
SGR-HIS-URA (1 L) Solution I Galactose  
Raffinose  
40 g 
20g 
 Add 720 ml of water and autoclaved 
Add 20 g of Agar for SGRA-HIS-URA solid medium 
Solution II A Yeast Nitrogen base 1.7 g 
NH4SO4 5 g 
 Add 80 ml of water and autoclaved 
 Solution II B Amino acid Drop Out  (DO) supplement (no Histidine, 
Uracil or Tryptophane) 
0.7 g  
Tryptophane  4 mg  
 Add 100 ml of water and filter sterilized 
 Solution II A and II B were mixed and added to solution I  
(When temperature falls below 45C, immediately poured over the plates under aseptic conditions for solid medium) 
 
YPGR (1L) Solution I Yeast extract  
Peptone 
10 g 
20 g 
 Add 800 ml of water and autoclaved 
Solution II Galactose  
Raffinose  
40 g 
20g 
 Add 200 ml of water and autoclaved 
Solution I and II  were mixed under aseptic conditions 
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Table 3.3.3 Culture media (contd) 
Media Stock  Volume/weight 
YPD (1 L) Solution I Yeast extract  
Peptone 
10 g 
20 g 
 Add 950 ml of water and autoclaved 
Add 20 g of Agar for YPDA solid medium 
 Solution II 40% stock solution of Dextrose 50 ml (2%) 
When Solution I cooled down to 55C, Solution II was added under aseptic conditions.  
(The medium was poured over the plates immediately under aseptic conditions.) 
PLB (1L)  Tryptone 
Yeast extract 
NaCl   
10 g 
5 g 
10 g 
 Add 1 L of water and autoclaved. pH 7.5 
 Add 20 g of Agar for PLB agar medium 
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Table 3.3.3 Culture media (contd) 
 Media Stock  Volume/weight 
SOC (1L)  Tryptone 20 g 
Yeast extract 5 g 
NaCl 0.584 g 
KCl 0.186 g 
MgCl2 2.003 g 
MgSO4  2.265 g 
Glucose 3.6 g 
 Add 1 L of water and autoclaved  
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Table 3.3.3 Culture media (contd)   
Media Stock Volume/weight 
GYT (100  ml) 10% Glycerol 
0.125% TE 
0.25% Tryptone 
 
 
Add up to 100 ml of water  
SD 2% Glucose/ 0.8% 
Agarose (8:1:1) (1 L) 
Solution I Glucose 
 
20 g dissolved in 800 ml of water and autoclaved 
Agarose 8 g dissolved in 100 ml of water and autoclaved 
Solution II A Yeast Nitrogen base 1.7 g 
NH4SO4 5 g 
 Add 90 ml of water and autoclaved 
Solution II B 2 mg/ ml Adenine 
10 mg/ ml Leucine 
10 mg/ ml Lysine  
10 mg/ ml Tryptophane 
2 ml 
3 ml 
3 ml 
2 ml 
Filter sterilized 
Solution II was added 1:10 to Solution I 
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Table 3.3.3 Culture media (contd) 
Media  Stock Volume/weight 
DMEM (1L) 
    
DMEM stock solution 500 ml 
FBS 50 ml 
Streptomycin/penicillin 5 ml 
2 mM glutamine  
 Mixed in laminar floor hood and filter sterilized 
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3.4 BIOINFORMATIC STUDY 
3.4.1 Identification of hypothetical enzymes Tg SLS and At IPCS 
Two candidate sphingolipid synthase coding sequences were previously identified in the 
complete genome database of the malaria parasite Plasmodium falciparum (plasmodb.org; 
Huitema et al., 2004). A WU-BLAST search (Gish, 1996-2001) http://blast.wustl.edu) was 
performed on the then incomplete Toxoplasma gondii genome database (toxodb.org).  
 
A single sequence orthologue was identified, Tg SLS accession number 50.m03164. The 
identified Leishmania major enzyme (Lmj IPCS; Denny et al., 2006) was used in BLAST 
search of the Arabidopsis thaliana genome sequence database (The Institute for Genomic 
Research) with the previously identified L. major IPCS (Denny et al., 2006). Three closely 
related candidates were identified: Arabidopsis thaliana IPCS 1-3, accession numbers 
At3g54020.1, At2g37940.1 and At2g29525.1. 
 
3.4.2 Membrane topology prediction of hypothetical protein of Tg SLS 
PHD protein prediction program (Expasy.ch) was used to predict the membrane topology 
of the identified hypothetical protein, Tg SLS. 
 
3.4.3 Sequence alignment and phylogenetic analysis 
Protein sequence alignments were performed using Clustal W (Jeanmougin et al., 1998). 
Phylogenetic analyses were performed on edited alignments using maximum parsimony 
(PHYLIP Phylogeny Inference Package, version 3.5) constructed with maximum 
parsimony using Phylip according to author‟s instructions. 
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3.5 AMPLIFICATION AND CLONING OF SPHINGOLIPID SYNTHASE OPEN 
READING FRAMES  
3.5.1 Tg SLS 
The 50.m03113 open reading frame was amplified from genomic T. gondii using Pfu 
polymerase (Appendix I, 1.1.1) and the 1 l of each of the primer pairs: 
 
5‟ Tg SLS EcoRI  cgcgaattcATGCCCAGAACAGAGATG  
3‟ Tg SLS HindIII  cccaagcttTTAGAGTCCCTCGATGGCGCGAACGAT  
or 
5‟ Tg SLS EcoRI  cgcgaattcATGCCCAGAACAGAGATG  
3‟ Tg SLS NsiI  cccatgcatTTAGAGTCCCTCGATGGCGCGAACGATG 
 
Cloning sites are shown in lower case, with coding sequence in upper case. 
 
The product was identified by running a 0.8% agarose gel impregnated with ethidium 
bromide. Positive and negative controls were run alongside using Tg SPT and water 
respectively. 
 
The amplified DNA product was purified with QIAGEN
®
 PCR Prep kit and digested (with 
restriction enzymes Bam HI and Hind III or EcoRI and NsiI according to manufacturers‟ 
instructions (Appendix I, 1.2)). Digested DNA was then purified again using the PCR Prep 
kit.  In parallel, the yeast expression vector pRS426MET25 (Appendix II) was digested 
with Bam HI and Hind III whilst the T. gondii expression vector pT8mycTyGFP 
(Appendix III) was digested with EcoRI and NsiI, both were fractionated on an agarose gel 
and purified using the PCR Prep Kit. The amplified Tg SLS were ligated into these using 
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T4 ligase according to the manufacturer‟s conditions (Appendix I, 1.3), creating pRS426Tg 
SLS and pT8mycTg SLSTy. These were transformed into XL-1 blue super competent cells 
(Stratagene
®
) according to manufacturers‟ instruction and selected on PLB plates with 25 
µg/ µl of amplicillin incubated at 37 C overnight. A negative control was performed with 
2 µl water instead of DNA. Individual colonies were picked and grown in 3 ml of PLB 
liquid medium with 25 µg/ µl of amplicillin at 37 C overnight. Plasmid purification using 
the QIAGEN
®
 Miniprep was done according to the manufacturer‟s protocol and DNA 
screen for the presence of the inserts by restriction digest. 
 
3.5.2 At IPCS 
At IPCS 1 was amplified from Arabidopsis cDNA (from total flower RNA) using 
FideliTaq (Appendix I, 1.1.3) and the primer pair: 
  
5‟ At IPCS 1 BamHI  cgcggatccATGACGCTTTATATTCGCCGCG  
3‟ At IPCS 1 EcoRI  ccggaattcTCATGTGCCATTAGTAGCATTATC  
 
As above the product was ligated into the yeast vector pRS426MET25 (Appendix I, 1.3 
and Appendix II) using the restriction sites shown, creating pRS426At IPCS 1, and clones 
selected. Due to the infidelity of cDNA production the plasmids selected were sequenced 
(MWG) to verify the coding region. Cloning sites are shown in lower case, with coding 
sequence in upper case. At IPCS 2 and 3 were similarly cloned in the vector by Yoko 
Okada (Durham University). 
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3.5.3 Tc IPCS 
Tc IPCS was amplified from Trypanosoma cruzi genomic DNA using FideliTaq 
(Appendix I, 1.1.3) and the primer pair: 
 
5‟ Tc IPCS BamHI  cgcggatccATGGTTTTAATGGGGCCTCATTCTGC 
3‟ Tc IPCS HindIII  cccaagcttTTATCACCAGTGTCCAAAATTCCCAC 
 
As above the product was ligated into the yeast vector pRS426MET25 (Appendix II) using 
the restriction sites shown, creating pRS426Tc IPCS, and clones selected. Given the near 
identity of the 2 isoforms of the enzyme (Sevova et al., 2010) the insert could have 
represented either Tc IPCS 1.1 or Tc IPCS 1.2. Sequence analyses (MWG) confirmed the 
chosen cloned to contain Tc IPCS 1.2, the vector being pRS426Tc IPCS 1.2. Cloning sites 
are shown in lower case, with coding sequence in upper case. 
 
3.5.4 Tb SLS 1 and 4 
Tb SLS 4 was amplified from Trypanosoma brucei genomic DNA using Pfu polymerase 
(Appendix I, 1.1.1) and the primer pair: 
 
5‟ Tb SLS1000 EcoRI ccggaattcATGATTAGTTACCCTTTCTTCTCCC 
3‟ Tb SLS1000 XhoI  ccgctcgagTCACACATACGCCCCACATTTAAAC 
 
As above the product was ligated into the yeast vector pRS426MET25 using the restriction 
sites shown (Appendix I, 1.3 and Appendix II), creating pRS426Tc IPCS, and clones 
selected. Cloning sites are shown in lower case, with coding sequence in upper case. Tb 
SLS 1 was similarly cloned by Pan Ssu-Ying (Durham University). 
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3.5.5 Hs SMS 1 and 2 
Hs SMS 1 and 2 were amplified from sequenced cDNA clones using Pfu polymerase 
(Appendix I, 1.1.1) and the primer pairs: 
 
5‟ Hs SMS1 BamHI  cgcggatccATGAAGGAAGTGGTTTATTG  
3‟ Hs SMS1 EcoRI   ccggaattcTTATGTGTCATTCACCAGCCGG  
or 
5‟ Hs SMS2 BamHI  cgcggatccATGGATATCATAGAGACAGCAAAAC  
3‟ Hs SMS2 EcoRI  ccggaattcTTAGGTCGATTTCTCATTGTCTTC 
 
As above the products were ligated into the yeast vector pRS426MET25 using the 
restriction sites shown (Appendix I, 1.3 and Appendix II), creating pRS426Hs SMS 1 and 
2, and clones selected. Cloning sites are shown in lower case, with coding sequence in 
upper case.  
 
3.6 TRANSFORMATION OF PRS426 BASED VECTORS INTO YEAST 
In the YPH499-HIS-GAL-AUR1 auxotrophic S. cerivisiae strain, expression of the 
essential AUR1 is suppressed in the presence of glucose (Denny et al., 2006). Therefore, 
mutant cells were grown in YPGR (Table 3.3.3) (wild type YPH499 in YPD (Table 3.3.3)) 
before harvesting during their exponential growth phase by centrifugation. Then the cells 
were re-suspended in sterile water, vortexed for 1 minute and washed by centrifuging. The 
pellet was re-suspended in 250 l of freshly prepared 1XTE / LiAc (Table 3.3.2) and 
transferred into an Eppendorf
®
 tube. 100 l of this cell suspension was mixed with 1 l of 
a pRS426 based vector and 10 l of Herring testis carrier DNA. 600 l of freshly prepared 
sterile PEG / LiAc (Table 3.3.2) was added to each tube, vortexed and incubated at 30 C 
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for 30 minutes. 70 l of sterile DMSO were added and mixed by gentle inversion of the 
tubes. The tubes were heat shocked by placing in a hot water bath of 42 C for 15 minutes 
and chilled on ice for 1-2 minutes immediately. The cells were pelleted by a quick spin and 
re-suspended in 500 l of 1X TE. 100 l of the cell suspension were spread over SGRA-
HIS-URA or SDA-HIS-URA plates (Table 3.3.3) and incubated at 30C for 4-5 days until 
the colonies appear. A negative control was performed with water instead of plasmid 
DNA. Individual colonies were then inoculated in SD-HIS-URA liquid medium (Table 
3.3.3).  A smear of cell culture was streaked out on SDA-HIS-URA (Table 3.3.3) plates for 
further use. Glycerol stocks were prepared by adding glycerol to 15% in a liquid culture, 
mixing and freezing at -80C (Appendix I, 1.4). 
 
3.7 METABOLIC LABELLING YEAST WITH NBD C6 CERAMIDE OR FL C5 
CERAMIDE  
The sphingolipid synthase complemented YPH499-HIS-GAL-AUR1 yeast was cultured in 
SD-HIS-URA medium at 30 C overnight. YPH499-HIS-GAL-AUR1 expressing Hs SMS 
1 or 2 (not complemented) were cultured in SGR-HIS-URA medium at 30 C overnight.  
2.5 OD600 units harvested by centrifugation and resuspended in either SD or SGR (Table 
3.3.3) with 5 M FL C5 ceramide or NBD C6 ceramide conjugated with 5 M defatted 
BSA prepared according to the manufacturer‟s protocol (Appendix I, 1.5). After incubation 
at 30 C for 1 hour, the yeast was washed twice with SD-HIS-URA or SGR-HIS-URA 
(Table 3.3.3). Cells were resuspended in C:M 1:1 (v/v) and homogenised using acid 
washed glass beads. The membrane lipids were then extracted into the organic solvents by 
bi-phasic separation (Fischl et al., 2000) and cell membrane debris removed by 
centrifugation. The contents in the organic phase were concentrated in the Rotavapor 
Eppendorf
®
 concentrator 5301 at 30 C for 20 minutes. The dried pellet was re-suspended 
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in 20 l of C:M:W 10:10:03 (v/v/v). Then a TLC assay was carried out and analysed as 
described below (3.11) and previously (Denny et al., 2006). 
 
3.8  SPHINGOMYELINASE ASSAY 
Lipid extracts of NBD C6 ceramide metabolically labelled yeast was dried with 50 g of 
sphingomyelin in the Eppendorf
®
 concentrator. The dried lipid was then reuspended in 600 
l of 20 mM Tris-HCl (pH 7.4), 10 mM MgCl2 and 0.05% (w/v) Triton X-100 (Table 
3.3.1). The suspensions were divided equally in to two LoBind
®
 tubes and 0.25 l of B. 
cereus sphingomyelinase added. Tubes were incubated at 37 C for 2 hours with 
continuous shaking. 1 l of acetic acid was added to stop the reactions. 600 l of C:M:W 
(10:10:03 v/v/v) were added and the organic layer was extracted and analysed as above 
(3.7). 
 
3.9 METABOLIC LABELLING OF TOXOPLASMA GONDII 
Parasites were maintained in VERO cells (kidney epithelial cells from the African Green 
Monkey) grown in DMEM supplemented with 10% fetal bovine serum (FBS) at 37 C and 
5% CO2 (Weiss and Kim, 2008). To purify parasites infected host cells were disrupted by 
passing through a narrow gauge needle and the milieux filtered through 3 and 5 m 
polycarbonate filters (Millipore
®
) to remove contaminating host material. T. gondii were 
isolated by centrifugation at 2877 x g for 5 minutes at room temperature, re-suspended in 
DMEM (Table 3.3.3) without serum, washed and counted using a haemocytometer. 10
7 
parasites were resuspended in 1 ml of serum-free DMEM before incubation for 30 minutes 
at 37 C, subsequently BSA conjugated FL C5 ceramide or NBD C6 ceramide (Appendix I, 
1.5) was added at 5 M and the sample incubated at 37 C for a further 2 hours. Parasites 
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were then pelleted by centrifugation and washed twice with DMEM. The products were 
extracted using the bi-phasic separation method and the lipid fraction analysed as above 
(3.7). 
 
3.10 METABOLIC LABELLING OF VERO MAMMALIAN CELLS 
The VERO cells were scraped from tissue culture flasks, re-suspended in serum-free 
DMEM without BSA and washed with centrifugation at 957 x g for 3 minutes at room 
temperature. 3x10
5 
cells were then labelled and lipids prepared as above (3.9).  
 
3.11 THIN LAYER CHROMATOGRAPHY (TLC) 
The fluorescence of the labelled lipid samples was measured at 480 nm (Fusion
®
 TM, 
Packard Bioscience) against a 100 l of methanol as a blank. Equilibrated samples were 
then loaded onto high performance (HP) TLC silica plates. Fractionation was performed in 
a solvent phase of C:M:0.25% KCl, 55:45:10 (v/v/v) for 2 hours 30 minutes. The plate was 
scanned using the Fuji
®
 FLA 3000 and analysed by AIDA Image, FLA software programs. 
 
3.12 MICROSOMAL FRACTIONATION OF COMPLEMENTED YEAST   
The Tg SLS complemented HIS-GAL-AUR1 were grown in volumes of at least 500 ml in 
SD-HIS-URA medium (Table 3.3.3) at 30 C over a period of 3-4 days until OD600= 0.6-
0.7. The cells were then harvested by centrifuged at 4785 x g for 15 minutes at 4 C and 
the pellet washed with ice-cold PBS (Table 3.3.1). They were then re-suspended in 50 ml 
of cold PBS and pelleted by centrifugation and the pellet weighed. 1 ml of STE buffer with 
protease inhibitor (Table 3.3.1) was added to the pellet with approximately 0.5 ml of acid 
washed glass beads. The cells were homogenised by vortexing for 1 minute and placed on 
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ice for a further minute, this was repeated 10 times over a period of 20 minutes. The 
homogenate was centrifuged at 4785 x g for 10 minutes and the supernatant removed to a 4 
ml poly-allomer centrifuge tube and kept in 4 C. 1 ml of STE buffer (Table 3.3.1) was 
added to the pellet again and homogenised as previously. This procedure was repeated 
until the poly-allomer tube was full. The preparation was subsequently centrifuged at 
27000 x g for 35 minutes at 4 C in the Beckman® L8-70M ultracentrifuge. The 
supernatant was removed to a new poly-allomer centrifuge tube and ultra-centrifuged at 
105000 x g for 1 hour 45 minutes at 4 C. The supernatant was removed and the pellet air 
dried then resuspended in 50 l of cold storage buffer (Table 3.3.1) before storage at -80 
C until further use (Figueiredo et al., 2005). 
 
3.13  ESTIMATION OF PROTEIN CONTENT OF MICROSOMAL FRACTION 
1 l of microsomal preparation was diluted in 800 l of water. 200 l of BioRad® bioassay 
dye reagent was added to each and mixed by inverting the tubes for a few turns. The 
absorbance was measured using Boeco
®
 S-30 spectrophotometer at 595 nm against a 
blank. The protein concentration was determined by reference to a BSA standard curve and 
adjusted to 10 mg/ ml. 
 
3.14 CHAPS WASHING OF MICROSOMES  
Microsomes at 10 mg/ ml were extracted in 2.5% (40 mM) of CHAPS for 1 hour on ice 
(Mina et al., 2010 b) in 4 ml poly-allomer centrifuge tubes. The tubes were topped up with 
STE buffer with protease inhibitor (Table 3.3.1) and ultra-centrifuged at 105000 x g for 1 
hour 45 minutes at 4 C. The pellet was re-suspended in 50 l of cold storage buffer (Table 
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3.3.1). The protein concentration was determined as above (3.13) and adjusted to 10 mg/ 
ml before storage at -80 C until further use. 
 
3.15 IN VITRO TG  SLS MICROSOMAL ASSAY 
5 l of 10 mM PI, 4 l of 13 mM PE and 4 l of 13 mM PC were air dried for 10-15 
minutes in LoBind
®
 (lipid low binding) centrifuge tubes. 20 l of Assay Buffer 
(Tris/EDTA/BSA) (Table 3.3.1) were added to each including a blank as a control. The 
tubes were sonicated for 2 minutes and kept on ice. 2 l of crude or CHAPS washed 
microsomal extract (20 g protein) were added to each and the final volume was adjusted 
to 48 l with water. 2 l of 5 M FL C5 ceramide or 2 l of 100 M NBD C6 ceramide 
were added to each tube and incubated at 30 C for 1 hour. 150 l of C:M:W 10:10:03 
(v/v/v) were added and the organic layer extracted by bi-phasic separation before TLC 
analyses as described above.  
 
3.16 AUREOBASIDIN A SENSITIVITY ASSAY  
4 µl of 10 mM PI were added to 1.5 ml LoBind
®
 tubes and air-dried for 15 minutes. 20 µl 
of Tris/EDTA/BSA buffer (Table 3.3.1) was added and the tubes sonicated for 2 minutes 
before chilling on ice. Appropriate concentrations (0 µM, 10 µM, 25 µM, 50 µM, 75 µM, 
100 µM, 125 µM, and 150 µM) of aureobasidin A in DMSO were added to the tubes. 2 µl 
(20 µg protein) of CHAPS-washed microsomes were added to each and the final volume of 
the reaction mixture was adjusted to 48 µl with sterile water. This was incubated at 30 C 
for 30 minutes before the addition of 2 µl of 100 µM NBD C6 ceramide and further 
incubation at 30 C for 1 hour. 150 l of C:M:W 10:10:03 (v/v/v) were added and the 
organic layer extracted by bi-phasic separation before TLC analyses as described above.  
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3.17 AGAR DIFFUSION ASSAY 
Complemented yeast cells were grown in SD-HIS-URA and harvested in the exponential 
phase of growth. 2.4 x 10
7
 (OD600=1 unit=10
7
) cells were resuspended in 14 ml of warm 
(45 C) SD-HIS-URA solution I with 2% agarose and 1 ml of Solution II added (Table 
3.3.3). After gentle mixing the solution was immediately poured over petri dishes and 
allowed to set under aseptic conditions. Then the appropriate volumes (1 µl, 2 µl and 3 µl) 
and concentrations (prepared in DMSO) of aureobasidin A (25 µM, 100 µM), 
cyclohexamide (50 µM), myriocin (1 mM) were dropped on to the plates with DMSO as a 
control before incubation for 3-5 days at 30 C.  
 
3.18 INVASION AND PROLIFERATION ASSAYS 
3.18.1 Cell culture and infection 
CHO-K1, temperature sensitive SPT mutant SPB-1 and SPB-1/cLCB-1 cells were grown 
in Ham‟s F-12 media supplemented with 10% FBS at 37°C or 33°C (permissive 
temperature) plus 5% CO2. For induction of the temperature-sensitive phenotype 10
5
 cells 
were seeded into 24-well plates and incubated at 33°C for 24 hours. The medium was then 
replaced with Ham‟s F12 medium supplemented with 10% FBS or, to form serum reduced 
media, 0.1% FBS, 1% Nutridoma-SP and 250 µM oleic acid, 5% fatty acid free BSA. The 
low-serum medium contains less than 1 µM sphingomyelin (Hanada et al., 1992). 
Myriocin was added in this phase as indicated and cell viability was quantified by Trypan 
Blue exclusion. Cells were then incubated at 39 °C for 72 hours before T. gondii, purified 
as above (3.9), were added at a ratio of 2 parasites to 1 host cell and allowed to invade for 
4 hours. Subsequently, after washing with PBS, cells were incubated for a further 24 hours 
in normal or serum reduced media before assay. 
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3.18.2 Invasion assay 
To establish the ability of the parasites to invade the various host cells under the 
experimental conditions the cells were fixed with methanol at -20°C for 10 minutes, dried, 
stained with 300 nM DAPI in PBS for 5 minutes and rinsed with PBS. Visualization on an 
Olympus
®
 1X-71 epifluorescent microscope allowed invasion to be scored in 100 host 
cells. 
 
3.18.3 Proliferation assay 
After the 4 hour invasion time 1.0 µ Ci of [5,6-
3
H] uracil was added per well and cultures 
incubated for 24 hours as before. Incorporation of [
3
H] uracil into trichloroacetic acid 
(TCA)-precipitable material was measured after this period. Supernatant was removed 
from the cells by aspiration, and then they were solubilised with 800 µl of 1% (w/v) SDS 
containing 100 µg of unlabelled uracil/ ml. 2.4  ml of 0.3 M TCA was then added and, 
after a 15 minute incubation at 4 °C, precipitates were collected on to glass fibre using a 
sampling manifold. The filters were washed twice with 0.3 M TCA and once with 95% 
ethanol, dried, placed in 10 ml of scintillation cocktail and the incorporated radioactivity 
then measured. Confluent non-infected cells incorporated very little [
3
H] uracil and the 
values of these were subtracted from the readings with infected cells to ensure 
measurements reflected parasite proliferation. 
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3.19 IMMUNOLOCALISATION OF TGSLS 
3.19.1 Transfection of Toxoplasma gondii 
Parasites were maintained in VERO cells and isolated by filtration as described above 
(3.9). After counting using a haemocytometer the T. gondii cells were transiently 
transfected with pT8myc-Tg SLS-Ty (Appendix III) as described by Weiss and Kim 
(2008). Briefly, parasites were resuspended in complete cytomix at 3.3 x 10
7
/ ml. 300 l of 
this was then mixed with 100 l of plasmid DNA (50-100 g) in cytomix in a 2 mm gap 
electroporation cuvette. This was electroporated with a single pulse of 1.5 kV, a resistance 
setting of 25 Ω and a capacitor setting of 25 F using a BTX BCM630 electroporator. 
Parasites were transferred to the confluent VERO cell cultures in 12 well plates with 
coverslips and incubated for 24-36 hours at 37 C. 
 
3.19.2  Immunolocalisation 
Transfected intracellular parasites were fixed with a solution of 1 ml of formaldehyde 
(37%), 0.4 g sucrose and 19 ml of water for 30 minutes at room temperature. Cells were 
blocked and permeabilised in 2.5% FBS and 0.2% Triton X 100 in PBS for 30 minutes. 
The primary antibody (anti-Ty antibody, BB2) was prepared at a 1:100 concentration in 
2.5% FBS and 0.1% Triton X100 and applied to the cells for 1 hour at room temperature. 
Coverslips were then washed 3 times with PBS for 5 minutes each and the secondary 
antibody, anti-mouse IgG (594 Alexa Fluor), applied (1:100 in 2.5% FCS and 0.1% Triton 
X100) for 1 hour. After washing as before the coverslips were stained with 300 nM DAPI 
in PBS for 5 minutes and rinsed with PBS. Coverslips mounted on a slide with 5 l of 
mounting solution and the edges sealed with a nail varnish before visualisation on an 
Olympus
®
 1X-71 epifluorescent microscope and image capture using QImaging Retiga 
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camera and OpenLab Improvison software. Images were subsequently manipulated using 
Adobe Photoshop. 
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4 THE ROLE OF HOST CELL SPHINGOLIPID BIOSYNTHESIS IN 
T. GONDII PROLIFERATION 
Although the parasitophorous vacuole (PV) does not intersect directly with the host 
vesicular trafficking pathways, Toxoplasma gondii remains dependent on host cells for a 
number of critical nutrients. Significant progress has been made in the understanding of the 
mechanisms T. gondii uses to scavenge nutrients from its host, especially in the case of 
lipid molecules (Bottova et al., 2009).  For example, it appears likely that when synthesis 
of host phosphatidylcholine (PC, a phosphoglycerolipid) is restricted T. gondii scavenge 
host choline and synthesize PC de novo (Charron and Sibley, 2002).  
 
T. gondii has also been demonstrated to synthesize sphingolipids de novo - the 
incorporation of tritiated serine into sphingolipid species demonstrated the presence of an 
active serine palmitoyltransferase (Tg SPT) (Azzouz et al., 2002; Pratt et al., in 
preparation). Serine was also incorporated into sphingomyelin (SM) and glycosphingolipid 
(GSL) species (Azzouz et al., 2002). However, the role of sphingolipids in host-pathogen 
interactions and pathogenesis remains unknown.   
 
To begin to understand the role of host sphingolipid synthesis in T. gondii pathogenesis 
Chinese Hamster Ovary (CHO) cells with a temperature sensitive (ts) SPT were used as 
hosts (Hanada et al., 1990). In this cell line, SPB-1, the LCB1 subunit of SPT is 
thermolabile and sphingolipids are depleted approximately 99% at the non-permissive 
temperature (39 C) when the cells are grown with reduced sera. Similar studies have 
demonstrated that the bacterium Chlamydia trachomatis is unable to replicate within these 
cells showing that host biosynthesis of sphingolipids is essential for intracellular growth of 
this pathogen (van Ooij et al., 2000). 
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Proliferation of T. gondii within SPB-1 cells, and the parental and LCB1 cDNA 
complemented lines as controls, was measured as described in Materials and Methodology. 
Briefly, before invasion, host cells were incubated for 24 hours in 10% FCS HAM media 
followed by 72 hours in 10% FCS or serum-reduced HAM media. In the same media T. 
gondii (strain RH, 2 parasites to 1 host cell) were then allowed to invade for 4 hours before 
washing and incubating for a further 24 hours. T. gondii proliferation was established by 
measuring [
3
H]-uracil incorporation (into RNA) during this time period, host incorporation 
into non-infected cells was subtracted. Notably, because they are confluent and non-
dividing incorporation of uracil into host cells is very low. To establish the role of host 
sphingolipids in T. gondii cell invasion, the numbers of infected cells were scored using 
microscopy after staining DNA using DAPI. Such experiments determined whether host 
sphingolipid biosynthesis is important for invasion and proliferation of T. gondii.  
 
All experiments were performed in triplicate at the SPB-1 permissive (33 C) and non-
permissive (39 C) temperatures. All results normalised with respect to controls- 
proliferation and invasion in parental CHO cells in the presence of 10% FCS. 
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Figure 4-1: Cells were cultured in 10% FCS or in serum reduced media at the permissive 
temperature (33 C). T. gondii proliferation in the SPT-compromised host cells (SPB-1) 
and control lines (CHO-K1 and SPB-cLCB1) was established. No difference in parasite 
proliferation was apparent in the three host cell lines. T. gondii proliferation was monitored 
by incorporation of [
3
H] uracil. All results were normalised with respect to T. gondii 
proliferation in wild type CHO-K1 cells in the presence of 10% FCS and expressed as % of 
CHO-K1 in 10% FCS media on the y axis.   
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Figure 4-2: Cells were cultured in 10% FCS or in serum reduced media at the non-
permissive temperature (39 C). In the serum reduced media parasite proliferation in the 
SPT- compromised host cells (SPB-1) was decreased compared to the control lines (CHO-
K1 and SPB-cLCB1). This effect was ablated by the presence of 10% FCS. All results 
normalised with respect to proliferation in parental CHO cells in the presence of 10% FCS. 
T. gondii proliferation was monitored by incorporation of [
3
H] uracil. All results were 
normalised with respect to T. gondii proliferation in wild type CHO-K1 cells in the 
presence of 10% FCS and expressed as % of CHO-K1 in 10% FCS media on the y axis. 
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Figure 4-3: Repeating the above experiment in the serum reduced media at the non-
permissive temperature of 39 C but in the presence or absence of 50 M myriocin, a 
specific inhibitor of the mammalian SPT. Myriocin at this concentration was shown to be 
non-toxic under the assay conditions by Trypan Blue exclusion assay (data not shown). T. 
gondii proliferation was monitored by incorporation of [
3
H] uracil. All results were 
normalised with respect to T. gondii proliferation in wild type CHO-K1 cells in the 
presence of 10% FCS and expressed as % of CHO-K1 in 10% FCS media on the y axis. 
Myriocin inhibits host SPT, similar effect to SPB-1 mutant. Notably, in the presence of this 
inhibitor reduced parasite proliferation in the parental and complemented CHO cells to 
levels seen in the SPB-1 mutant. Myriocin had no effect on proliferation in the mutant 
CHO cells. 
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Figure 4-4: To ensure that the effects observed above were due to the role of host 
sphingolipid biosynthesis on proliferation, rather than a defect in invasion, the numbers of 
infected cells was established under the same conditions as above in serum reduced media 
at the non-permissive temperature of 39 C. The effects of 50 M myriocin were also 
established. After DAPI staining and microscopy as described above, 100 host cells of 
each line were scored for the presence or absence of T. gondii parasites. The results are 
expressed as % of cell infected on the y axis. This clearly demonstrated that host SPT 
function and sphingolipid biosynthesis play no apparent role in invasion and the 
differences observed above were due to a defect in proliferation. 
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SUMMARY 
Taken together these results indicate that host sphingolipid biosynthesis plays a role in 
parasite proliferation but not invasion. Although the presence of large quantities of sera, 
and the complex lipids contained within, ablates this indicating that the T. gondii is able to 
scavenge sphingolipid from the extracellular environment. However, even in reduced sera 
media proliferation was still ~70% of that in wild type and complemented mutant CHO 
cells indicating that the parasite de novo sphingolipid biosynthetic pathway is likely to play 
an important role in pathogenicity. 
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5 EXPLORING T. GONDII COMPLEX SPHINGOLIPID 
BIOSYNTHESIS 
As discussed above T. gondii has been demonstrated to synthesize sphingolipids de novo 
with the tritiated serine being incorporated into complex sphingolipid proposed to be 
incorporated into the phosphosphingolipid SM (Azzouz et al., 2002). The presence of SM 
was later confirmed in a lipidomic analysis using mass spectrometry although it is less 
prominent than in host mammalian cells (Welti et al., 2007). This approach also uncovered 
ethanolamine phosphorylceramide (EPC) as a relatively abundant phosphosphingolipid in 
the parasites, approximately 100-fold more abundant than in the host where this lipid 
species is rare (Welti et al., 2007). However, it should be noted that this work could not 
distinguish between parasite lipids synthesized de novo and those scavenged from the host 
cell (Welti et al., 2007). In a further study, employing metabolic labelling, the non-
mammalian phosphosphingolipid, inositol phosphorylceramide (IPC), was proposed to be 
present (Sonda et al., 2005). Despite this progress the identity of the enzyme(s) responsible 
for the synthesis of the T. gondii phosphosphingolipid remained unknown. 
 
5.1 IDENTIFICATION OF THE T. GONDII SPHINGOLIPID SYNTHASE (TG 
SLS)                                                                                 
5.1.1  Identification of the hypothetical protein Tg SLS 
BLAST search of the (then) incomplete genome database (toxodb.org) with the predicted 
Plasmodium falciparum sphingomyelin synthases (Pf SMS 1 and Pf SMS 2 - PFF1210w 
and PFF1215w; Huitema et al., 2004) identified one hypothetical protein in T. gondii 
representing a candidate functional orthologue. Tg SLS (50.m03113 chromosome 14) had 
a predicted molecular weight of 47 kDa and demonstrated 28% identity, 47% similarity to 
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Pf SMS 1 and 27% identity, 55% similarity to Pf SMS 2. BLAST analysis of Tg SLS 
against the NCBI protein database showed that the hypothetical protein had 23% identity 
and 38% similarity to the human SMS 1 (Huitema et al., 2004). Subsequently, based on 
primary sequence analyses, 50.m03164 was also proposed as the Tg SLS by Welti et al., 
(2007). The predicted amino acid sequence of this predicted protein indicates that it 
possess multiple transmembrane domains (Figure 5-1). 
 
Figure 5-1: Predicted protein sequence of hypothetical protein 50.m03113 (Tg SLS) with 8 
predicted transmembrane domains (red) and the sphingolipid synthase conserved domains 
D 1-4 (bold underlined) (Huitema et al., 2004). 
 
MPRTEMAESDSKGLPAEEDQVPALWATVHSVKFYLGRFVLATLYVFTCVYLMCLCSVASD 
TFFDPRTQKSLPDRIHDQMLDSKPLFFATPFVVDAVTVGIIIVTIFRHAAFLKVPLNLLV 
GTRFLFLLGSLYMCRGIAIIITTVPPSRRNCVPPPVMSVGSFFYLGVLQMFSMRNECTGM 
IISGHSTITCCCMATWLLYGNANREDQDTKGVLFYEVARFLATRLQKVRASARQLTTQYA 
ITPAFDVEEGSETVPQAESEEELSSASGVFVQEDRRKTRVAAFLRLNLLRSLCLVVGVVN 
LCLIVCSFNHYSIDVFMALNFTFGAWCLYHCILSLIWAEKEERDKRQKVALLRSEGIAAG 
AATDSDADALSEASTVSSLESGALVTGSTVKKAEPPNPPKENKPGFSAINFPLVRIGVSI 
VRAIEGL 
 
Further analyses of the conserved domains demonstrated the conservation of D1-4 in Tg 
SLS (Figure 5-2). Within D3 and D4 are the 3 residues (2 histidines, H and an aspartate, D) 
defining the catalytic triad that are conserved in evolution and essential for function 
(Huitema et al., 2004; Denny et al., 2006).  
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Figure 5-2: Protein sequence alignment of D1, D2, D3 and D4 from Hs SMS 1 and 2, Pf 
SMS 1 and 2 and Tg SLS. The residues highlighted in red are identical; those in green 
strongly similar; in blue weakly similar. The 3 residues of the predicted catalytic triad 
within D3 and D4 are designated by *. 
 
   D1     D2     
 
HsSMS1 PLPD   RRFFCIVGTLYLYRCITMYVT 
HsSMS2 PLPD   RRFCFILGTLYLYRCITMYVT 
PfSMS1 PLKD   IRIILLLSFIYCIRSFFIYVT 
PfSMS2 PLSD   CRFLYIVGSFYIIRGLLIYVT 
TgSLS SLPD   TRFLFLLGSLYMCRGIAIIIT 
      D3    D4 
          *  *   *  
HsSMS1 CGDYLYSGHT HYTVDVVVAYYITTRLFWWYH 
HsSMS2 CGDFLFSGHT HYTIDVIIAYYITTRLFWWYH 
PfSMS1 CTDLVISGHT HYTVDVLMGYVFGGSVFLFYH 
PfSMS2 CADLIVSGHS HYTSDVLLGIIFGVFMFSFYH 
TgSLS CTGMIISGHS HYSIDVFMALNFTFGAWCLYH 
  
The predicted topology of Tg SLS is shown in Figure 5-3. Like the Leishmania, human and 
other sphingolipid synthases it is a transmembrane protein (Denny et al., 2006; Huitema et 
al., 2004). However, Tg SLS is predicted to possess 8 rather than 6 transmembrane 
domains. Despite this difference the catalytic triad (2 H, 1 D) is arranged at one membrane 
face as in related enzymes. The figure shows the arrangement predicted at the Golgi.  
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Figure 5-3: Predicted membrane topology of the Tg SLS at the Golgi membrane with the 
catalytic triad oriented towards the Golgi lumen. 
 
5.1.2 Tg SLS is a functional orthologue of the S. cerivisiae AUR1 
Previous work in the laboratory had constructed and used an engineered yeast strain 
(YPH499-HIS-GAL-AUR1) with the essential IPC synthase (AUR1p) under the control of 
a galactose promotor (Denny et al., 2006). In the presence of galactose as the carbon 
source the yeast could express AUR1 and grow. However, with glucose AUR1 expression 
was suppressed and the yeasts were non-viable unless complemented by AUR1 or a 
functional orthologue. This approach allowed the identification of the Leishmania major 
IPC synthase (Denny et al., 2006). Using this approach the ability of Tg SLS to 
complement this line was established. 
 
Since Tg SLS did not have introns in its coding sequence the open reading frame was 
amplified by PCR directly from genomic DNA and cloned into the yeast expression vector 
pRS426MET (URA) creating pRS426Tg SLS. This vector was transformed into YPH499-
HIS-GAL-AUR1 and clones selected by their ability to grow in the absence of uracil and 
the presence of glucose (Figure 5-4). 
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Figure 5-4: Successful complementation of YPH499-HIS-GAL-AUR1 by pRS426Tg SLS. 
Growth of the yeast is supported on SGR (galactose as carbon source) with pRS426Tg SLS 
(Tg SLS), a positive control – pRS426Sc AUR1 (Sc AUR1) and a negative control – empty 
pRS426 (pRS). In contrast only pRS426Tg SLS and the positive control could grow on SD 
(glucose as carbon source).  
 
 
 
This complementation indicated that Tg SLS is a functional orthologue of AUR1. 
 
To begin to establish the role of the AUR1 functional orthologue Tg SLS, the 
complemented YPH499-HIS-GAL-AUR1 mutant yeast was metabolically labelled with 
NBD C6 ceramide when grown in SD (non-permissive media; Figure 5-5).  
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Figure 5-5: Separation by HPTLC of lipids extracted from YPH499-HIS-GAL-AUR1 
yeast transformed with various plasmids following metabolic labelling using NBD C6 
ceramide with either glucose (SD) or galactose (SGR) as carbon sources. The positive 
control, YPH499-HIS-GAL-AUR1 pRS426 Sc AUR1 synthesized IPC as expected when 
grown in non-permissive SD. In contrast, the mutant complemented by Tg SLS synthesized 
a product that migrates with IPC and a second, minor, product migrating with SM. The 
negative control of the mutant containing empty vector pRS426 synthesized no products 
when incubated in non-permissive SD, but IPC synthase activity was restored in 
permissive SGR. Similarly labelled mammalian VERO cells served as markers for GSL, a 
putative EPC and SM. O is the origin, ceramide (CER) is at the front. 
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This indicated that Tg SLS supports the synthesis of IPC correlating with its status as a 
functional orthologue of AUR1. However, it also catalysed the synthesis of a product co-
migrating with SM, supporting previous evidence for the synthesis of this species in T. 
gondii (Azzouz et al., 2002). There is no evidence that Tg SLS drives the formation of 
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EPC, which has been identified as a major phosphosphingolipid in the parasite (Welti et 
al., 2007). 
 
The presence of IPC has previously been proposed on the basis on metabolic labelling with 
tritiated inositol and analyses of synthesized lipid species following mild alkaline treatment 
(Sonda et al., 2005). In this same study, electron microscopy analyses of T. gondii-infected 
HFF treated with 10 μg/ ml of aureobasidin A (Ab A) for 24 hours showed severe 
alterations in the parasite-containing vacuoles, with an increase in T. gondii vacuolization 
and a loss of intracellular structures leading to cell death (Sonda et al., 2005). Ab A is a 
potent antibiotic active against a variety of pathogenic fungi shown to inhibit IPC synthase.  
 
Based on the anti-protozoal effect of Ab A Sonda et al., (2005) proposed a putative T. 
gondii IPC synthase as the Ab A target. Having isolated a functional orthologue of the S. 
cerevisae AUR1 the sensitivity of Tg SLS was analysed by diffusion assay (Figure 5-6). 
The sphingolipd bypass mutant AGD was used as a negative control. AGD is able to grow 
without synthesizing sphingolipids and therefore is able to tolerate loss-of-function 
mutations in both serine palmitoyltransferase and IPC synthase (Nagiec et al., 1997). 
Myriocin is an inhibitor of SPT mediating the first step in sphingolipid biosynthesis, Ab A 
inhibits the IPC synthase of S. cerevisiae and, perhaps, T. gondii (Sonda et al., 2005).  
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Figure 5-6: Agar diffusion assays of YPH499-HIS-GAL-AUR1 complemented with Sc 
AUR1 or Tg SLS.  AGD yeast lacking functional SPT and AUR1 was the negative control. 
Volumes of 1, 2 and 3µl of Myriocin, aureobasidin A and DMSO spotted on to yeast 
plates. As expected, Sc AUR1 was sensitive to myriocin (Myr) and aureobasidin A at 
25µM and 100µM (Ab A25 and Ab A100) whilst the AGD was insensitive to both 
inhibitors. Interestingly, Tg SLS was resistant to Ab A at both concentrations but was 
hyper-sensitive to myriocin as evidenced by large zones of exclusion. 
 
 
 
These results showed that Tg SLS conferred Ab A resistance to the yeast. The hyper-
sensitivity to myriocin resembled that seen in the same mutant yeast complemented by the 
Leishmania major IPC synthase (Denny et al., 2006). The reasons for this are unknown but 
perhaps reflect a suboptimum functionality of the protozoan sphingolipid synthases in the 
yeast making the complemented lines more sensitive to upstream inhibition of sphingolipid 
biosynthesis (myriocin and SPT). 
 
To confirm the Ab A resistance properties of Tg SLS, pRS426Tg SLS was transformed 
into wild type yeast, YPH499, and was empty pRS426 as a control. The growth of these 
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was analysed on SD-URA with or without Ab A. YPH499-HIS-GAL-AUR1 pRS426Tg 
SLS was also analysed as a further control (Figure 5-7). 
 
Figure 5-7: YPH499 transformed with pRS426Tg SLS or empty pRS426 and YPH499-
HIS-GAL-AUR1 (HGA) pRS426Tg SLS streaked onto SD-URA with or without 4.5 µM 
Aureobasidin A (Ab A). Tg SLS confers Ab A resistance to YPH499. 
  
 
 
Together the data in Figures 5-6 and 5-7 clearly indicate that Tg SLS is insensitive to Ab A 
suggesting that the anti-protozoal effects observed with this drug (Sonda et al., 2005) are 
not due to inhibition of this enzyme. 
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5.2 BIOCHEMICAL ANALYSES OF TG SLS 
Given the observation that Tg SLS appears to support the synthesis of 2 products (IPC and 
SM) biochemical analyses were necessary to fully establish its functionality. Utilising the 
Tg SLS complemented yeast microsomes were isolated and used in biochemical assays as 
described in Materials and Methodology. Incubating the microsomes with FL C5 ceramide 
as described lead to the formation of complex lipid products that could be analysed after 
fractionation by HPTLC. FL C5 ceramide was used in this experiment due to its stability 
relative to NBD C6 ceramide and the enhanced labelling of T. gondii parasites seen as a 
result (Figure 5-8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 05: EXPLORING T. GONDII COMPLEX SPHINGOLIPID BIOSYNTHESIS 
 
121 
 
Figure 5-8: HPTLC separation of lipids after incubation of isolated microsomes, whole 
parasites (Toxo) and mammalian (VERO) cells with FL C5 ceramide. Microsomal material 
from Sc AUR1 yeast produced IPC as expected, Tg SLS microsomes lead to the formation 
of one product migrating with IPC and another with SM (arrows). This was in agreement 
with the metabolic labelling in Figure 5.5. Isolated metabolically labelled T. gondii (Toxo) 
produced 3 major complex sphingolipid products predicted to be GSL, EPC and SM. This 
result was in agreement with previous analyses (Azzouz et al., 2002; Welti et al., 2007). 
However, a fourth minor product was also apparent co-migrating with IPC (arrow). O is 
the origin, ceramide (CER) is at the front. 
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These data support those in Figure 5-5 and indicate that Tg SLS is a dual function enzyme 
catalysing the production of both IPC and SM. In addition, the synthesis of the 
phosphosphingolipids SM, EPC and IPC is indicated in isolated, intact T. gondii parasites. 
Whilst Tg SLS may be involved in the synthesis of SM and IPC there was no evidence of it 
having a role in EPC production. 
 
To further understand this dual functionality the microsomes were washed with CHAPS to 
reduce or remove contaminating substrate associated with microsomal membranes, in this 
case ceramide, phosphatidylinositol (PI) and phosphatidylcholine (PC). CHAPS is a 
zwitterionic detergent used to solubilize biological macromolecules such as proteins 
(Garner, Smith and Hoper, 2007). It is used as a non-denaturing solvent in the process of 
protein purification and is especially useful in purifying membrane proteins, such as Tg 
SLS, which are often sparingly soluble or insoluble in aqueous solution due to their native 
hydrophobic cellular environment (Aeed et al., 2004). The washed microsomal fractions 
could then be reacted with different donor substrates (PI, PE or PC) singly or in 
combination and fluorescent NBD C6 ceramide, the acceptor substrate (Figure 5-9). 
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Figure 5-9: HPTLC separation of lipids after reaction of CHAPS-washed microsomes with 
NBD C6 ceramide and either no donor substrate (-) or PI, PE or PC, or combinations of 
these. Only the addition of PI led to increase in the production of a product, this migrated 
with IPC. The addition of PE and PC did not lead to any significant increase in product 
formation. The addition of PE and PC in combination or with PI has no additional effect. 
PI - phosphatidyl inositol, PE - phosphatidyl ethanolamine, PC - phosphatidyl choline, O - 
origin of solvent front, ceramide (CER) is at the front. 
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These results indicate that Tg SLS only functions as an IPC synthase in this assay since 
only PI is functional as a donor substrate. In addition, unlike the similarly functional 
Trypanosoma brucei orthologue (Chapter 6; Mina et al., 2009) neither PE nor PC were 
significantly inhibitory (as quantified after scanning) suggesting they are not competitive 
binders. Intriguingly, the addition of PC alone lead to a small apparent increase in IPC 
production. To investigate further the experiment was repeated 3 times. The fluorescence 
intensity of IPC was quantified with each of the 3 donor substrates (Figure 5-10).  
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Figure 5-10: IPC produced in in vitro assay with no donor substrate (B), 
phosphatidylinositol (PI), phosphatidylethanolamine (PE) or phosphatidylcholine (PC). 
AFU – Arbitrary Fluorescence Units). Mean of 3 independent experiments, standard 
deviation indicated. 
 
These data revealed no apparent increase in the production of IPC (or any other products) 
apart from on the addition of PI as donor substrate. This confirmed that Tg SLS functions 
as an IPC synthase. However, given the observation that Tg SLS appears to catalyse the 
formation of SM (Figures 5-5 and 5-8), the failure of the enzyme to utilise PC as donor 
substrate is surprising. All donor substrates employed were from bovine liver extracts, 
mixed natural product for PC the predominant species is C36:2. In contrast, S. cerevisiae, 
where Tg SLS appears to function as an SM synthases, possesses predominantly C32:2 and 
C34:2 PC (Boumann et al., 2003). To investigate whether these shorter lipids are accepted 
preferentially by Tg SLS, C28:2, C30:2 and C32:2 PC were assayed. None of these 
functioned as donor substrates for SM production (data not shown) and any SM synthase 
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role of the enzyme remains unclear. 
 
To further analyse the resistance of Tg SLS to Ab A inferred from cellular assays (Figure 
5-6 and 5-7) CHAPS-washed microsomes with PI were pre-incubated with a series of 
concentrations of Ab A (0 - 200 µM) before the addition of acceptor substrate, NBD C6 
ceramide (Figure 5-11). 
 
Figure 5-11: Inhibitory effect of aureobasidin A (Ab A) on Tg SLS assayed in vitro.  
Fluorescence intensity of IPC was established following fractionation by HPTLC and 
normalised with respect to a control (0 µM Ab A). Mean of 3 independent experiments, 
standard deviation indicated. 
 
 
IPC production was diminished by approximately 40% in the presence of 50 µM Ab A. 
However, there was no significant impact when the concentration of Ab A was increased 
in the assay. Correlating with cellular assays Tg SLS is relatively resistant to the potent 
fungal IPC synthase inhibitor, Ab A. This demonstrates that Tg SLS, and by extension IPC 
synthesis, is not the target of Ab A in T. gondii as previously proposed (Sonda et al., 
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2005). It is possible that the effects of Ab A against T. gondii noted by Sonda et al., (2005) 
were due to other, non-specific, modes of actions as previously noted for the kinetoplastid 
intracellular pathogen, T. cruzi (Figueiredo et al., 2005; Salto et al., 2003). 
 
5.3 CONFIRMATION OF THE PRESENCE OF IPC IN T. GONDII 
TACHYZOITES 
As mentioned above metabolic labelling of T. gondii tachyzoites with tritiated inositol, 
followed by analysis the lipids synthesized by HPTLC, revealed the presence of a lipid 
proposed to be IPC (Sonda et al., 2005). The results above identify the Tg SLS and 
confirm it functions as an IPC synthase. In addition, FL C5 ceramide labelling of T. 
gondii tachyzoites demonstrated the presence of a synthesized sphingolipid co-migrating 
with IPC (Figure 5-8). However, the metabolic labelling studies described here and 
previously do not provide definitive evidence of the presence of IPC in T. gondii parasites. 
In order to confirm the presence of this parasite specific lipid species further analyses are 
required using mass spectrometry. These studies were carried out in collaboration with Dr 
Sabrina Sonda (Zurich) and Dr Josefina Casas (Barcelona) by liquid chromatography-mass 
spectrometry (LC-MS) analysis (Munoz-Olaya et al., 2008) of lipids extracted from T. 
gondii (RH strain) and host cells (MEF).  
 
Briefly, Toxoplasma gondii were harvested from infected MEF host cells by passage 
through a 26-gauge needle and purified by separation on Sephadex-G25 columns 
(Amersham). Sphingolipid extracts were prepared as described (Merrill et al., 2005) and 
analysed using the Waters Aquity UPLC (Ultra Performance Liquid Chromatography) 
system connected to a Waters LCT Premier orthogonal accelerated time of flight mass 
spectrometer (Waters, Millford, MA) (Bottova et al., 2009) operated in negative 
electrospray ionization to detect IPC (Denny et al., 2004). Positive identification of IPC 
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was based on the accurate mass measurement with an error <5 ppm and its LC retention 
time (Bottova et al., 2009). The resultant spectra are shown in Figure 5-12. 
  
Figure 5-12: (A). Analyses of fractions from UPLC column, x-axis is time in minutes that 
fractions are eluted from the column. Fractions containing mass of 778.523, mass of 
hypothetical IPC, were detected in the negative ion spectra. Whilst the T. gondii lipids 
demonstrated a fraction with this mass, the same fraction from the mammalian MEF host 
cells lacks this species. 
(B). Mass spectrometry analyses of this fraction showed a good match with the 
hypothetical species expected from IPC. 778.5239 and a protonated species, 779.5273. The 
elemental composition report strongly suggested that this represented IPC: formula C40 
H77 N O11 P, IPC C18:1/C16:0. 
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These data confirm the presence of IPC in T. gondii tachyzoites and correlate with the 
identification of Tg SLS, an enzyme which functions as an Ab A resistant IPC synthase. A 
previous lipidomic analysis of T. gondii tachyzoites had failed to identify IPC (Welti et al., 
2007). Notably, this study did not fractionation the material prior to mass spectrometry 
analyses perhaps leading to minor species being undetected. 
 
5.4 THE SUBCELLULAR LOCALISATION OF T. GONDII 
The Golgi apparatus is regarded as the primary site for phosphosphingolipid synthesis and, 
for example, human SM synthase has been localised here (Huitema et al., 2004). To begin 
to establish the localisation of Tg SLS in T. gondii tachyzoites the open reading frame was 
cloned into the expression vector pT8 with a C-terminal TY epitope tag (Appendix III). 
Transient transfection of this plasmid into T. gondii as described in Materials and 
Methodology, allowed the localisation of Tg SLS using a specific monoclonal antibody 
provided by Prof Keith Gull, Oxford (Figure 5-13).  
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Figure 5-13: Epi-fluorescent microscopy image of Tg SLS-TY stained with a specific 
monoclonal antibody (B, red). 4‟, 6-diamidino-2-phenylindole (DAPI) stain was used to 
stain the nuclei to visualise the parasites (A, blue). C- overlay of images of A and B 
showing the tachyzoite nuclei and the localisation of Tg SLS-TY into distinct foci (arrow).   
 
 
 
The distinct structures in which Tg SLS resides may represent the Golgi apparatus. 
However, further analyses (co-localisation with known markers and / or immuno-electron 
microscopy) will be required to confirm this. 
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SUMMARY 
Tg SLS was identified as an AUR1 functional orthologue conferring Ab A resistance to S. 
cerevisiae. However, unlike AUR1, Tg SLS was able to produce 2 complex sphingolipids: 
a major species co-migrating with IPC and a minor species co-migrating with SM. 
Biochemical analyses confirmed that the enzyme functions as a true IPC synthase and that 
this action is Ab A resistant. However, SM synthase (or EPC synthase activity) could not 
be constituted in vitro. These 2 species had previously been identified as major T. gondii 
phosphosphingolipids in lipidomic analyses (Welti et al., 2007). The presence of IPC has 
only been inferred from metabolic labelling studies (Sonda et al., 2005). LC-MS analyses 
in this study have confirmed the presence of IPC in the parasite, although perhaps as only a 
minor species. Therefore, the Tg SLS is proposed to function as an IPC synthase in vivo, 
with this activity likely to be localised to the Golgi apparatus. 
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6 OTHER SPHINGOLIPID SYNTHASES 
6.1 MAMMALIAN SPHINGOMYELIN SYNTHASES (HS SMS)  
The predominant sphingolipid in mammals is sphingomyelin (SM) which is formed by the 
transfer of phosphocholine from the donor substrate phosphatidylcholine (PC) to the 
acceptor substrate ceramide. The enzyme responsible for this is SM synthase which has 2 
isoforms in human cells, Hs SMS 1 and Hs SMS 2 (Huitema et al., 2004). These isoforms 
are both transmembrane proteins maintaining the four evolutionarily conserved domains, 
D1-4, and the catalytic triad essential for functionality (Figure 6-1, Hs SMS 1 as an 
example). However, whereas Hs SMS 1 is Golgi localized, Hs SMS 2 is found at the 
plasma membrane. Neither these enzymes were demonstrated to function as IPC synthases 
(Huitema et al., 2004). 
 
Figure 6-1: Protein coding sequence of Hs SMS 1 with 6 transmembrane domains (red 
underlined), active site residues (bold) and conserved domains (D1-4 grey highlight). Hs 
SMS 2 shares this structure. 
MKEVVYWSPKKVADWLLENAMPEYCEPLEHFTGQDLINLTQEDFKKPPLCRVSSDNGQ 
 
RLLDMIETLKMEHHLEAHKNGHANGHLNIGVDIPTPDGSFSIKIKPNGMPNGYRKEMI 
                     D1 
KIPMPELERSQYPMEWGKTFLAFLYALSCFVLTTVMISVVHERVPPKEVQPPLPDTFF 
              D2     
DHFNRVQWAFSICEINGMILVGLWLIQWLLLKYKSIISRRFFCIVGTLYLYRCITMYV 
               D3 
VTTLPVPGMHFNCSPKLFGDWEAQLRRIMKLIAGGGLSITGSHNMCGDYLYSGHTVML 
              D4 
TLTYLFIKEYSPRRLWWYHWICWLLSVVGIFCILLAHDHYTVDVVVAYYITTRLFWWY 
 
HTMANQQVLKEASQMNLLARVWWYRPFQYFEKNVQGIVPRSYHWPFPWPVVHLSRQVK 
 
YSRLVNDT 
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6.2 DO HS SMS 1 OR HS SMS 2 RESCUE THE YEAST AUR1 MUTANT? 
The Hs SMS 1 and Hs SMS 2 open reading frames were amplified from cDNA cloned (Dr 
Joost Holthuis, Utrecht) and ligated into the pRS426MET yeast expression vector. 
However, on transformation neither pRS426Hs SMS 1 nor pRS426Hs SMS 2 
complemented the YPH499-HIS-GAL-AUR1 yeast (Denny et al., 2006) indicating that 
SM synthase activity alone is not sufficient to rescue the mutant (Figure 6-2). As described 
in Chapter 3, in YPH499-HIS-GAL-AUR1 yeast the essential IPC synthase (AUR1) is 
under the control of a galactose promotor and, therefore, will not grow in the presence of 
the suppressor glucose. This auxotrophic mutation can be overcome by complementation 
as shown in Chapter 3. 
 
Figure 6-2: YPH499-HIS-GAL-AUR1 transformed with pRS426 Hs SMS 1 and pRS426 
Hs SMS 2 and grown on permissive (SGR, Galactose) and non-permissive (SD, Glucose) 
media. Hs SMS 1 and Hs SMS 2 transformed yeast only grew in the presence of galactose, 
as did yeast transformed with empty vector (pRS). In contrast Sc AUR 1 complemented 
yeast could grow on SD media (in the presence of glucose). 
 
 
CHAPTER 06: OTHER SPHINGOLIPID SYNTHASES 
 
136 
 
Although the human enzymes are known to be functional when expressed in yeast 
(Huitema et al., 2004) it is clear that expression cannot compensate for the loss of AUR1. 
Therefore, it is likely that IPC itself is essential for yeast survival and growth. 
 
6.3 TRYPANOSOMA BRUCEI SPHINGOLIPID SYNTHASES (Tb SLS) 
6.3.1 Identification of Tb SLS 
Trypanosoma brucei is an insect vector-borne kinetoplastid protozoan parasite related to 
the Leishmania species. Both of these parasites cause neglected tropical diseases (NTDs), 
African sleeping sickness (African trypanosomiasis) and leishmaniasis, respectively. Four 
gene sequences (accession numbers Tb09211.1000, Tb09.211.1010, Tb09.211.10 and 
Tb09.211.1030) were first identified by Denny et al., (2006) in the genome database 
(genedb.org) as sequence orthologues of the Leishmania major IPC synthase (Lmj IPCS), a 
putative drug target. Like Lmj IPCS and Tg SLS (Chapter 5), Tb SLS possess the 
conserved D1, D2, D3 and D4 domains first identified in the SM synthase family (Denny 
et al., 2006; Sutterwala et al., 2008).  
 
One of the predicted T. brucei SLS isoforms (Tb09.211.1000; Tb SLS 4) was the focus of 
this study. In addition, the isoform most distant from Tb SLS 4 with respect to the internal 
variable domain (Tb09.211.1030; Tb SLS 1) was also subjected to preliminary analyses 
(Mina et al., 2009). 
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6.3.2 Tb SLS 1 and Tb SLS 4 are functional orthologues of AUR1 
Tb SLS 1 and Tb SLS 4 open reading frames were amplified from genomic T. brucei Lister 
427 and ligated into the pRS426MET yeast expression vector. Unlike the mammalian SMS 
isoforms above, both the T. brucei orthologues complemented the YPH499-HIS-GAL-
AUR1 mutant yeast line indicating that they are functional orthologues of AUR1p (Figure 
6-3).  
 
Figure 6-3: Transformation with pRS426Tb SLS 4 and pRS426Tb SLS 1, as well as 
pRS426Sc AUR1, rescue the auxotrophic mutant YPH499-HIS-GAL-AUR1 allowing it to 
grow in non-permissive SD (glucose containing) media. As expected empty pRS426 did 
not complement the auxotrophic mutant. However, all lines are viable in the absence of 
glucose and the presence of galactose (SGR). 
 
 
 
To begin to understand the full function of Tb SLS 1 and Tb SLS 4, the complemented 
YPH499-HIS-GAL-AUR1 mutants were metabolically labelled with NBD C6 ceramide 
when grown in SD (non-permissive media; Figure 6-4).  
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Figure 6-4: Separation by HPTLC of lipids extracted from YPH499-HIS-GAL-AUR1 
yeast transformed with various plasmids following metabolic labelling using NBD C6 
ceramide in non-permissive SD (glucose as the carbon source). As expected Sc AUR1 
complemented yeast synthesize only labelled IPC. However, in contrast Tb SLS 1 and Tb 
SLS 4 synthesized two predominant sphingolipid species, one of which co-migrated with 
IPC, the other with SM. In addition, in Tb SLS 4 complemented yeast a minor labelled 
species was evident which co-migrated with the predicted EPC detected in labelled 
mammalian VERO cells. O, origin; IPC, inositol phosphorylceramide; SM, sphingomyelin; 
EPC, ethanolamine phosphorylceramide; CER, ceramide (migrating at the front). 
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Tb SLS 1 and Tb SLS 4 complemented YPH499-HIS-GAL-AUR1 yeast were shown to 
synthesize two major labelled lipid species. One of these co-migrated with SM, the other 
with IPC. The latter at levels equivalent to those produced in the AUR1 complemented 
yeast (Figure 6-4). In addition, Tb SLS 4 complemented yeast synthesized a third species 
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co-migrating with the putative EPC produced by labelled VERO cells. Notably, unlike 
IPC, SM is known to be present in the pathogenic blood stream form of the parasite 
(Patnaik et al., 1993). IPC is found in insect stage procyclic parasites (Guther et al., 2006).  
 
Given this lifecycle distribution Tb SLS 4 was chosen for further study due to the relative 
predominance of the SM-like species in the labelled complemented yeast. Importantly, the 
SM-like species proved to be susceptible to sphingomyelinase (SMase; which breaks down 
SM into phosphorylcholine and ceramide) when lipid extracts were treated with this 
enzyme, thereby confirming its identity (Figure 6-5 A). The putative EPC was also 
sensitive which is may be not surprising given the structural similarity between the head 
groups species, choline (C5H14NO) and ethanolamine (C2H7NO).  
 
In contrast the IPC produced was insensitive to this enzyme treatment. Extracts from the 
auxotrophic mutant expressing Hs SMS 2, which produce an equivalent quantity of 
labelled SM under permissive conditions (SGR), acted as a control for SMase activity. As 
a further control YPH499-HIS-GAL-AUR1 cells harbouring an empty vector (pRS426) 
were cultured in both permissive (SGR) and non- permissive (SD) media. Both lines grew 
equivalently in both media for 16 h and for a further 8 h after dilution to an optical density 
0.3 OD600, and remained viable. Labelling of these dividing cells with NBD C6 ceramide in 
their respective media under the same conditions as above demonstrated that in non-
permissive SD no labelled IPC is produced, demonstrating the down-regulation of AUR1p 
(Figure 6-5 B). 
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Figure 6-5: (A) Sphingomyelinase (SMase) treatment of lipids extracted from YPH499-
HIS-GAL-AUR1 complemented with Tb SLS 4, grown in SD and labelled with NBD C6 
ceramide demonstrated that the predicted SM species is SMase sensitive, as is the putative 
EPC. In contrast the predicted IPC is insensitive. As a control, YPH499-HIS-GAL-AUR1 
expressing Hs SMS 2, grown in permissive galactose (SGR media) was utilized as they 
produce equivalent quantities of labelled SM to the Tb SLS 4 line.  
(B) The yeast IPC synthase (AUR1) is down-regulated in YPH499-HIS-GAL-AUR1 cells 
transformed with empty vector (pRS426) incubated in non-permissive SD under the same 
conditions as the SMase treated samples.  
NBD C6 ceramide labelled lipid extracts fractionated by HPTLC, representative of at least 
three independent experiments. O, origin; IPC, inositol phosphorylceramide; SM, 
sphingomyelin; EPC, ethanolamine phosphorylceramide; CER, ceramide (migrating at the 
front). All lipid extracts normalised with respect to cell mass. 
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These data indicated that Tb SLS 4 is capable of synthesizing IPC, SM and EPC making it 
a novel tri-functional enzyme. In addition, it has been demonstrated to function as a 
„reverse‟ IPC synthase, releasing ceramide from IPC at the expense of DAG (Mina et al., 
unpublished). In this it resembles the human SM synthases (Huitema et al., 2004). 
However, biochemical analyses of microsomal extracts only demonstrated IPC synthase 
activity, neither SM nor EPC synthase function was reconstituted (Mina et al., 2009). The 
A B 
CHAPTER 06: OTHER SPHINGOLIPID SYNTHASES 
 
143 
 
reasons for this remain unclear, particularly since in competition analyses the bovine liver 
derived donor substrates PC and PE were both shown to inhibit IPC synthase function, 
indicating that they bind to the enzyme. 
 
A parallel study, using a Leishmania expression system, defined Tb SLS 4 as a dual-
functional SM / EPC synthase and, importantly, confirmed by inhibition RNA (RNAi) our 
laboratory‟s observations (Mina et al., 2009) that the T. brucei enzymes are essential and 
so represent a new drug target for the NTD caused by these protozoa (Sutterwala et al., 
2008). Subsequent work elsewhere used a cell-free system to analyse the function of all 4 
Tb SLSs and defined Tb SLS 1 as the primary IPC synthase, Tb SLS 2 as an EPC synthase 
and Tb SLS 3 and 4 as the primary SM synthases (Sevova et al., 2010). 
 
6.4 THE TRYPANSOMA CRUZI  IPC SYNTHASE, Tc IPCS 
6.4.1 Identification of Tc IPCS 
The insect vector carried kinetoplastid Trypanosoma cruzi is the causative agent of 
Chaga‟s disease (American trypanosomiasis). T. cruzi is known to synthesize IPC, the non-
mammalian phosphosphingolipid, via a previously unidentified IPC synthase found in all 
stages of its lifecycle (Figueiredo et al., 2005). However, two very closely related (minor 
polymorphisms in allelic genes) orthologues of the Tb SLSs have now been identified in 
the genome database (genedb.org; Tc IPCS 1.1 - Tc00.1047053506885.124 and Tc IPCS 
1.2 - Tc00.1047053510729.290; Denny et al., 2006). Again like Lmj IPCS, Tb SLS and Tg 
SLS (Chapter 5), Tc IPCS 1.1 and 1.2 possess the conserved D1, D2, D3 and D4 domains 
first identified in the SM synthase family (Denny et al., 2006; Sutterwala et al., 2008).  
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6.4.2 Tc IPCS is a functional orthologues of AUR1 
Tc IPCS open reading frames were amplified from genomic T. cruzi Lister 427 and ligated 
into the pRS426MET yeast expression vector. A single clone was chosen and sequence 
analysis revealed it to be Tc IPCS 1.2, Tc IPCS 1.1 was not analysed. Like the T. brucei 
orthologues Tc IPCS 1.2 complemented the YPH499-HIS-GAL-AUR1 mutant yeast line 
indicating that the T. cruzi enzymes are functional orthologues of AUR1p (Figure 6-6).  
 
Figure 6-6: Tc IPCS 1.2 complemented the yeast AUR1 auxotrophic mutant YPH499-HIS-
GAL-AUR1. Auxotrophic mutant yeast transformed with pRS426 either empty or bearing 
Sc AUR1 or Tc IPCS 1.2 and grown under permissive (SGR, galactose containing) or non- 
permissive conditions (SD, glucose containing). pRS426 - mutant yeast with empty 
pRS426MET25, AUR1 - mutant yeast with Sc AUR1; Tc IPCS - mutant yeast with Tc 
IPCS 1.2. 
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To ascertain the function of Tc IPCS 1.2 (and by extension Tc IPCS 1.1) the complemented 
YPH499-HIS-GAL-AUR1 mutants were metabolically labelled with NBD C6 ceramide 
when grown in SD (non-permissive media; Figure 6-7).  
 
Figure 6-7: Separation by HPTLC of lipids extracted from YPH499-HIS-GAL-AUR1 
yeast transformed with various plasmids following metabolic labelling using NBD C6 
ceramide in non-permissive SD (glucose as the carbon source). As expected Sc AUR1 
complemented yeast synthesize only labelled IPC. Similarly, Tc IPCS 1.2 synthesized a 
single sphingolipid species co-migrating with IPC. The yeast IPC synthase (AUR1) is 
down-regulated in YPH499-HIS-GAL-AUR1 cells transformed with empty vector 
(pRS426) incubated in non-permissive SD, but is expressed when assayed following 
growth in permissive SGR (galactose as the carbon source) under the same conditions.  
O, origin; IPC, inositol phosphorylceramide; CER, ceramide (migrating at the front). 
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6.4.3 Biochemical analyses of Tc IPCS 1.2 
To confirm the functionality of Tc IPCS 1.2 biochemical analyses were performed as for T. 
gondii Tg SLS (Chapter 5). In brief, complemented yeast microsomes were isolated, 
washed with the zwitterionic detergent CHAPS to remove endogenous substrate and used 
in biochemical assays as described in Materials and Methodology. These microsomes, 
together with identically treated material from Sc AUR1 complemented mutant yeast, were 
incubated with acceptor substrate NBD C6 ceramide and with or without donor substrate 
phosphatidylinositol (Figure 6-8). 
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Figure 6-8: HPTLC separation of lipids after incubation of isolated CHAPS-washed 
microsomes from Tc IPCS 1.2 and Sc AUR1 complemented YPH499-HIS-GAL-AUR1 
with acceptor substrate NBD C6 ceramide and with no donor substrate (-) or with 
phosphatidylinositol (PI). Tc IPCS 1.2 function is dependent on the addition of PI. As 
previously noted Sc AUR1 does not function with the bovine liver PI employed here (Mina 
et al., 2009). O, origin; IPC, inositol phosphorylceramide; CER, ceramide (migrating at the 
front). 
 
 
These data demonstrate that the T. cruzi SLS orthologue functions as a true IPC synthases. 
A subsequent study elsewhere has supported this finding (Tc IPCS 1.1; Sevova et al., 
2010). In this it resembles Leishmania species rather than the more closely related T. 
brucei. This may be hypothesized to be due to the intracellular stages of the lifecycle 
shared by T. cruzi and Leishmania species. In contrast, T. brucei is an extracellular 
parasite. 
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6.5 THE ARABIDOPSIS IPC SYNTHASE, At IPCS 
6.5.1 Identification of At IPCS 1, At IPCS 2 and At IPCS 3 
Despite the presence of IPC and IPC synthase activity being long known in plant species 
(Bromley et al., 2003) the enzyme(s) responsible for synthesis remain unidentified. A 
homology search of the Arabidopsis genome database (Arabidopsis.org) with the protein 
sequence of the protozoan IPC synthase from Leishmania major (Lmj IPCS; Denny et al., 
2006) identified open reading frames encoding three highly related sequence orthologues 
named as Arabidopsis IPC synthase 1 (At IPCS 1 – At3g54020.1), At IPCS 2 
(At2g37940.1) and At IPCS 3 (At2g29525.1) demonstrating 26%, 29% and 31% identity to 
the protozoan protein. Subsequently, At IPCS 2 has been isolated, characterised and 
designated ERH1 (Wang et al., 2008). 
 
6.5.2 At IPCS 1, At IPCS 2 and At IPCS 3 are functional orthologues of AUR1 
The open reading frames of At IPCS 1, At IPCS 2 and At IPCS 3 were cloned from cDNA 
into pRS426MET25 to create pRS426At IPCS 1-3. All three restored the growth of the 
AUR1 auxotrophic mutant YPH499-HIS-GAL-AUR1, as did the ectopic expression of Sc 
AUR1 (Figure 6-9). Therefore, At IPCS 1-3 serve as functional orthologues of the fungal 
AUR1p. 
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Figure 6-9:  At IPCS 1-3 complemented a yeast AUR1 auxotrophic mutant YPH499-HIS-
GAL-AUR1. Auxotrophic yeast transformed with pRS426 either empty or bearing Sc 
AUR1 or At IPCS 1-3 and grown under permissive (SGR, galactose as carbon source) or 
non-permissive conditions (SD, glucose as carbon source). pRS426 - mutant yeast with 
empty pRS426MET25, Sc AUR1 - mutant yeast with Sc AUR1; At IPCS 1-3 - mutant 
yeast with At IPCS 1-3. 
 
 
 
The At IPCS1 complemented YPH499-HIS-GAL-AUR1 mutants were subsequently 
metabolically labelled with NBD C6 ceramide when grown in SD (non-permissive media; 
Figure 6-10).  
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Figure 6-10: Separation by HPTLC of lipids extracted from YPH499-HIS-GAL-AUR1 
yeast transformed with various plasmids following metabolic labelling using NBD C6 
ceramide in non-permissive SD (glucose as the carbon source). As expected Sc AUR1 
complemented yeast synthesize only labelled IPC, as did the wild type control YPH499. 
Similarly, At IPCS 1 synthesized a single sphingolipid species co-migrating with IPC. The 
yeast IPC synthase (AUR1) is down-regulated in YPH499-HIS-GAL-AUR1 cells 
transformed with empty vector (pRS426) incubated in non-permissive SD, but is expressed 
when assayed following growth in permissive SGR (galactose as the carbon source) under 
the same conditions. IPC, inositol phosphorylceramide; CER, ceramide (migrating at the 
front). 
 
 
 
These data indicated that At IPCS 1 is an IPC synthase like the fungal Sc AUR1, although 
its turnover appeared low when compared to controls. These observations were 
subsequently confirmed by biochemical assay of At IPCS 1, 2 and 3 (Mina et al., 2010). 
Together with Wang et al., 2008 this work identified the key missing link in plant 
sphingolipid biosynthesis. 
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6.6 THE AUREOBASIDIN A SENSITIVITY OF IDENTIFIED SPHINGOLIPID 
SYNTHASES 
Aureobasidin A (Ab A) is a specific fungal IPC synthase inhibitor (Nageic et al., 1997). 
The efficacy of Ab A was established against Tb SLS 4, Tc IPCS 1.2 and At IPCS 1 by 
diffusion assay of YPH499-HIS-GAL-AUR1 complemented yeast. Sc AUR1 
complemented YPH499-HIS-GAL-AUR1 served as a positive control (Figure 6-11). 
 
Figure 6-11: Agar diffusion assays of YPH499-HIS-GAL-AUR1 complemented with Sc 
AUR1, Tb SLS 4, Tc IPCS 1.2 or At IPCS 1. Ab A at 25 µM, 100 µM and vehicle (DMSO) 
were applied in 1, 2 and 3µl volumes. As expected Sc AUR1 was sensitive to Ab A at both 
concentrations. However, both Tc IPCS 1.2 and At IPCS 1, like Tg SLS (Chapter 5), were 
insensitive to Ab A. Interestingly, Tb SLS 4 was sensitive to Ab A at both concentrations. 
 
 
 
Lmj IPCS complemented yeast are relatively refractory to Ab A (Denny et al., 2006), so 
perhaps the insensitivity of the T. cruzi enzyme to this drug is unsurprising. However, the 
sensitivity of Tb SLS 4 clearly indicates divergence, although the primary sequence data 
provided no clue as to the molecular mechanism of sensitivity / resistance. Although, 
notably T. brucei bloodstream form parasites were also sensitive to Ab A (Mina et al., 
2009; Sevova et al., 2010). In addition, microsomal assay indicated that the IC50 of Tb SLS 
4 is < 1 nM (Mina et al., 2009). Extracts from wax beans showed IPC synthase to be 
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similarly Ab A sensitive, < 1 nM (Bromley et al., 2003). In contrast At IPCS 1-3 has been 
shown by diffusion (Figure 6-11) and biochemical assay (Mina et al., 2010) to be Ab A 
resistant. This indicated that subtle features of these evolutionarily divergent IPC synthases 
define Ab A sensitivity / resistance. 
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SUMMARY 
These data clearly demonstrate that SM synthesis alone (from Hs SMS 1 or 2) is not able 
to compensate for the lack of IPC synthase activity in the auxotrophic AUR1 mutant, 
YPH499-HIS-GAL-AUR1 (Figure 6-2). This indicated that the IPC synthase function of 
Tg SLS that complements for the AUR1 defect (Chapter 5).  
 
Like T. gondii the kinetoplastid parasite Trypanosoma brucei (the causative agent of 
African sleeping sickness, African trypanosomiasis) has been shown to possess both SM 
(Patnaik et al., 1993) and IPC (Guther et al., 2006). The identification of orthologues of the 
characterised Leishmania IPC synthase (Denny et al., 2006) allowed analyses of the T. 
brucei enzymes. Both Tb SLS 1 and Tb SLS 4 complement the YPH499-HIS-GAL-AUR1 
mutant indicating that they possess a functional IPC synthase (Figure 6-3). However, like 
Tg SLS, both produce products co-migrating with IPC and SM markers, Tb SLS 4 also 
synthesizes a sphingolipid co-migrating with EPC (Figure 6-4). Analysis confirmed that 
the product from Tb SLS 4 was SM (Figure 6-5), but in vitro studies demonstrated only 
IPC synthase activity (Mina et al., 2009). In this Tb SLS 4 resembled Tg SLS and the SM 
synthase action of both remains unclear, although analyses elsewhere have indicated that 
Tb SLS 4 is the principle SM synthase in T. brucei and Tb SLS 1 the primary IPC synthase 
(Sevova et al., 2010). 
 
Notably unlike the closely related T. brucei enzymes, the Trypanosma cruzi (Chaga‟s 
disease, American trypanosomiasis) orthologue functioned only as an IPC synthase, as 
demonstrated by metabolic labelling (Figure 6-7) and biochemical analysis (Figure 6-8). Is 
this it resembled the related Leishmania (Denny et al., 2006) and distant Arabidopsis 
(Figure 6-10; Mina et al., 2010) enzymes? No indication of the basis for the functional 
diversity of the T. brucei enzyme compared to closely related kinetoplastid orthologues is 
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apparent from the primary sequence data. However, this diversity was further evidenced by 
the sensitivity of Tb SLS 4 to aureobasidin A (Ab A), a potent inhibitor of the fungal 
enzyme (Figure 6-11; Mina et al., 2009). In contrast, the Leishmania (Denny et al., 2006) 
and T. cruzi (Figure 6-11) enzymes are resistant to Ab A. This result was surprising, 
however it should be noted that whilst the Arabidopsis IPC synthase is resistant to the drug 
(Figure 6-11; Mina et al., 2010) the enzyme from wax beans is, like Tb SLS 4, acutely 
sensitive (Bromley et al., 2003). 
 
Therefore the molecular basis of Ab A sensitivity / resistance and IPC / SM / EPC synthase 
function remains unknown. However, the functional characterisation of orthologues from 
mammals, plants, protozoa and fungi should facilitate further detailed studies in the future. 
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7 THE EVOLUTION OF THE EUKARYOTIC SPHINGOLIPID 
SYNTHASE 
As discussed above the identified T. gondii and P. falciparum sphingolipid synthases share 
conserved domains (1-4) with the previously identified animal SMS‟s (Huitema et al., 
2004) and kinetoplastid protozoan SLS‟s (Denny et al., 2006; Sutterwala et al., 2008). 
Domains 3 and 4 contain the residues forming the catalytic triad of the enzyme and these, 
but not domains 1 and 2, are conserved in both fungi and plants (Mina et al., 2010 a). This 
lack of domains 1 and 2 has been hypothesized to be related to the use of ceramide by the 
animal and kinetoplastid enzymes compared with phytoceramide by plants and fungi 
(Mina et al., 2010 a). However, there is no evidence for this.  
 
The catalytic triad believed to form from domains 3 and 4 promotes nucleophilic attack on 
lipid phosphate ester bonds, this is thought to lead to the transfer of choline- or inositol 
phosphate from phosphoglycero lipids to ceramide or phytoceramide to form SM and IPC 
respectively. The conservation of the catalytic triad in the eukaryotic SLSs indicates that 
they share a common mechanism of action and are likely to have evolved from a common 
ancestor. Conversely, the prokaryotic SMS lacks an identifiable catalytic triad and is likely 
to have evolved independently (Luberto et al., 2003).  Previous phylogenetic analyses have 
shown that the plant, kinetoplastid, animal and plant SLS‟s form distinct but related clades. 
Given the functional identification of the apicomplexan SLS in this study it was decided to 
repeat the analysis with the addition of the T. gondii and P. falciparum sequences. 
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7.1 PHYLOGENETIC ANALYSES OF THE EUKARYOTIC SPHINGOLIPID 
SYNTHASES 
7.1.1 Sequence alignment 
Predicted protein sequences from representative animal, plant, fungal and protozoan 
species were selected from the genome databases.  Following an initial Clustal W 
alignment of the complete protein sequences a region of relative conservation was chosen 
for further analyses, this represented amino acids 92 to 362 of the identified T. gondii 
enzyme. This region contained the conserved domains 1-4 of the animal SMS‟s. 
Realigning the conserved region using Clustal W gave the alignment shown in Figure 7-1. 
 
Figure 7-1: Sequence alignment of a region of the eukaryotic SLS corresponding to amino 
acids 92-362 of the T. gondii enzyme (Tg SLS). In the mammalian SMS‟s this region 
contains the conserved domains 1-4. Domain 1, domain 2, domain 3 and domain 4 are 
illustrated in Hs SMS 1 and in the apicomplexan sequences. The 2 histidine (H) and 
aspartate (D) residues forming the catalytic triad are highlighted in bold in all proteins. The 
human lipophosphate phosphatase (Hs LPP 1), a hydrolase, is predicted to possess the 
same mode of action with respect to a catalytic triad (Sigal et al., 2005). In these analyses 
Hs LPP 1 functions as an out group, i.e. a protein that is related but of a different family 
that allows the consideration of the evolution of SLS evolution. 
Homo sapiens LPP 1 (out group) accession number: O14494; T. gondii SLS: 50.m03113; 
P. falciparum SMS 1&2: PFF1210w and PFF1215w; Arabidopsis thaliana IPCS 1-3: 
At3g54020.1, At2g37940.1, At2g29525.1; T. brucei SLS 1-4: Tb09.211.1030, 
Tb09.211.1020, Tb09.211.1010, Tb09.211.1000; T. cruzi IPCS 1&2: 
Tc00.1047053506885.124, Tc00.1047053510729.290; L. major IPCS: LmjF35.4990; 
Aspergillus fumigatus AUR1p: AAD22750; Candida albicans AUR1p: AAB67233; 
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Pneumocystis carinii AUR1p: CAH17867; Saccharomyces cerevisiae AUR1p: 
NP_012922; Schizosaccharomyces pombe AUR1p: Q10142; Caenorhabditis elegans 
SMS1-3: Q9U3D4, AAA82341, AAK84597; Homo sapiens sapiens SMS 1&2: 
AB154421, Q8NHU3; Mus musculus SMS 1&2: Q8VCQ6, Q9D4B1. 
 
TbSLS2     ERMPDPKVTK PLPDLGFELL TKVPGMYVLA DCCIGFLNIL SVFTAFKLYL  
TbIPC4     ERMPDPKVTK PLPDLGFELL TKVPGMYVLA DCCIGFLNIL SVFTAFKLYL  
TbIPC3     ERMPDPKVTK PLPDLGFELL TKISFLSVVT DVLIAFLSSL SFFTLWKLYL  
TbIPC1     --MPDPKVTK PLPDLGFEVL HKYPFLFSVA DCCIGFLNIL SVFTAFKLYL  
TcIPC1     ARMPDPKVVR PLPDIGFEVF PKVGWLEHVT DVCIFILNFL SLLVAFKLYL  
TcIPC2     ARMPDPKVVR PLPDIGFEVF PKVGWLEHLT DVCIFILNFL SLLVVFKLYL  
LmIPCS     ARMPDPEKVR PLPDLLLESI PKVALLENGT NVIIFLLNAT TVVVGFKVFL  
HsSMS1     GMPNGYRK-- EMIKIPMPEL ERSQYPMEWG KTFLAFLYAL SCFVLTTVMI  
MmSMS1     GMPNGFRK-- EMIKIPMPEP ERSQYPMEWG KTFLAFLYAL SCFVLTTVMI  
HsSMS2     GLRKGTKKYP DYIQIAMPTE SRNKFPLEWW KTGIAFIYAV FNLVLTTVMI  
MmSMS2     GLRKGAKKYP DYIQISMPND SKNKFPLEWW KTGIAFVYAL FNLILTTVMI  
AtIPC1     EITTEIGLLA ENWKYLLAGL LCQYIHGLAA RGVHYIHRPG PTLQDSGFFV  
AtIPC3     EITTEIGRLA ENWKYLLAGI LCQDIHGLAA KGGHDIHRPG TTLQDSGFFV  
AtIPC2     EISTEIGLLA ENWKYLLAGL ICQYIHGLAA KGVHYIHRPG PTLQDLGFFL  
AfAUR1     FTLLLVSLLL PITRQFFLPF LPIAGWLIFF YACQFIPSDW RPAIWVRVLP  
SpAUR1     ACLLAIALTV PLTRQIFFPA IVIITWAILF YSCRFIPERW RPPIWVRVLP  
PcAUR1     VLLYVLLLIF PITRMFFRPF LPIVSWLILF YACRFIPSSM RPHIWISILP  
CaAUR1     ILAFATCFLI PLTSQFFLPA LPVFTWLALY FTCAKIPQEW KPAITVKVLP  
ScAUR1     YCFLGTLFII PATSQFFFNA LPILTWVALY FTSSYFPDDR RPPITVKVLP  
CeSMS1     PLLPDEGPSH AVRLEMPGDK PASPHDRFPK TPLKTLVAFL MLVVAAAGNT  
CeSMS2     INIDPIDPEP TPIRKEFTCE DTFHHEHHGN SEGFKTLTAF LCLMLSAFLN  
CeSMS3     MGSVSKTVIS ARGASPDDEQ NGTKNGISNG SEWAKCIFLF FFLFIAGMSN  
PfSMS1     YFEGQENIKK SVEIKNCPYK KKMLKIFLRR LVCATIIGII GICIQCYFII  
PfSMS2     MSNISISRNS TINEEEILSE YRLCKILLIK LMFALLFLLI ALIIQGFFMI  
TgSLS      VVDAVTVGII IVTIFRHAAF LKVPLNLLVG TRFLFLLGSL YMCRGIAIII  
HsLPP1     SRHTPFQRGV FCNDESIKYP YKEDTIPYAL LGGIIIPFSI IVIILGETLS  
 
TbSLS2     LHRHCVGSGE PELPCNIPGV SRFFLSVWLC KENCR----- IELRNVHTIA  
TbSLS4     LHRHCVGSGE PELPCNIPGV SRFFLSVWLC KENCR----- IELRNVHTIA  
TbSLS3     LHRHCVGSGE PELPCNIPGV SRFFLSVWLC KENCR----- IELRNVHTIA  
TbSLS1     LHRHCVGSGE PELPCNIPGV SRFFLSVWLC KENCR----- IELRNVHTIA  
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TcIPC1     LHRQNEGLDE LQPFSCCPLI GKIIFGVWDR GRQSG----- IEKRDAHLIV  
TcIPC2     LHRQNEGLDE LQPFSCCPLI GKIIFGVWDS GRQSG----- IEKRDAHLIA  
LmjIPC     LERHMNGLPR VTFLVGVPKI GSFLNRMAFG VLDSGRRP-- FPLKNVFPIM  
HsSMS1     SVVHERVPPK EVQPPLPDTF FDHFNRVQWA FSICEING-- MILVGLWLIQ  
MmSMS1     SVVHERVPPK EVQPPLPDTF FDHFNRVQWA FSICEING-- MILVGLWLFQ  
HsSMS2     TVVHERVPPK ELSPPLPDKF FDYIDRVKWA FSVSEING-- IILVGLWITQ  
MmSMS2     TVVHERVPPK ELSPPLPDKF FDYFDRVKWA FSVSEING-- MVLVGLWITQ  
AtIPC1     LPELGQDKGF ISETVFTCVF LSFFLWTFHP FIVKS----- --KKIYTVLI  
AtIPC3     LPELGQHKGF ISETAVTCGF PSVFLGTSQP FIVKS----- --KKIYTVLI  
AtIPC2     LPELGQERSY ISETVFTSVF LSFFLWTFHP FILKT----- --KKIYTVLI  
AfAUR1     ALENILYGAN ISNILSAHQN VVLDVLAWLP YGICHYGA-- PFVCSAIMFI  
SpAUR1     TLENILYGSN LSSLLSKTTH SILDILAWVP YGVMHYSA-- PFIISFILFI  
PcAUR1     TLENILYGVR LSSLLSNHTH FFLDILAWIP YGIIHFGA-- PFITAIVIYL  
CaAUR1     AMETILYGDN LSNVLATITT GVLDILAWLP YGIIHFSF-- PFVLAAIIFL  
ScAUR1     AVETILYGDN LSDILATSTN SFLDILAWLP YGLFHFGA-- PFVVAAILFV  
CeSMS1     ITLSWIHERY PLTPPLPDIV FELIPKIPWG LRLCENLM-- IGSFVSLLVL  
CeSMS2     FFLLTVIHDV VPRQPLPDLT FMIIPQQRWA WSVGDVLS-- TVSSVVAFTI  
CeSMS3     WAVLAYTHDY VPRESLPDIV FSLVSEQRWA SSLGDFCV-- ALCIVMLGAL  
PfSMS1     LSDTYYKTGD EPLKDRLHEI FKEIPAFMNT PFVNGSIMFF LAITLLRFGL  
PfSMS2     YSDSYYKSNT QPLSDRIHDL FG-NPPKWIS YKLSNTLIAI LTLSFLKIIL  
TgSLS      TTVPPSRRNC VPPPVMSVGS FFYLGVLQMF SMRNECTGMI ISGHSTITCC  
HsLPP1     VYCNLLHSNS FIRNNYIATI YKAIGTFLFG AAASQSLT-- ----------  
 
 
TbSLS2     WI-------- --RFITSYAL LLLFRSVVIV MTSLPAPDDL CQ--DPPKIE  
TbSLS4     WI-------- --RFITSYAL LLLFRSVVIV MTSFPAPDDL CQ--NPPKIE  
TbSLS3     WI-------- --RFITSYAL LLLFRSLVIV MTSMPTPVDK CQ--NPPKIE  
TbSLS1     WI-------- --RFITSYAL LLLSRSVIMV VTSLPNPDDL CQ--DPPKIE  
TcIPC1     WI-------- --RYFTTYFI VMLFRAIVVV MTSYPATDNH CQ--NPVKIT  
TcIPC2     WI-------- --RYFTTYFI VLLFRAIVVV MTSYPATDNH CQ--NPMKIT  
LmjIPC     AI-------- --RFLTSYAV VMVFRAFVIM GTSYPATDNH CQ--NPQVIE  
HsSMS1     WLLLKYKSII SRRFFCIVGT LYLYRCITMY VTTLPVPGMH FN--CSPKLF  
MmSMS1     WLLLKYKSII SRRFFCIVGT LYLYRCITMY VTTLPVPGMH FN--CSPKLF  
HsSMS2     WLFLRYKSIV GRRFCFIIGT LYLYRCITMY VTTLPVPGMH FQ--CAPKLN  
MmSMS2     WLFLRYKSIV GRRFFFIMGT LYLYRCITMY VTTLPVPGMH FQ--CAPKLN  
AtIPC1     WC-------- --RVLAFLVA CQFLRVITFY STQLPGPNYH CR--EGSELA  
AtIPC3     WC-------- --RVLAFLVA CQFLRVITFY STQLPGPNYH CR--EGSELA  
AtIPC2     WC-------- --RVLAFLVA CQFLRVITFY STQLPGPNYH CR--EGSKVS  
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AfAUR1     FGPPGTVPLF ARTFGYISMA AVTIQLFFPC SPPWYENLYG LA--PADYSM  
SpAUR1     FAPPGTLPVW ARTFGYMNLF GVLIQMAFPC SPPWYENMYG LE--PATYAV  
PcAUR1     SSPPGTLPVF AKCFGYLNLI GVIIQLVFPC SPPWYESLYG SQ--LANYSM  
CaAUR1     FGPPTALRSF GFAFGYMNLL GVLIQMAFPA APPWYKNLHG LE--PANYSM  
ScAUR1     FGPPTVLQGY AFAFGYMNLF GVIMQNVFPA APPWYKILYG LQ--SANYDM  
CeSMS1     ILFHRHRWIV LRRLCFIGSI LYGMRCITMM VTPVPKADED FE--CSPRFG  
CeSMS2     IFLHHQRWIV LRRTFLLGAI MYGLRAVILG VTFLPPSFHN RDEICQPQVN  
CeSMS3     LVIHQHRGTI LKRVVFCAGT LYAMRSVTLA ATQLPSGYTD NQGRCRDQVE  
PfSMS1     FCPLLLSITI LIRIILMLSF IYCIRSFFIY VTTLPCPIPT CQPLKHKTLV  
PfSMS2     FNSIYLSIAI ICRFLYIVGS FYIIRGLLIY VTSLPATLET CLPLESGNFL  
TgSLS      CMATWLLYGN ANREDQDTKG VLFYEVARFL ATRLQKVRAS ARQLTTQYAI  
HsLPP1     ---------- ----DIAKYS IGRLRPHFLD VCDPDWSKIN CSDGYIEYYI  
 
TbSLS2     NPVKNVILTV ---------- --LTAGGGSI HCGDLMYSGH TVILTLHLMF  
TbSLS4     NPVKNVILTV ---------- --LTAGGGSI HCGDLMYSGH TVILTLHLMF  
TbSLS3     NPVKNVILTV ---------- --LTAGGGSI HCGDLMYSGH TVILTLHLMF  
TbSLS1     NRVKDVILTV ---------- --LTAGAGSI HCGDLMYSGH TVILTLHLMF  
TcIPC1     NPVKNVIMTL ---------- --VTFGSGFI HCGDLMFSGH TVPITLSLLV  
TcIPC2     NPVKNVIMTL ---------- --VTFGSGSI HCGDLMFSGH TVSITLSLLV  
LmjIPC     HPVLNVILTL ---------- --VTLGSGAI HCGDLMFSGH TMILSLAFIL  
HsSMS1     GDWEAQLRRI MKLIAGGG-- --LSITGSHN MCGDYLYSGH TVMLTLTYLF  
MmSMS1     GDWEAQVRRI MKLIAGGG-- --LSITGSHN MCGDYLYSGH TVMLTLTYLF  
HsSMS2     GDSQAKVQRI LRLISGGG-- --LSITGSHI LCGDFLFSGH TVTLTLTYLF  
MmSMS2     GDSQAKIQRI LRLISGGG-- --LSITGSHI LCGDFLFSGH TVVLTLTYLF  
AtIPC1     RLPRPHNVLE VLLLNF---- ----PRGVIY GCGDLIFSSH MIFTLVFVRT  
AtIPC3     RLPRPHNVLE VLLLNF---- ----PRGVIY GCGDLIFSSH MIFTLVFVRT  
AtIPC2     RLPWPKSALE VLEIN----- ----PHGVMY GCGDLIFSSH MIFTLVFVRT  
AfAUR1     PGNPAGLARI DELFG----- --IDLYTSGF RQSPVVFGAF PSLHAADSTL  
SpAUR1     RGSPGGLARI DALFG----- --TSIYTDGF SNSPVVFGAF PSLHAGWAML  
PcAUR1     GGSAGGLARI DSFFG----- --TKVYTSIF PASPLVFGAF PSLHSGHATL  
CaAUR1     HGSPGGLGRI DKLLG----- --VDMYTTGF SNSSIIFGAF PSLHSGCCIM  
ScAUR1     HGSPGGLARI DKLLG----- --INMYTTAF SNSSVIFGAF PSLHSGCATM  
CeSMS1     ENATFSLIVM RGVWSMFGLG LNLFDNQKVV LCGDYIYSGH TLVLVVSALF  
CeSMS2     RTAMYGMEIA TRFLTYVIT- LGLTSGQDKI LCGDLMFSGH TVVLTIMYFV  
CeSMS3     SEAGVFFGRL FEQTIRIG-- ---FQSKDQM LCGDLLFSGH TLVMVTCSLA  
PfSMS1     ENLYTFYLII ---------- -----TAQVY ECTDLVISGH TAFTTLLTFF  
PfSMS2     FNLLQIIKIN ---------- -----TNLVY VCADLIVSGH SFSTTIFLMF  
TgSLS      TPAFDVEEGS ---------- -----ETVPQ AESEEELSSA SGVFVQEDRR  
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HsLPP1     CRGNAERVKE ---------- -----GRLSF YSGHSSFSMY CMLFVALYLQ  
 
 
TbSLS2     HWIYGAMVH- --WSFRPVVT VVAIFGYYCI VASRFHYTDD VLVAIYLTIA  
TbSLS4     HWIYGAMVH- --WSFRPVVT VVAIFSYYCI VASRFHYTDD VLVAIYLTIA  
TbSLS3     HWIYGAMVH- --WSFRPVVT VVAIFGYYCI VASRSHYTDD VLVAIYLTIA  
TbSLS1     HWIYGAMVH- --WSFRPVVT VVAIFGYYCI VASRFHYTDD VLVAIYLTIA  
TcIPC1     QWIYGSMLH- --WVFRPASV LLVLLSFYSI IASRSHYTDD ILVSFYITVT  
TcIPC2     QWIYGSMLH- --WVFRPASV LLVLLSFYSI IASRSHYTDD ILVSFYITVT  
LmjIPC     AWDYSPFLHP --WAVRVWVS VLLPISYYCI LASRSHYTDD ILVAMYVMIA  
HsSMS1     IKEYSPRRL- --WWYHWICW LLSVVGIFCI LLAHDHYTVD VVVAYYITTR  
MmSMS1     IKEYSPRRL- --WWYHWICW LLSVVGIFCI LLAHDHYTVD VVVAYYITTR  
HsSMS2     IKEYSPRHF- --WWYHLICW LLSAAGIICI LVAHEHYTID VIIAYYITTR  
MmSMS2     IKEYSPRHF- --WWYHLVCW LLSAAGIICI LVAHEHYTVD VIIAYYITTR  
AtIPC1     YQKYGSKRF- ----IKLLGW VIAILQSLLI IASRKHYTVD VVVAWYTVNL  
AtIPC3     YQKYGSKRF- ----IKLLGW VIAILQSLLI IASRKHYTVD VVVAWYTVNL  
AtIPC2     YQKYGTKRF- ----IKLFGW LTAIVQSLLI IASRKHYSVD VVVAWYTVNL  
AfAUR1     AALFMSQVF- --PRLKPLFV IYTLWMWWAT MYLSHHYAVD LVGGGLLATV  
SpAUR1     EALFLSHVF- --PRYRFCFY GYVLWLCWCT MYLTHHYFVD LVGGMCLAII  
PcAUR1     EALFLSCIF- --PKTTPYFV IYVLWLWWCT MYLTHHYFID LIGGSCLAVF  
CaAUR1     EVLFLCWLF- --PRFKFVWV TYASWLWWST MYLTHHYFVD LIGGAMLSLT  
ScAUR1     EALFFCYCF- --PKLKPLFI AYVCWLWWST MYLTHHYFVD LMAGSVLSYV  
CeSMS1     IGEYSPRRF- --YILHWLSW LVCSVGVIFL VLSHGHYTID VILSYFACTR  
CeSMS2     QLQYTPRGL- --VILRYIAA PITFLGIAAL VVSGGHYTMD VLIAYWLTSH  
CeSMS3     VAYYLPKSI- --KPLQWVSH VACLIGMICM TISRTHYTID VVIAYWLSNM  
PfSMS1     WFFYERNIY- ----VKTTIF LYSIYIYIII IISRFHYTVD VLMGYVFGGS  
PfSMS2     SFYYINNVI- ----IKFIIF TFSCFIYAII IIGFIHYTSD VLLGIIFGVF  
TgSLS      KTRVAAFLRL --NLLRSLCL VVGVVNLCLI VCSFNHYSID VFMALNFTFG  
HsLPP1     ARMKGDWARL LRPTLQFGLV AVSIYVGLSR VSDYKHHWSD VLTGLIQGAL  
 
TbSLS2     TFIAVGHNAD GAPWQLQLFI RWLPCCGANS REMTEDSQ 
TbSLS4     TFIAVGHNAD GAPWQLQLFI RWWPCCGANS REMTEDSQ 
TbSLS3     TFIAVGHNAD GAPWQLQLFI RWLPCCGANS REVTEDSQ 
TbSLS1     TFIAVGHNAD GAPWQLQLFI RWLPCCGANS REVTEDGV 
TcIPC1     TFLVLRHSPE GAPWQLQLLI GWWPCCASNE EAEDSDRH 
TcIPC2     TFLVLRHSPD GAPWQLQLLI GWWPCCVSNE ETEDSDRN 
LmjIPC     TYKVIDHAET GAPWQMQLLI RWMPWPGANT IEKWTADE 
HsSMS1     LFWWYHTMAN QQVLKEASQM NLLARVWWYR PFQYFEKN 
CHAPTER 07: THE EVOLUTION OF THE EUKARYOTIC SPHINGOLIPID SYNTHASE 
 
163 
 
MmSMS1     LFWWYHTMAN QQVLKEASQM NLLARVWWYR PFQYFEKN 
HsSMS2     LFWWYHSMAN EKNLKVSSQT NFLSRAWWFP IFYFFEKN 
MmSMS2     LFWWYHSMAN EKNLKVSSQT NFLSRAWWFP IFYFFEKN 
AtIPC1     VVFFLDKKLP ELPDRTTALL PVISKDRTKE ESHKLLNG 
AtIPC3     VVFFLDKKLP ELPDRTTALL PVISKDRTKE ESHKLLNG 
AtIPC2     VVFCLDKKLP ELPDRTAVLL PVISKDRTKE ENHKLLNG 
AfAUR1     AFYFAKTRFM PRVQNDKMFR WDYDYVE-YG DSALDYGY 
SpAUR1     CFVFAQKLRL PQLQTGKILR WEYEFVI-HG HGLSEKTS 
PcAUR1     IFYIANYNYS SHIYSRNLFR WDYHNVI-YD SSKTDPEV 
CaAUR1     VFEFTKYKYL PKNKEGLFCR WSYTEIEKID IQEIDPLS 
ScAUR1     IFQYTKYTHL PIVDTSLFCR WSYTSIEKYD ISKSDPLA 
CeSMS1     VFWAYHTQAA HPSIRLSVQN HQAKEFWFPL LRWFEGDI 
CeSMS2     VFWSYHQIFE MRKDDRPQAP LSRLWWFWLC YWFESDVA 
CeSMS3     VFRMYHAYCE VDMCMERRKS ILYSWWPCRI VDWLEQDI 
PfSMS1     VFLFYHYLVD VAARRYALNT SVFPQTYGFS GSFTDRFQ 
PfSMS2     MFSFYHIMLD ISSQYYIFNK LFEIKIISNN KNIHAKPF 
TgSLS      AWCLYHCILS LIWAEKEERD KRQKVALLRS EGIAAGAA 
HsLPP1     VAILVAVYVS DFFKERTSFK ERKEEDSHTT LHETPTTG 
 
 
It can be seen that the Tg SLS domain 1 does not align with the equivalent domains from 
either the apicomplexan P. falciparum enzyme or that from mammals, in fact it is not even 
present in the region analyzed. Similarly, whilst Pf SMS 1 and 2 domains 2 and 3 clearly 
align with Hs SMS 1, these regions of Tg SLS do not. In this Tg SLS resembles the fungal 
sequences used in this analysis with respect to domain 3. However, domain 4 is perfectly 
aligned in all sequences analyzed (Figure 7-1). This indicates that the T. gondii enzyme is 
divergent with respect to its primary sequence (only 27-28% identity to Pf SMS; chapter 
5). However, it is clearly functional and topology prediction indicated that despite 
possessing 8, rather than the more common 6, transmembrane domains the catalytic triad 
can still form. 
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7.2 PHYLOGENETIC ANALYSES OF THE NEWLY EXPANDED 
EUKARYOTIC SPINGOLIPID SYNTHASE (SLS) FAMILY 
To begin to understand the evolutionary relationships of the newly expanded eukaryotic 
SLS family a phylogenetic analyses were undertaken using the alignment shown in Figure 
7-1.  Using a Maximum Parsimony algorithm as described in Materials and Methodology, 
a single tree, shown in Figure 7-2, was generated 
(http://evolution.genetics.washington.edu/phylip.html). Under Maximum Parsimony the 
simplest model of evolution is used where the most direct path of the mutation of one 
residue to another is assumed. As discussed above Tg SLS did not fully align with the 
other SLS proteins analysed, however in this preliminary analysis the complete data set 
(including gaps) was used to avoid discarding potentially useful information. Subsequent 
studies may consider focusing on the region including only D4 which aligned well across 
all sequences chosen (Figure 7-1).  
 
Figure 7-2: Maximum parsimony analyses of Animalae, Fungi, Trypanosomatidae, Plantae 
and Apicomplexa sphingolipid synthase sequences. Bootstrap scores >60 shown, this 
indicates the number of times out of 100 analyses this node is reproduced and thus is a 
measure of certainty. Accession numbers as in Figure 7-1. 
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Despite the divergence of Tg SLS from Pf SMS, the apicomplexan enzymes clearly form a 
new clade of SLS proteins. This study therefore expands the repertoire of known SLS‟s to 
the Apicomplexa and reinforces the hypothesis that these key enzymes share a conserved 
mechanism of action and are derived from a common eukaryotic ancestor. Furthermore, in 
relation to the out group (Hs LPP 1) the apicomplexan sequences group with the Animalae 
and Fungi. In contrast, the Trypanosomatidae group with the Plantae (Figure 7-2). 
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8 DISCUSSION  
Sphingolipids are ubiquitous in the Eukaryota and sphingolipid biosynthetic pathway is 
largely conserved across eukaryotic evolution. Complex sphingolipids and their precursors 
are involved in many cellular processes including cell signalling (e.g. for apoptosis via 
ceramide) and the formation of functional lipid microdomains, rafts (Futerman and 
Hannun, 2004). However, there is a major divergence after the formation of ceramide 
species, in mammals, the major complex sphingolipid is sphingomyelin (SM) whereas in 
kinetoplastid protozoans, fungi and plants inositol phosphoryl ceramide (IPC) is the 
primary phosphosphingolipid (Dickson and Lester, 1993; Sperling and Heinz, 2003; Denny 
et al., 2006).  
 
IPC is not found in mammalian systems and enzyme responsible for its synthesis, IPC 
synthase (AUR1 in yeast), has been identified as a target for novel antifungal agents 
(Nagiec et al., 1997). In support of this several speciﬁc inhibitors have been demonstrated 
to have potent antifungal activity (Georgopapadakou, 2000) which is believed to occur 
through the accumulation of the acceptor substrate phytoceramide which induces apoptosis 
(Fischl et al., 1986). The enzyme responsible for mammalian SM synthesis has also been 
characterized (Huitema et al., 2004). It employs the same mode of action as AUR1p, 
utilizing a catalytic triad with an activated histidine residue in the active site (Huitema et 
al., 2004), and is essential for mammalian cell growth (Tafesse et al., 2007).  
 
More recently, the IPC synthase of the kinetoplastid protozoan parasite Leishmania major 
(Lmj IPCS) was isolated and characterized (Denny et al., 2006). It is encoded by a single 
copy gene and its mode of action has been subsequently explored and found to resemble 
that of its sister enzymes in yeast and mammals (Mina et al., 2010 b and 2011).  
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Orthologues of Lmj IPCS were found in the related kinetoplastids Trypanosoma brucei and 
T. cruzi, but these remained uncharacterized until the start of this study (Denny et al., 
2006).  
 
In contrast, the gene encoding plant IPC synthase remained unidentified before the work 
reported here, although the enzyme activity has been recorded in bean microsomes 
(Bromley et al., 2003). Similarly, the enzymes responsible for phosphosphingolipid 
biosynthesis (SM, IPC or ethanolamine phosphorylceramide: EPC) in the apicomplexan 
protozoan parasites remain little studied. Although, Plasmodium falciparum (the causative 
agent of lethal cerebral malaria) encodes 2 orthologues (Pf SMS 1 and 2) of the 
mammalian enzymes (Huitema et al., 2004) and is known to synthesize SM (Haldar et al., 
1991; Gerold and Schwarz, 2001). The related, model apicomplexan T. gondii (Kim and 
Weiss, 2008) has been shown to harbour SM and, compared to the host cell, large 
quantities of EPC (Welti et al., 2007). In addition, metabolic labelling studies indicated de 
novo synthesis of SM (Azzouz et al., 2002) and IPC (Sonda et al., 2005), however the 
enzyme(s) responsible for these activities remained unknown. 
 
The parasitic lifestyle means that a pathogen may be able to scavenge enough sphingolipid 
to make synthesis non-essential or even redundant. For example, T. gondii can both 
scavenge and synthesize phosphatidylcholine (PC) de novo (Charron and Sibley, 2002). 
The balance between these two sources is unclear, but when host PC is restricted de novo 
synthesis is increased (Charron and Sibley, 2002). Whether or not sphingolipids are 
scavenged remains unknown, and if de novo synthesis is non-essential then the status of 
the parasite pathway as a drug target can be in doubt. 
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The ability of T. gondii to grow in any nucleated mammalian cell line makes it a model 
system to investigate the role of host cell factors in parasite proliferation (Kim and Weiss, 
2008). Therefore, utilizing a CHO cell line (SPB-1) with a temperature sensitive serine 
palmitoyltransferase (SPT) the role of host sphingolipid biosynthesis was investigated 
(Chapter 4). The bacterial pathogen Chlamydia trachomatis, which does not synthesize 
sphingolipids, does not replicate in this cell line under non-permissive conditions 
indicating that scavenged sphingolipids are essential for growth (van Ooij et al., 2000). In 
contrast, T. gondii was able to proliferate in sphingolipid reduced conditions (99% 
depletion, van Ooij et al., 2000) although only at ~70% of that seen in wild type or 
complemented SPB-1 cells (Figure 4-2). The specific SPT inhibitor myriocin gave a 
similar result (Figure 4-3). This small defect was rescued by the addition of serum to the 
media indicating that the parasites are able to scavenge sphingolipid. However, it is likely 
that unlike C. trachomatis, de novo sphingolipid biosynthesis is important for proliferation 
indicating that it may represent a valid drug target. 
 
This is supported by the presence of sphingolipid biosynthesis in T. gondii (Azzouz et al., 
2002), and in order to investigate this pathway further the sphingolipid synthase (Tg SLS) 
was identified using a bioinformatic approach (Chapter 5). Tg SLS is encoded by a single 
copy gene and like the kinetoplastid enzymes (Denny et al., 2006) has the conserved 
domains (D 1-4) found in the SM synthase family, with D 3 and 4 containing the catalytic 
triad (Figure 5-3; Huitema et al., 2004). Also, like these other synthases (Huitema et al., 
2004; Levine et al., 2000) Tg SLS is Golgi localized (Figure 5-13).  
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However, unlike the human SM synthases (Figure 6-2), Tg SLS was able to complement 
an auxotrophic yeast mutant previous used to characterize the Leishmania enzyme (Figure 
5-4; Denny et al., 2006). Metabolic labeling and biochemical assay using yeast-derived 
microsomes indicated that Tg SLS is able to catalyse the production of SM and, 
predominately, IPC (Figures 5-5 and 5-6). However, further analyses using detergent 
washed (to remove endogenous substrate) microsomes only showed the production of IPC 
when donor (phosphatidylinositol - PI, PC or phosphatidylethanolamine - PE) and acceptor 
(ceramide) substrates were added (Figure 5-9). In addition, neither PC nor PE 
demonstrated any inhibition of PI binding to the enzyme.  
 
These data strongly indicated that Tg SLS is primarily an IPC synthase and a functional 
orthologue of AUR1. Its role as a SM synthase remains unclear. The presence of IPC 
synthase activity in T. gondii was proposed by Sonda et al (2005), but conclusive proof of 
the presence of IPC in the parasites was not forthcoming (Welti et al., 2007). However, 
metabolic labeling of isolated parasites with fluorescent-labelled ceramide indicated the 
presence of IPC in T. gondii (Figure 5-6). This was confirmed using LC-MS (Figure 5-12) 
and represents the first identification of IPC in the Apicomplexa. 
 
With the identification of Tg SLS and it primary product in T. gondii consideration was 
given to its potential as a drug target. Sonda et al., (2005) showed that Aureobasidin A (Ab 
A) demonstrated an anti-parasitic effect against T. gondii in vitro. Ab A is a cyclic 
depsipeptide (isolated from the fungus Aureobasidium pullulans) and is a known inhibitor 
of the fungal AUR1p (Takesako et al., 1991). It is a comparatively large molecule with a 
number of side chains, several of which are believed to be important for activity (Aeed et 
al., 2009). Confirmation of the mode of action of Ab A against Tg SLS could provide the 
opportunity to consider it in terms of drug compound. However, Ab A showed little 
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activity against Tg SLS either by diffusion assay (Figure 5-6) or in biochemical assay 
(Figure 5-11). Indeed, the enzyme confers Ab A resistance to S. cerevisiae (Figure 5-7). 
These data demonstrated that Tg SLS, whilst a functional orthologue of AUR1p, is not the 
target of Ab A in T. gondii, and the activity observed is probably due to off target effects as 
seen in Trypanosoma cruzi (Figueiredo et al., 2005). However, Tg SLS may still represent 
a valid target for novel antiprotozoals. 
 
Novel antiparasitics are also very much needed for the neglected tropical diseases caused 
by the kinetoplastid protozoa (WHO.int). As discussed the Leishmania IPC synthase (Lmj 
IPCS) has already been characterized (Denny et al., 2006; Mina et al., 2010b; Mina et al., 
2011) but the orthologues apparent in the Trypanosoma species were unstudied at the start 
of this project (Chapter 6). Again employing the auxotrophic yeast mutant, YPH499-HIS-
GAL-AUR1, the two T. brucei and one T. cruzi orthologues studied were shown to be 
functional orthologues of AUR1p (Figures 6-3 and 6-6). Tc IPCS 1.2 demonstrated itself to 
be a conventional IPC synthase by producing only IPC in both metabolic labeling and 
biochemical analyses (Figures 6-7 and 6-8). These data have subsequently been confirmed 
by others (Sevova et al., 2010), and in this it resembled Leishmania (Denny et al., 2006) 
which, like T. cruzi, is an intracellular pathogen.  
 
In contrast, both Tb SLS orthologues examined from the extracellular pathogen T. brucei 
were able to synthesize both IPC and SM, and Tb SLS 4 putatively mediated the 
production of EPC (Figures 6-4 and 6-5). However, subsequent analyses using the 
microsomal system described here have only been able to demonstrate IPC synthase 
activity, although both putative alternative donor substrates (PC and PE) inhibit this 
activity indicating that they are binding to the same site on the enzyme (Mina et al., 2009). 
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This dual functionality reflects the developmental changes observed in the sphingolipid 
profile of T. brucei in differentiation from the procyclic (PCF) to the bloodstream forms 
(BSF) (Sutterwala et al., 2008). Interestingly, whilst IPC predominates in PCFs, SM does 
so in BSFs (Sutterwala et al., 2008). It may be speculated that this change from a non-
mammalian sphingolipid (IPC) content towards a mammalian (SM) one help this 
extracellular parasite evade the host immune system.  
 
Alternatively, IPC may have an important role to play in resistance to degradative 
processes in both the insect gut and in the vacuoles harbouring Leishmania, T. cruzi and T. 
gondii. A similar role for IPC has been proposed in Cryptococcus neoforms, pathogenic 
fungi able, like Leishmania, to proliferate within macrophages (Luberto et al., 2001). 
Either way, Tb SLS and Tc IPCS may prove to be valid drug targets, indeed interference 
RNA has been used to demonstrate this in T. brucei (Sutterwala et al., 2008; Mina et al., 
2009). In addition, diffusion assay (Figure 6-11) and biochemical analyses (Mina et al., 
2009) showed Tb SLS 4 to, like yeast, be inhibited by Ab A. Furthermore, the antifungal 
demonstrated submicromolar efficacy against BSF T. brucei in vitro (Mina et al., 2009). 
Analyses in L. major have shown genetically that Lmj IPCS is also an essential protein 
(Denny, personal communication). These data indicated that the T. brucei and Leishmania 
enzymes represent novel drug targets and, by extension supported this to be the case for 
orthologues in T. cruzi and T. gondii. 
 
The Ab A sensitivity of Tb SLS 4 represents the exception in the Kinetoplastida (Denny et 
al., 2006; Mina et al., 2009; Figure 6-11) and the molecular basis of Ab A sensitivity or 
resistance remains unknown. However, the Arabidopsis IPC isoforms isolated here as 
functional orthologues of AUR1p (Figure 6-9) are all Ab A resistant, by diffusion assay 
(Figure 6-11) or biochemical assay (Mina et al., 2010 a). In contrast, the IPC synthase 
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activity from bean extracts was shown to be acutely Ab A sensitive (Bromely et al., 2003) 
as the orthologue from rice (Oryza sativa; Denny, personal communication), indicating 
that the Ab A resistance / sensitivity profiles of related organisms may be complex. In 
addition, like the protozoan enzymes, the plant IPC synthase has now been shown to be 
essential for growth and may represent a novel herbicide target (Wang et al., 2008). 
 
Although the products of the sphingolipid synthases vary between Kingdoms (mammals vs 
fungi) and even genera (T. brucei vs T. cruzi) the mechanism of action of this expanding 
family of enzymes is conserved and indicates a common ancestor. Presumably it is the 
binding of substrates that dictates function (Mina et al., 2011). In keeping with this 
relatedness, phylogenetic analyses (Chapter 7) of various members of this family groups 
them into 5 clades: Animalae, Fungi, Plantae, Trypanosomatidae and Apicomplexa (Figure 
7-2). The Apicomplexa represent a new group within this family and tree most closely with 
the Animalae and Plantae, perhaps reflecting their evolutionary origin although support for 
this is weak.   
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SUMMARY 
The yeast Saccharomyces cerivisiae has proven to be an excellent tool to study basic 
cellular processes (Ko, Cheah and Fischl, 1994). In this study the engineered yeast strain 
YPH499-HIS-GAL-AUR1 (Denny et al., 2006) was used to isolate and then study the 
sphingolipid synthases from the model apicomplexan parasite T. gondii; the kinetoplastid 
pathogens T. cruzi and T. brucei; and the model plant A. thaliana. Collectively these 
represent promising drug and herbicide targets for future investigations and the use of a 
transgenic yeast system will allow the production of cost effective material for, for 
example, the screening of large compound libraries. 
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9 FUTURE WORK 
Despite efforts to develop an effective anti-T. gondii vaccine, chemotherapy remains the 
only treatment for T. gondii infections (Striepen et al., 2000). A key factor in developing 
specific anti-T. gondii treatments is the identification of essential metabolic pathways that 
are restricted to the parasite and can be targeted with little or no mammalian toxicity. My 
results indicate that the characterization of the sphingolipid biosynthetic pathway of T. 
gondii, and the Tg SLS in particular, may lead to the rational development of new 
compounds as promising candidates for anti-apicomplexan treatments. 
 
Tg SLS is an aureobasidin A resistant IPC synthase, however it also synthesized a minor 
product that co-migrates with SM. Due to the very low concentration of this species, 
visualisation and quantification after sphingomyelinase treatment were not successful. 
Therefore, employing more sensitive techniques such as mass spectrometry would be 
advantageous. However, Tg SLS remains a promising target and other further analyses are 
recommended: 
 
9.1 KINETIC ANALYSES 
Determination of kinetic parameters is recommended to characterise Tg SLS in terms of 
substrate binding and activity. Similar studies with Lmj IPCS have shown the enzyme 
employs a ping-pong mechanism with ceramide being the rate limiting substrate (Mina et 
al., 2010 b). This knowledge has been used to probe the possibility of inhibiting the 
enzyme with ceramide analogues (Mina et al., 2011). The materials generated and 
knowledge gained in these studies should be used to confirm Tg SLS has a similar 
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mechanism of action and to consider the possibility of developing rationally designed 
inhibitors. 
9.2 SITE DIRECTED MUTAGENESIS (SDM) 
The biochemical study proposed above should be complemented using SDM to confirm 
that the catalytic triad, composed of two histidines and an arginine in the D3 and D4 
domains, is essential for activity. Mutation of the histidine in D4 has been shown to 
inactivate the yeast AUR1 (Levine et al., 2000) and Lmj IPCS (Mina and Denny, personal 
communication). Changing this residue in Tg SLS, to alanine for example, should be 
considered. The ability of this to complement the mutant yeast could then be investigated.  
 
9.3 ANALYZING TG  SLS IN AN IPC SYNTHASE NEGATIVE BACKGROUND  
More sophisticated analyses of mutated Tg SLS could be provided by expressing the 
enzyme in an IPC synthase null cell, rather than relying on a negative phenotype, death, in 
a complementation assay. Two approaches are suggested: expression in mammalian cells 
or in sphingolipid deficient mutant yeast (Nagiec et al., 2007). 
 
pc DNA 3.1/Myc-His (+) A, B, C are vectors designed for high-level expression, 
purification and detection of recombinant proteins in a wide range of  mammalian hosts 
(Figure 9-1; invitrogen.com). 
 
 
 
 
 
 
CHAPTER 09: FUTURE WORK 
 
179 
 
Figure 9-1: pcDNA 3.1/myc-His vector with multiple cloning site and applicable 
restriction enzymes 
 
 
Cloning the Tg SLS in to pcDNA 3.1/Myc-His vector and transfecting it into a mammalian 
cell line would allow expression levels of mutant or wild type Tg SLS to be assessed via 
the epitope tag and Western blotting, and the activity profile of the enzyme to be assessed 
by metabolic labeling with NBD C6 ceramide. This would facilitate IPC synthase activity 
to be analyzed, but any SM (or EPC) synthase activity could be masked by the endogenous 
activity of the mammalian cell.  
 
AGD yeast lack a functional AUR1p and SPT, and they survive by making unusual 
phospholipids (Nagiec et al., 1997). Expression of Tg SLS in these mutants would allow 
the analysis of the enzyme in a cell background free from sphingolipid biosynthesis. 
However, in keeping with the observations of Nageic et al., (2007) transformation of AGD 
has proven difficult and this approach has yet to prove successful (Mina and Denny, 
personal communication). 
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9.4 TG SLS KNOCK-OUT 
Unequivocal proof that Tg SLS is a valid drug target will come from the analyses of 
transgenic T. gondii in which Tg SLS is deleted via homologous recombination. T. gondii 
represents an excellent system for these kinds of experiments due to the array of genetic 
tools available. For example if, as expected, Tg SLS represents an essential activity, the 
tetracycline trans-inducible system utilization could be used (Meissner et al., 2007). In this 
protein expression is placed under the control of an inducible promoter so that it can be 
down regulated on the addition of tetracyclin during the course of an assay.  
 
These analyses are essential to demonstrate whether Tg SLS is essential and so a drug 
target, they will also indicate the role of the enzyme and sphingolipids in parasite 
proliferation and pathogenesis. 
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APPENDIX (I) 
STANDARD PROTOCOLS 
 
1.1   PCR 
1.1.1 Amplification of the gene of interest with proof reading enzyme 
 
Template DNA   0.5 µl (0.5-1.0g/ml) 
3‟ Primer    1 µl (100M) 
5‟ Primer    1 µl 
2.5mM dNTP    5 µl 
10X Pfu buffer   5 µl 
Pfu DNA polymerase    1 µl 
Nuclease free water   36.5 µl  for the final volume of 50 µl 
 
PCR program was set as,  
95 C 2 minutes (fin hold)  
30 cycles 
95 C 30 seconds 
55 C 30 seconds (annealing) 
72 C 2 minute 20 seconds (extension) 
72 C 5 minutes (final extension) 
4 C hold 
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1.1.2 Amplification of the gene of interest with GoTaq polymerase 
 
Go Taq green master mix  12.5 µl 
3‟ primer    0.5 µl 
5‟ primer    0.5 µl 
Template DNA   2.5 µl 
Nuclease free water   9 µl  for the final volume of 25 µl 
  
PCR program was set as,  
95 C 2 minutes (fin hold) 
30 cycles 
95 C 30 seconds 
55 C 30 seconds (annealing) 
72 C 1 minute 10 seconds (extension) 
72 C 5 minutes (final extension) 
4 C hold      
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1.1.3   Amplification of the gene of interest with FideliTaq polymerase 
Template DNA   2 µl 
3‟ primer    0.5 µl 
5‟ primer    0.5 µl 
10mM dNTP    1 µl 
10X PCR Buffer   5µl 
FideliTaq DNA polymerase  0.5µl 
Nuclease free water   40.5 µl  for the final volume of 50 µl 
 
PCR program was set as,  
95 C 2 minutes (fin hold) 
30 cycles 
94 C 30 seconds 
55 C 30 seconds (annealing) 
68 C 1 minute 30 seconds (extension) 
68 C 5 minutes (final extension) 
4 C hold 
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1.2   DIGESTION OF A PCR PRODUCT 
 
1.2.1   For specific restriction enzyme in a specific buffer 
DNA     20 µl 
Nuclease free water   6.8 µl 
10X Buffer H    2 µl  
10mg/ml BSA    0.2 µl 
Restriction enzyme   1 µl   (final volume of 30 µl) 
Incubated at 37 C for 2 hours in Perkin Elmer DNA Thermal Cycler 
 
1.2.2   In the presence of a common buffer 
 
DNA     15.8 µl 
Restriction enzyme I   1 µl 
Restriction enzyme II   1 µl 
10X Buffer     2 µl  
10mg/ml BSA   0.2 µl   (final volume of 20 µl) 
Incubated at 37 C overnight in Perkin Elmer DNA Thermal Cycler 
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1.3   LIGATION OF DNA IN TO A VECTOR 
1.3.1   Ligation using Perkin Elmer DNA Thermal Cycler 
Purified digested DNA  7 µl 
Purified digested vector  1 µl 
10X Ligase buffer   1 µl 
3 µ/µl DNA ligase   1 µl 
Incubated at 14 C overnight in Perkin Elmer DNA Thermal Cycler 
 
1.3.2   Ligation using PCR programmer  
Purified digested DNA  2 µl (or water for control) 
Purified digested vector  10 µl 
 
Incubated at 65 C for 15 minutes at the PCR programmer. When the temperature dropped 
down to 18-20 C, the program was paused and the followings were added. 
 
Ligase buffer    1 µl 
T4 DNA ligase   1 µl 
Incubated at 16 C for 30 minutes for the extension and fin hold at 4 C  
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1.4   PREPARATION OF GLYCEROL STOCKS 
500 µl of purified mini prep sample or cell culture were transferred in to a sterile screw cap 
micro centrifuge tube. 500 µl of 80% glycerol were added and vortexed. This was stored at 
-80 C for until further use. 
 
1.5   NBD C6 CERAMIDE AND BSA CONJUGATION 
1 mg of NBD C6 ceramide was dissolved in 1.740 ml of Chloroform: ethanol (19:1 v/v) 
and 1 mM of NBD C6 ceramide stock was prepared. 50 µl of 1 mM stock was concentrated 
in a 1.5 ml LoBind
®
 Eppendorf tube for 1 hour at 35 C. Dried pellet was re-suspended in 
200 µl of absolute ethanol. 10 ml of DMEM without BSA was filter sterilized and 3.4 mg 
of de-fatted BSA were added and mixed. 200 µl of NBD C6 ceramide dissolved in ethanol 
was pipetted in to 10 ml of DMEM added with defatted BSA while mixing on a vortex 
mixture. The resulted solution of 5 µM NBD C6 ceramide: 5 µM BSA was aliquoted as 1 
ml in LoBind
®
 Eppendorf tubes and stored at -20 C.  
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APPENDIX (II) 
pRS 426 MET 25 vector 
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APPENDIX (III) 
pT8MycTy vector 
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a b s t r a c t
Sphingolipids are important components of eukaryotic membranes, particularly the plasma membrane,
and are involved in a diverse array of signal transduction processes. In the Eukaryota the biosynthetic
pathway for the formation of these lipid species is largely conserved. However, in contrast to mammals
which produce sphingomyelin (SM), several pathogenic fungi and protozoa synthesize inositol phos-
phorylceramide (IPC) as the primary phosphosphingolipid. This process is catalyzed by the enzyme IPC
synthase, a recognized target for anti-fungals encoded by the AUR1 gene in yeast. Recently, functional
orthologues of the AUR1p have been identiﬁed in a group of insect vector-borne pathogenic protozoa,
the Kinetoplastida, which are responsible for a range of so-called neglected diseases. Of these the Try-
panosoma brucei species are the causative agents of human African trypanosomiasis in many of the most
under-developed regions of Africa. The available treatments for these diseases are limited, of decreasing
efﬁcacy, and often demonstrate severe side-effects. Against this background the T. brucei sphingolipid
synthase, an orthologue of the yeast AUR1p, may represent a promising target for novel anti-protozoals.
Our studies identify an isoform of this protein as a novel bi-functional enzyme capable of catalyzing
the synthesis of both IPC and SM, both known to be present in the parasite. Furthermore, the synthase is
essential for parasite growth and can be inhibited by a known anti-fungal at low nanomolar levels in vitro.
Most notably this drug demonstrates trypanocidal activity against cultured bloodstream form parasites.
Thus, the T. brucei sphingolipid synthase represents a valid and promising drug target.
© 2009 Elsevier B.V. All rights reserved.
1. Introduction
Trypanosoma brucei species are protozoan parasites of the order
Kinetoplastidae and the etiological agents of both human African
trypanosomiasis (HAT, sleeping sickness), and diseases of econom-
ically important animals (e.g. nagana in cattle) [1]. These diseases
are endemic in much of sub-Saharan Africa, with HAT causing a
burden of approximately 1.6 million disability adjusted life years
 Since the initial submission of this work to Molecular and Biochemical Par-
asitology a paper has been published in Molecular Microbiology identifying and
characterising the same family of enzymes in Trypanosoma brucei: Sutterwala S.S.,
Hsu F.F., Sevova E.S., Schwartz K.J., Zhang K., Key P., Turk J., Beverley S.M., Bangs J.D.
Developmentally regulated sphingolipid synthesis in African trypanosomes (2008)
70:281–296.
∗ Corresponding author at: Centre for Bioactive Chemistry, Department of Chem-
istry, Durham University, Durham, DH1 3LE, UK. Tel.: +44 0 191 334 3983.
E-mail address: p.w.denny@durham.ac.uk (P.W. Denny).
1 These authors contributed equally to this work.
(http://www.who.int/tdr/). This distribution across some of the
most under-developed regions of the world is coupled with a
paucity of effective therapies, with those available being either
too expensive (e.g. eﬂornithine) or exhibiting catastrophic side-
effects (e.g. melarsoprol). Together with the leishmaniases (caused
by the related Leishmania species) HAT has been described as an
emerging or uncontrolled disease. Therefore, there is an urgent
need for new, validated drug targets and anti-HAT compounds to
combat a disease causing in excess of 50,000 deaths per annum
[2].
Sphingolipids are a diverse group of amphipathic lipids that
perform essential functions in eukaryotes. For example, the unmod-
iﬁed sphingolipid ceramide acts as a secondary signalling molecule
[3] and more complex species are implicated in the formation and
function of signal transduction complexes [4,5]. The primary phos-
phosphingolipid species in mammalian species, including humans,
is sphingomyelin (SM). SM is formed by the transfer of the phospho-
rylcholine head group from phospholipid phosphatidylcholine (PC)
to ceramide, a reaction catalyzed by SM synthase [6]. In contrast
0166-6851/$ – see front matter © 2009 Elsevier B.V. All rights reserved.
doi:10.1016/j.molbiopara.2009.06.002
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fungi, plants and at least some protozoa produce inositol phos-
phorylceramide (IPC) as their primary phosphosphingolipid [7].
In these organisms IPC synthase catalyzes the transfer of phos-
phorylinositol from phosphatidylinositol (PI) to ceramide [8–10].
IPC synthase has long been established and studied as a target
for novel anti-fungals [11,12]. More recently this enzyme has come
under scrutiny as a potential target for anti-protozoals [13]. With
the recent identiﬁcation and characterization of the Leishmania IPC
synthase (LmIPCS; [10]) it has become possible both to validate this
protozoan activity as a drug target and, furthermore, begin to inves-
tigate potential inhibitors, including those known to act against the
fungal IPC synthase. Four closely related orthologues of LmIPCS are
apparent in the T. brucei database [10], and mass spectrometry of
isolated fractions has revealed that whilst the predominant phos-
phosphingolipid in pathogenic bloodstream form parasites is SM
[14]; insect stage, procyclic T. brucei also contain IPC [15].
Here we describe the characterization of the African try-
panosome, T. brucei, sphingolipid synthase 4 (TbSLS4) which
demonstrates itself to be a novel bi-functional enzyme with the
ability to catalyze the biosynthesis of both IPC and SM, thus
reﬂecting the sphingolipid proﬁle of the parasite. Importantly,
the IPC synthase activity of TbSLS4 is acutely sensitive to the
well characterized speciﬁc fungal inhibitor aureobasidin A [11,12]
and pathogenic bloodstream form T. brucei are rapidly killed at
sub-micromolar concentrations of this drug. Furthermore, down-
regulation of TbSLS1–4 using inhibition RNA (RNAi) in bloodstream
form parasites demonstrated that the enzyme activity is essential
for growth thus validating it as a target for the development of new
anti-HAT therapies.
2. Materials and methods
2.1. Functional identiﬁcation of the T. brucei sphingolipid synthase
A common, conserved AUG start codon was predicted for all
four TbSLS isoforms by examination of the genome sequence
(www.genedb.org). Subsequently, TbSLS1 (Tb09211.1030) and
TbSLS4 (Tb09211.1000) were ampliﬁed with Pfu polymerase
(Promega) from T. brucei strain Lister 427 genomic DNA using
primer pairs (homologous sequence underlined): TbSLS1—CCG-
GAATTCATGATTAGTTACCCTTTCTTCTCCC and CCGCTCGAGTCATAC-
CTCGTTAGTTGATAC; TbSLS4—CCGGAATTCATGATTAGTTACCCTTTC-
TTCTCCC and CCGCTCGAGTCACACATACGCCCCACATTTAAAC;
The PCR products were subsequently cloned into the yeast
expression vector pRS426 MET [16] to give pRS426 TbSLS1 and
pRS426 TbSLS4. These, together with pRS426 AUR1, pRS426 human
sphingomyelin synthase 1 and 2 (HsSMS1 and 2) and empty vector
(pRS426), were used to transform the YPH499-HIS-GAL-AUR1 Sac-
charomyces cerevisiae strain [10]. Transformants were selected on
non-permissive SD medium (0.17% Bacto yeast nitrogen base, 0.5%
ammonium sulphate and 2% dextrose) or permissive SGR medium
(0.17% Bacto yeast nitrogen base, 0.5% ammonium sulphate, 4%
galactose and 2% rafﬁnose) containing the appropriate nutritional
supplements at 30 ◦C.
2.2. Metabolic labelling and analyses
Yeast were grown to exponential phase in SD or SGR as indicated
and 2.5 OD600 units incubated in 1 ml of SD or SGR supplemented
with 5M of NBD C6-ceramide (Invitrogen) conjugated to fat-
depleted bovine serum albumin (Sigma–Aldrich) for 120 min at
30 ◦C. Yeast were harvested by centrifugation and washed twice
with phosphate buffered saline. Chloroform/methanol (0.4 ml; 1:1,
v/v) was added and cells were disintegrated with glass beads. The
pellet was re-extracted with chloroform/methanol/water (10:10:3)
and the lipid fraction isolated by phase separation. After drying
in a rotavapor (Eppendorf Concentrator 5301) reaction products
were re-suspended in 20l of 10:10:3 and cell mass equivalents
fractionated using HPTLC silica plates (Merck) and the eluent sys-
tem chloroform:methanol:aqueous 0.25% KCl (55:45:10). Imaging
and quantiﬁcation was carried out using a FLA3000 scanner (Fuji-
ﬁlm) and AIDA Image Analyzer® software (version 1.3). Vero cells
were labelled and processed for use as controls and standards as
previously described [10].
Sphingomyelinase (Bacillus cereus, Sigma–Aldrich) was used to
identify sphingomyelin in the NBD C6-ceramide lipids extracted
from the complemented yeast as previously described [17]. Brieﬂy,
YPH499-HIS-GAL-AUR1 S. cerevisiae complemented with pRS426
TbSLS4 (in SD) or transformed with pRS426 HsSMS2 or empty vec-
tor (in permissive SGR, or for a limited period SD) were grown
to exponential phase. After adjustment to an optical density of
0.5 OD600 in 5 ml of either SD or SGR, cells were labelled for 16 h
with 2M of NBD C6-ceramide conjugated to fat-depleted bovine
serum albumin as previously described [6]. Labelled lipid fractions
from these were prepared and dried as above with 50g of sph-
ingomyelin (Sigma–Aldrich), and re-suspended, with sonication in
a water bath, in 600l of 20 mM Tris–HCl (pH 7.4), 10 mM MgCl2
and 0.05% (w/v) Triton X-100. Subsequently, samples (300l) were
incubated with or without 2 units of B. cereus sphingomyelinase
(Sigma–Aldrich) at 37 ◦C for 120 min. Equivalent lipid extracts were
fractionated and analyzed as above.
2.3. In vitro assay of TbSLS4 activity
Microsomal membranes from exponentially growing YPH499-
HIS-GAL-AUR1 pRS426 TbSLS4, pRS426 LmIPCS or pRS426 AUR1
[10] were prepared as previously described [18] and the iso-
lated membrane fraction re-suspended in storage buffer (50 mM
Tris–HCl pH 7.4, 20% (v/v) glycerol, 5 mM MgCl2) with Complete®
EDTA-free Protease Inhibitor Cocktail (Roche Applied Science) at
a protein concentration of 10 mg/ml. The microsomal membranes
were subsequently washed in 2.5% CHAPS (w/v; Sigma–Aldrich;
4 ◦C, 60 min), isolated by centrifugation (150,000 × g, 4 ◦C and
90 min), re-suspended in storage buffer at 10 mg/ml and stored at
−80 ◦C until use.
The assay mix contained 100M donor substrate (bovine liver
PI, PC or PE, Avanti Polar Lipids), 10g of microsomes, 100 mM
Tris–HCl, 10 mM EDTA, 6 mg/ml BSA and 5M NBD C6-ceramide
[19]. Following incubation at 30 ◦C for 60 min the reaction was
quenched by the addition of 150l of chloroform:methanol:water
(10:10:3). After biphasic separation the organic layer was removed,
processed and analyzed as above.
For inhibition experiments the reaction mix was pre-incubated
for 30 min with appropriate quantities of aureobasidin A (Takara)
before the addition of NBD C6-ceramide.
2.4. Parasite culture
Bloodstream form T. brucei strains Lister 427 and its
engineered variant, Single Marker Bloodstream form (SMB,
T7RNAP::TETR::NEO; [20]) were maintained in vitro at 37 ◦C with
5% CO2 in HMI-9 medium supplemented with 10% FCS and, for SMB,
2.5g/ml G418.
2.5. Inhibition RNA (RNAi) of TbSLS
An 165 base pair sequence fragment common to all four
TbSLS open reading frames was ampliﬁed from genomic
DNA using Pfu polymerase and primer pair (homologous
sequence underlined): CATAGATCTAGAGGTTCCATACACTGTG and
CATAGATCTAGACGAGAGGCAACGATGC.
This PCR product was cloned into the RNAi vector p2T7 [21] and,
following linearization, 10g transfected into SMB T. brucei and
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Fig. 1. Transformation with pRS426 TbSLS4 and pRS426 TbSLS1, as well as pRS426 AUR1 (the S. cerevisiae IPC synthase), rescues the auxotrophic mutant YPH499-HIS-GAL-
AUR1 allowing it to grow in the presence of glucose (SD media). YPH499-HIS-GAL-AUR1 pRS426 (empty vector) does not grow in the presence of glucose (SD), however all
lines are viable in the absence of glucose and the presence of galactose (SGR).
transformants selected using 2g/ml phleomycin (Sigma–Aldrich).
Following induction with 1g/ml doxycycline cell growth was
determined at 24 h intervals by light microscopy using an Improved
Neubauer Haemocytometer.
48 h post-induction total RNA was isolated (RNeasy®, Qiagen)
and RT-PCR was performed (SuperScript II, Invitrogen) using the
primer pairs:
TbSLS: AAACTGTACCTTCTTCACCG and CGAGAGGCAACGATGC;
Tb  tubulin: GGAGCGCATCAATGTGTAC and CAGGCAGCAGGT-
GACGCCG.
2.6. T. brucei susceptibility to aureobasidin A
T. brucei Lister 427 were cultured in the presence of various
concentrations of aureobasidin A. Growth was analyzed at 24 h
intervals as above.
3. Results and discussion
3.1. Identiﬁcation and characterization of the T. brucei
sphingolipid synthase
Four tandem gene sequences (Tb09211.1030, Tb09.211.1020,
Tb09.211.1010 and Tb09.211.1000; here annotated TbSLS1–4 to
reﬂect their 5′–3′ order) were previously identiﬁed in the T. bru-
cei genome database (www.genedb.org) as sequence orthologues
of the inositol phosphorylceramide synthase (LmIPCS) from the
related kinetoplastid parasite, Leishmania [10]. The predicted open
reading frames encode four closely related trans-membrane pro-
teins with more than 90% identity and 94% similarity. Most variation
occurs at the carboxy-termini, a region predicted to lie on the
cytosolic side of the membrane away from the active site at the
Golgi lumen, with another variable domain close to and within
the second predicted trans-membrane domain [10]. One of the
predicted T. brucei sphingolipid synthase isoforms (Tb09.211.1000;
TbSLS4) was the focus of this study. In addition, the isoform most
distant from TbSLS4 with respect to the internal variable domain
(Tb09.211.1030; TbSLS1) was also subjected to preliminary analy-
ses.
The auxotrophic mutant S. cerevisiae strain, YPH499-HIS-GAL-
AUR1, has the essential AUR1 IPC synthase gene under the control
of a galactose inducible promoter. Therefore it is unable to grow
in the presence of the repressor glucose, a phenotype that is res-
cued by the ectopic expression of LmIPCS [10]. Similarly, TbSLS4
and TbSLS1 expression complemented the YPH499-HIS-GAL-AUR1
mutant yeast line indicating that they are also functional ortho-
logues of the yeast AUR1 gene (Fig. 1). The yeast IPC synthase (AUR1)
also complemented this mutant line. Signiﬁcantly, neither HsSMS1
nor HsSMS2 complemented the YPH499-HIS-GAL-AUR1 yeast (data
not shown) indicating that sphingomyelin synthase activity alone
is not sufﬁcient to rescue the mutant.
To understand the function of the T. brucei sphingolipid synthase,
the auxotrophic YPH499-HIS-GAL-AUR1 yeast cells complemented
with either TbSLS4, TbSLS1 or yeast AUR1 were metabolically
labelled with ﬂuorescent NBD C6-ceramde, a substrate for sph-
ingolipid synthases, including those from the kinetoplastids [10].
Under the conditions described, the AUR1 complemented S. cere-
visiae auxotrophic mutant synthesized IPC as the only labelled
product. In contrast, both TbSLS4 and TbSLS1 complemented
mutant yeast were shown to synthesize two major labelled lipid
species. One of these co-migrated with SM, the other with IPC.
The latter at levels equivalent to those produced in the AUR1
complemented yeast (Fig. 2A). In addition, TbSLS4 complemented
yeast synthesized a third species which co-migrated with an
unknown lipid (X) produced by labelled mammalian cells (Vero).
As a control YPH499-HIS-GAL-AUR1 cells harbouring an empty
vector (pRS426) were cultured in both permissive (SGR) and non-
permissive (SD) media. Both lines grew equivalently in both media
for 16 h and for a further 8 h after dilution to an optical den-
sity 0.3 OD600, and remained viable (by plating on permissive
media, data not shown). Labelling of these dividing cells with
NBD C6-ceramde in their respective media under the same con-
ditions as above demonstrated that in non-permissive SD no
labelled IPC is produced, indicating the down-regulation of AUR1p
(Fig. 2B).
TbSLS4 was chosen for further study due to the relative pre-
dominance of the SM-like species in the labelled complemented
yeast. Unlike IPC, SM is known to be present in the pathogenic
bloodstream form of the parasite [14]. The labelled SM-like species
(and the unknown X) proved to be susceptible to sphingomyelinase
(which breaks down SM into phosphorylcholine and ceramide)
when lipid extracts were treated with this enzyme, thereby con-
ﬁrming its identity (Fig. 3A). In contrast the IPC produced was
insensitive to this enzyme treatment. Extracts from the auxotrophic
mutant expressing HsSMS2, which produce an equivalent quantity
of labelled SM under permissive conditions (SGR), acted as a control
for SMase activity.
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Fig. 2. (A) Metabolic labelling of yeast IPC synthase (AUR1) complemented YPH499-
HIS-GAL-AUR1 with NBD C6-ceramide in glucose-containing media (SD) showed
that they synthesize only labelled IPC. In contrast the same mutant line, labelled
under the same conditions, but complemented with TbSLS4 or TbSLS1 synthesized
two predominant sphingolipid species, one of which co-migrated with IPC, the other
with SM. In addition, in TbSLS4 complemented yeast a minor labelled species (X) was
evident which co-migrated with an unknown detected in labelled mammalian cell
(Vero) extracts, in which the predominant complex sphingolipid is SM. (B) The yeast
IPC synthase (AUR1) is down-regulated in YPH499-HIS-GAL-AUR1 cells transformed
with empty vector (pRS426) when incubated in non-permissive, glucose-containing
media (SD). This is demonstrated by the lack of detectable IPC in yeast metaboli-
cally labelled with NBD C6-ceramide in SD under the same conditions as above. In
galactose-containing, glucose-free media (SGR) the synthesis of IPC is clearly evi-
dent. NBD C6-ceramide labelled lipid extracts fractionated by HPTLC, representative
of at least three independent experiments. O, origin; IPC, inositol phosphorylce-
ramide; SM, sphingomyelin; Cer, ceramide (migrating at the front); X, unknown
sphingolipid. All lipid extracts normalised with respect to cell mass.
Together these data suggest that TbSLS4 is a novel bi-functional
enzyme acting as both a SM and an IPC synthase. This is con-
sistent with previous analyses which demonstrated that the
parasite harbours both SM [14] and IPC phosphosphingolipids
[15].
3.2. In vitro analyses of TbSLS4 activity
To further investigate the function of TbSLS4, microsomal mate-
rial was isolated from the TbSLS4 and AUR1 complemented yeast
as described and used in an in vitro assay utilising the common
acceptor substrate NBD C6-ceramide and the candidate donor sub-
strates bovine liver PI, PC and phosphatidylethanolamine (PE; a
potential substrate for ethanolamine phorphorylceramide synthe-
sis [22]). Notably, when assayed, the yeast AUR1 crude microsomal
material showed signiﬁcant IPC synthase turnover, but demon-
strated little signiﬁcant increase in this on the addition of the
donor substrate PI. As expected, no detectable SM synthesis was
observed with or without the addition of PC (Fig. 4A). In order
to clearly assign enzyme function this assay was reﬁned accord-
ing to data obtained from the analysis of LmIPCS (Mina et al. in
preparation). In brief, microsomal fractions were washed with ice-
Fig. 3. (A) Sphingomyelinase (SMase) treatment of lipids extracted from YPH499-
HIS-GAL-AUR1 complemented with TbSLS4, grown in glucose-containing media
(SD) and labelled with NBD C6-ceramide, demonstrated that the predicted sphin-
gomyelin species is SMase sensitive, as is unknown X. In contrast the predicted IPC
is insensitive. As a control, YPH499-HIS-GAL-AUR1 expressing human SM synthase
2 (HsSMS2, grown in permissive SGR media) was utilized as they produce equiva-
lent quantities of labelled SM to the TbSLS4 line. (B) The yeast IPC synthase (AUR1)
is down-regulated in YPH499-HIS-GAL-AUR1 cells transformed with empty vector
(pRS426) incubated in non-permissive SD under the same conditions as the SMase
treated samples. This is demonstrated by the lack of detectable IPC in yeast metabol-
ically labelled with NBD C6-ceramide in SD. In galactose-containing, glucose-free
media (SGR) the synthesis of IPC is clearly evident. NBD C6-ceramide labelled
lipid extracts fractionated by HPTLC, representative of at least three independent
experiments. O, origin; IPC, inositol phosphorylceramide; SM, sphingomyelin; Cer,
ceramide (migrating at the front); X, unknown sphingolipid. All lipid extracts nor-
malised with respect to cell mass.
cold 2.5% 3-[3-(cholamidopropyl) dimethylammonio]-1-propane
sulfonate (CHAPS) to remove endogenous (i.e. yeast) substrates.
This facilitated analyses of the effect of adding exogenous substrate
to the reaction—in this case the candidate donor substrates (PI, PC or
PE) plus the known acceptor substrate NBD C6-ceramide. Without
the addition of the donor substrate the CHAPS-washed AUR1 micro-
somes, compared to the crude unwashed sample, demonstrated a
relatively low level of IPC synthase turnover and, as expected no
evidence of SM synthase function (Fig. 4A, crude and washed).
Importantly, the addition of PI or PC had no discernable effect
on enzyme turnover in the washed sample indicating that the
yeast IPC synthase is either substrate speciﬁc (and unable to uti-
lize bovine PI) or that the detergent treatment had disrupted the
protein (Fig. 4A, +PI and +PC washed). In contrast, assay of iden-
tically treated TbSLS4 microsomes showed that the addition of PI
led to a large (more than 12-fold) increase in the formation of IPC
(Fig. 4B, +PI). This demonstrated that TbSLS4 functions as an IPC
synthase, an activity not attributable to background AUR1 expres-
sion.
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Fig. 4. Detergent-washed microsome extracts from YPH499-HIS-GAL-AUR1 TbSLS4 yeast demonstrate IPC synthase enzyme turnover on the addition of the donor substrate
PI and acceptor substrate NBD C6-ceramide, but no further production of other sphingolipid species on the addition of alternative donors PC and PE. (A) The addition of bovine
liver PI led to a marginal increase in IPC production in unwashed (crude) AUR1 microsomes when compared to the control (−). In CHAPS-treated microsomes (washed) IPC
synthase (AUR1) turnover was minimal without donor substrate (−) and unchanged by the addition of either PI or PC as donors. This demonstrated that the yeast IPC synthase
(AUR1) was unable to utilize these donor substrates under the experimental conditions. (B) In contrast, assay of TbLS4 microsomes (CHAPS-treated, as the washed sample in A)
demonstrated a greater than 12-fold increase in IPC over a sample without donor substrate (−) on the addition of PI. PC and PE had no demonstrable effect on enzyme turnover.
However, both inhibited IPC synthesis when added together with PI at equivalent molar quantities: PC by approximately 4-fold and PE by approximately 2-fold. NBD C6-
ceramide labelled lipid extracts fractionated by HPTLC and quantiﬁed as described, standard deviation of three independent experiments shown. AFU, arbitrary ﬂuorescence
units; IPC, inositol phosphorylceramide; SM, sphingomyelin; –, no donor substrate added; PI, bovine liver phosphatidylinositol; PC, bovine liver phosphatidylcholine; PE,
bovine liver phosphatidylethanolamine.
Surprisingly, given the identiﬁcation of SM as a TbSLS4 product
above (Fig. 3A), bovine PC – a potential donor substrate for a SM syn-
thase – had no signiﬁcant effect on enzyme activity (Fig. 4B, +PC).
The addition of PE was similarly ineffectual (Fig. 4B, +PE). However,
when PC or PE were added simultaneously as molar equivalents
with PI to the assay system, the quantity of IPC produced decreased
4- and 2-fold respectively. This suggested that both PC and PE bind
competitively with PI to the same region of the enzyme (Fig. 4B,
+PI + PC and +PI + PE).
Taken together these results indicate that TbSLS4 functions as
an IPC synthase but also binds PC (and PE) and can participate in
the synthesis of SM. The lack of in vitro SM synthase activity in the
presence of exogenous PC is surprising and may relate to substrate
speciﬁcity (see yeast AUR1 and bovine PI, Fig. 4A, washed). One
possibility is that TbSLS4, in this assay, is unable to utilize bovine
liver PC. This donor substrate is a mixed natural product with pre-
dominantly C36:2 PC. In contrast, S. cerevisiae, where both TbSLS4
and TbSLS1 function as SM synthases, predominantly possesses
C32:2 and C34:2 PC [23]. Perhaps TbSLS favours these relatively
short acyl groups? However, T. brucei procyclic and bloodstream
forms harbour signiﬁcant quantities of C36, C38 and C40 PC species
[14,24,25], indicating that any substrate selectivity is perhaps due
more subtle structural differences. In support of this, although
TbSLS4 can utilize bovine liver PI (predominantly C38:4) efﬁciently
as a substrate for IPC synthesis, procyclic form parasites (known
to synthesize IPC [15]) harbour only trace levels of the C38:4 PI
[14].
3.3. Inhibition of TbSLS4 using a known anti-fungal agent
IPC synthase is a recognized target for anti-fungal drugs and
the natural product aureobasidin A is a widely utilized and speciﬁc
experimental inhibitor [26]. This drug also speciﬁcally inhibits the
activity of Leishmania LmIPCS, a TbSLS orthologue, albeit at a con-
centration several orders of magnitude higher than those for the S.
cerevisiae enzyme [10].
To establish the efﬁcacy of aureobasidin A against the T. bru-
cei enzyme the previously described in vitro assay was employed
using CHAPS-washed TbSLS4 microsomes with NBD C6-ceramide
and bovine PI as receptor and donor substrates respectively. As a
control identically prepared LmIPCS microsomes were assayed in
the same manner. Given the inactivity of the yeast enzyme in this
assay system it was not possible to include this as a further control.
The synthesis of labelled IPC was used as a measure of IPC synthase
turnover. From this assay it was evident that the T. brucei enzyme
is acutely sensitive to the drug (Fig. 5A). Following reanalysis of the
linear portion of the curve (0–0.5 nM aureobasidin A), the turnover
was calculated to be 50% inhibited (IC50) by 0.42 nM aureobasidin
A. TbSLS4 turnover was undetectable at a concentration of 50 nm
aureobasidin A. In contrast, the IC50 for LmIPCS inhibition by aure-
obasidin A was more than 200,000 times higher, with precipitation
of the drug at concentrations above 100M (Fig. 5B) preventing the
determination of an absolute value.
3.4. Validation of TbSLS as a target of anti-protozoals
Using a sequence fragment common to all four TbSLS isoforms
an RNAi construct was prepared in the p2T7 vector [21] and used
to speciﬁcally inhibit TbSLS expression in cultured bloodstream
form T. brucei (SMB). Non-induced TbSLS RNAi cells grew in a sim-
ilar manner to control SMB parasites carrying empty vector with
or without the doxycycline. In contrast, doxycycline induction of
TbSLS RNAi saw the parasites cease division and led to some cell
death as scored by light microscopy. RT-PCR, using  tubulin as
a control, conﬁrmed the speciﬁcity of the TbSLS mRNA inhibition
(Fig. 6).
This genetic approach validated TbSLS as an essential enzyme for
pathogenic bloodstream form parasite growth. Given the in vitro
data shown above in which aureobasidin A was demonstrated to
inhibit TbSLS4, the efﬁcacy of this natural compound was tested
against cultured bloodstream form T. brucei (Lister 427; Fig. 7).
When the concentration of aureobasidin A was 1M cell growth
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Fig. 5. The fungal IPC synthase inhibitor aureobasidin A is active against TbSLS activity. (A) TbSLS4 IPC synthase turnover determined using the described in vitro assay in
the presence of aureobasidin A (AbA). The IC50 was calculated from the linear portion of the curve as being 0.42 nM. (B) L. major IPC synthase turnover was conﬁrmed to be
relatively refractory to AbA [10]. The IC50 was in excess of 100M, more than 200,000 times greater than that for TbSLS4. Turnover, as determined by IPC production, was
scored as 100% in the absence of the inhibitor.
was completely inhibited and the parasites were scored as dead by
light microscopy after 24 h. The EC50 of aureobasidin A against the
parasites was estimated from these data as being below 250 nM.
However, it is the trypanocidal activity of this compound at higher
concentrations that is of most signiﬁcance.
3.5. Summary
Previous studies using pharmacological and genetic inhibition
of the ﬁrst step in sphingolipid biosynthesis, catalyzed by serine
palmitoyltransferase, showed that this pathway is essential for the
viability of both bloodstream and procyclic forms of T. brucei [17,27].
This is in contrast to the related protozoan parasite Leishmania
major where this enzyme, though essential for sphingolipid biosyn-
thesis, is non-essential for both viability and pathogenesis [28,29].
These studies indicate that sphingolipid biosynthesis could be a
viable drug target in the African trypanosomes.
The sphingolipid biosynthetic pathway is largely conserved
across the Eukaryota. However, whilst animal cells synthesize the
phosphosphingolipid SM, yeast and plants, plus at least some proto-
zoa, produce IPC [7]. The IPC synthase of pathogenic fungi has long
been validated and studied as a drug target [11], and the recent iden-
tiﬁcation of a functional orthologue in the protozoan Kinetoplastids,
the causative agents of several so-called neglected diseases, has led
to its consideration as a target for anti-protozoal agents [10]. In this
study we conﬁrm that two of the four closely related T. brucei ortho-
logues (TbSLS4 and 1) of the Leishmania IPC synthase (LmIPCS) are
also functional orthologues of the S. cerevisiae enzyme encoded by
AUR1. However surprisingly, unlike the Leishmania enzyme (and
AUR1) TbSLS4 and 1 are able to catalyze the synthesis of both IPC
and SM, which reﬂects the known sphingolipid content of T. brucei
cells [15]. In an in vitro assay system utilizing TbSLS4 complemented
AUR1 mutant yeast microsomes, it was demonstrated that the T.
brucei enzyme was able to function as an IPC synthase. Although PC
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Fig. 6. TbSLS is an essential enzyme in bloodstream form T. brucei. (A) Inhibition RNA of TbSLS. Cell counts over a 48 h period: () mock transfected cells non-induced; (×)
mock tranfected cells induced by 1g/ml doxycline; () TbSLS RNAi cells non-induced; () TbSLS RNAi cells induced by 1g/ml doxycline. Error bars for standard deviation
over three replicates are shown. (B) RT PCR using total RNA isolated from TbSLS RNAi parasites with or without doxycycline induction (Doxy). RT, reverse transcriptase. TUB,
 tubulin control.
(and PE) was demonstrated to be a competitive binder with respect
to PI, SM synthase activity could not be constituted possibly due
to some level of speciﬁcity with respect to the donor substrate
PC. Clearly, substrate speciﬁcity and the mechanism of action of
TbSLS4 warrant further investigation to disentangle the detected
IPC synthase function from the apparent SM synthase activity.
Determination of the kinetic parameters of TbSLS4 would facilitate
this, for example with respect to determining the binding constants
for the apparent competitive IPC synthase inhibitors—PC and PE. In
this respect it should be noted that the T. brucei enzyme is unlike
its orthologues from the other kinetoplastid parasites where both
the Leishmania (Fig. 5B) and Trypanosoma cruzi enzymes (Casbon
and Denny, unpublished) demonstrate only IPC synthase activity
in the in vitro system employed here. It is also clearly important
to fully analyse the other three TbSLS isoforms to determine their
function.
The known yeast and fungal IPC synthase inhibitor, aureoba-
sidin A, has previously been shown to be active against the related
kinetoplast, Leishmania species, inhibiting growth, but not affecting
viability, in culture [30]. However, it has been demonstrated that the
L. major IPC synthase is refractory to aureobasidin A (Fig. 5B) and
that its affect against this species in culture is non-speciﬁc [28]. A
similar situation has been observed with respect to the causative
agent of Chagas disease, T. cruzi [19]. In contrast, this study showed
that aureobasidin A demonstrated a high level of efﬁcacy against
TbSLS4 turnover in vitro, with an IC50 of 0.42 nM. In light of these
results demonstrating the ability of a known inhibitor to affect
enzyme activity, it was important to validate TbSLS as a potential
target of anti-trypanosome drugs. Simultaneous RNAi of all four
closely related isoforms of TbSLS demonstrated that this enzyme
is essential for growth and so represents a new, much needed
anti-protozoal target. Furthermore, aureobasidin A proved highly
effective and trypanocidal against cultured bloodstream form T.
brucei, with a sub-micromolar EC50.
Together these data raise the possibility of the discovery of a
new generation of lead inhibitors directed against TbSLS, ultimately
leading to novel drugs for the treatment of human African try-
panosomiasis.
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Fig. 7. Aureobasidin A is trypanocidal against bloodstream form T. brucei. Cell counts
over 72 h with (); 1M aureobasidin A (AbA); () 250 nM AbA; () control. Error
bars for standard deviation over three replicates are shown.
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Abstract Sphingolipids are key components of eukaryotic
plasma membranes that are involved in many functions,
including the formation signal transduction complexes. In
addition, these lipid species and their catabolites function as
secondary signalling molecules in, amongst other processes,
apoptosis. The biosynthetic pathway for the formation of
sphingolipid is largely conserved. However, unlike mamma-
lian cells, fungi, protozoa and plants synthesize inositol
phosphorylceramide (IPC) as their primary phosphosphin-
golipid. This key step involves the transfer of the phos-
phorylinositol group from phosphatidylinositol (PI) to
phytoceramide, a process catalysed by IPC synthase in plants
and fungi. This enzyme activity is at least partly encoded by
the AUR1 gene in the fungi, and recently the distantly related
functional orthologue of this gene has been identified in the
model plant Arabidopsis. Here we functionally analysed all
three predicted Arabidopsis IPC synthases, confirming them
as aureobasidin A resistant AUR1p orthologues. Expression
profiling revealed that the genes encoding these orthologues
are differentially expressed in various tissue types isolated
from Arabidopsis.
Keywords Arabidopsis  AUR1  Expression 
Inositol phosphorylceramide  IPC synthase  Sphingolipids
Abbreviations
AbA Aureobasidin A
BSA Bovine serum albumin
Cer Ceramide
IPC Inositol phosphorylceramide
NDB C6-ceramide 6-((N-(7-nitrobenz-2-oxa-1,3-diazol-
4-yl)amino) hexanoyl)sphingosine
PI Phosphatidylinositol
SD Synthetic minimal media with
glucose
SGR Synthetic minimal media with
galactose
SM Sphingomyelin
Introduction
The diverse, amphipathic sphingolipids consist of a long
chain base backbone with long-chain fatty acid and polar
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alcohol attachments. These lipid species are ubiquitous
membrane components of eukaryotic cells, as well as being
found in some prokaryotic organisms and viruses (Smith
and Merrill 2002). Studies in mammals and yeast have
shown that they are important structural components of
membranes and also serve as bioactive molecules involved
in cell signalling and regulation (Dickson et al. 2006;
Fernandis and Wenk 2007; Hanada et al. 1992). The
unmodified sphingolipid, ceramide, is an intermediate in
complex sphingolipid biosynthesis in the Golgi apparatus.
These complex species ultimately concentrate in the outer
leaflet of the plasma membrane where, with sterols, they
form lipid raft microdomains (Futerman and Hannun
2004). Rafts have been proposed to be central to a multi-
tude of cellular processes, from the polarized trafficking of
lipid-modified proteins (Brown and London 1998) to the
formation of signal transduction complexes (Magee et al.
2002; Pierce 2002). Furthermore, sphingolipid metabolites
such as ceramide and phosphorylated sphingosine (sphin-
gosine-1-phosphate), are central to intracellular signal
transduction processes that regulate cell growth, differen-
tiation and apoptosis (programmed cell death—PCD;
Futerman and Hannun 2004).
The biosynthesis of sphingolipids shows commonality
between mammals, fungi and plants up to the formation of
ceramide (phytoceramide in plants and fungi), but the
predominant complex phosphosphingolipid species subse-
quently synthesized differs. Mammals produce sphingo-
myelin (SM; a ceramide unit with a phosphorylcholine
moiety), whereas fungi and plants synthesize inositol
phosphorylceramide (IPC) by the transfer of the phospho-
rylinositol group from phosphatidylinositol (PI) to phyto-
ceramide, a reaction catalysed by IPC synthase. This
enzyme was shown to be at least partly encoded by the
AUR1 gene in yeast and other fungi (Nagiec et al. 1997),
and recently an accessory protein involved in IPC synthase
activity (KEI1p) in these organisms has been identified
(Sato et al. 2009). However, the plant enzyme remained
unidentified although the activity had been measured in
bean microsomes (Bromley et al. 2003). Then, during a
screen for factors involved in PCD defence mechanisms, an
AUR1 functional orthologue was identified in Arabidopsis.
However, the encoded protein demonstrated little homol-
ogy to the yeast AUR1p, having most similarity to the
more recently identified animal sphingomyelin synthases
(Wang et al. 2008). This lack of similarity to the long
known fungal enzyme (Nagiec et al. 1997) lay behind the
previously fruitless search for the plant orthologue (Dunn
et al. 2004).
Here we demonstrate that all three orthologues identi-
fiable in the Arabidopsis genome database represent
aureobasidin A resistant functional orthologues and that,
through phylogenetic analyses, these represent a new group
of sphingolipid synthases within the wider enzyme family.
Furthermore, we show the expression profile of all three
isoforms in the tissues of Arabidopsis. This demonstrated
that there is differential expression of IPC synthase, an
enzyme central to the synthesis of plasma membrane
sphingolipids (Dunn et al. 2004) and a regulator of PCD
(Wang et al. 2008) in this plant species.
Materials and methods
Complementation of auxotrophic AUR1 mutant yeast
with AtIPCS1-3
Arabidopsis IPC synthase 1, 2 and 3 (AtIPCS1–At3g54020.1,
AtIPCS2–At2g37940.1 and AtIPCS3–At2g29525.1)
were amplified from Arabidopsis cDNA using primers 50
AtIPCS1 EcoRI gaattcATGACGCTTTATATTCGCCGCG
and 30 AtIPCS1 SalI gtcgacGAGCAGAGATCTCATGTG
CC; 50 AtIPCS2 EcoRI gaattcATGACACTTTATATTCG
TCGTG and 30 AtIPCS2 SalI gtcgacTCACGCGCCATT
CATTGTG; 50 AtIPCS3 EcoRI gaattcATGCCGGTTTAC
GTTGATCGCG and 30 AtIPCS3 SalI gtcgacTCAATGAT
CATCTGCTACATTG.
The products were subsequently cloned into the yeast
vector pRS426MET25, creating pRS426 AtIPCS1-3. In the
YPH499–HIS–GAL–AUR1 S. cerevisiae strain expression
of the essential AUR1 gene (Nagiec et al. 1997) is under the
control of the GAL1 promoter and is repressed in the
presence of glucose (Denny et al. 2006). YPH499–HIS–
GAL–AUR1 was transformed with pRS426 AtIPCS1-3 and
pRS426 AUR1 and functionally complemented transfor-
mants selected on non-permissive SD medium containing
necessary nutritional supplements (Denny et al. 2006).
Diffusion assay of complemented auxotrophic AUR1
mutant yeast
YPH499–HIS–GAL–AUR1 pRS246 AtIPCS1-3 and
YPH499–HIS–GAL–AUR1 pRS246 AUR1 were assayed
for susceptibility to aureobasidin A (Takara) and myriocin
(Sigma) as previously described (Nagiec et al. 2003). Briefly,
2.4 9 107 logarithmically dividing cells were embedded in
15 ml of YPD-agarose (1% yeast extract, 2% peptone, 2%
dextrose, 0.8% agarose) on 100 cm2 square Petri dishes
(Sarstedt). Inhibitors were applied in Me2SO at the concen-
trations described below and the dishes incubated at 30C.
Microsomal assay of AtIPCS
For in vitro assay microsomal membranes were prepared
from YPH499–HIS–GAL–AUR1 pRS246 AtIPCS1-3 and
YPH499–HIS–GAL–AUR1 pRS246 AUR1 and assayed as
400 Plant Mol Biol (2010) 73:399–407
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described (Mina et al. 2009). In brief, assays were per-
formed in 50 ll of 100 mM Tris HCl pH 7.4, 10 mM
EDTA and 6 mg/ml defatted BSA, with or without 1 mM
PI (soybean, Avanti Polar Lipids; predominant species
C16:0-C18:2) and 5 lM aureobsidin A, and with 2 ll of
microsomes (10 mg/ml protein) and 2 ll of 5 mM NBD
C6-Ceramide (Molecular Probes) in DMSO. After incuba-
tion at 30C for 60 min the reaction was stopped by the
addition of 150 ll of chloroform/methanol/water (10:10:3
v/v/v) and the lipid fraction isolated by phase separation.
This process facilitated reproducible quantitative analyses
of IPC formation. Following equilibriation (Synergy HT,
Bio-tek) samples were analysed by high performance thin-
layer chromatography (Denny et al. 2001; Ralton and
McConville 1998), imaged using a FLA3000 scanner (Fuji)
and quantified using the Aida V3.11 software package.
Plant growth and harvesting of material
Arabidopsis thaliana (Col-0) plants were grown under
long-day conditions (16 h day/8 h night) and the following
tissues were harvested at specific development stages
(Boyes et al. 2001). Rosette leaves were collected at stage
3.90, cauline leaves and stem were collected at stage 5.10,
roots and flowers were collected at stage 6.50, siliques
were collected at stage 8.00.
RNA isolation and RT
Plant tissue was harvested and immediately frozen in liquid
nitrogen. Total RNA was isolated using an RNeasy Plant
Mini Kit (Qiagen), including DNAse I digestion, according
to the manufacturers instructions.
RNA integrity was tested by electrophoresis on 1%
agarose gels and was quantified by measuring the absor-
bance at 260 nm. The A260 nm/A280 nm ratios of purified
RNA samples were in the range of 2.0 to 2.1 and were
determined to be free of genomic DNA by the absence of
larger, intron containing, PCR products.
RT reactions were carried out on 1.0 lg of total plant
RNA using Superscript III reverse transcriptase (Invitro-
gen) and oligo dT primer according to the manufacturers
instructions.
Real-time qRT-PCR conditions and analysis
Steady-state levels of RNA for each AtIPCS gene in plant
material were analysed using SYBR green to monitor DNA
synthesis with a Rotor-Gene RG-3000 (Corbett Research)
instrument. Amplification was achieved with the following
gene-specific primers; AtIPCS1-forward 50-AGCCTCTTG
ATTATTGCGTC-30 and AtIPCS1-reverse 50-AACAACG
GCATTGCTCCCT-30 to give a 145 bp product; AtIPCS2-
forward 50-AGCCTCTTGATCATTGCCTC-30 and AtI-
PCS2-reverse 50-GACTGCTGTGTTGCTCCCA-30 to pro-
duce a 145 bp product; AtIPCS3-forward 50-TGGCTTAT
GGCAGTAATACAG-30 and AtIPCS3-reverse 50-GCCAG
AAATGGCAGAACGTTCT-30 to produce a 141 bp prod-
uct. To determine the highest specificity and sensitivity
qPCR profile for each AtIPCS transcript, titration experi-
ments were performed over a range of MgCl2 concentra-
tions (1.5 to 5 mM) and primer concentrations from (0.1 to
0.5 lM). Concentrations were considered optimal at the
lowest CT value that reproducibly gave an amplicon of the
correct size in the absence of primer dimers. Based on
results of these optimization experiments, qPCR assays for
the AtIPCS1 transcript contained 3 mM MgCl2 and 0.5 lM
of each primer; the AtIPCS2 transcript 3 mM MgCl2 and
0.4 lM of each primer; and the AtIPCS3 transcript 4 mM
MgCl2, 0.4 lM of the forward and 0.5 lM of the reverse
primer. The reactions (total volume 20 ll) also contained
2 ll of 109 PCR buffer, 10 pg of cDNA, 200 lM dNTPs,
SYBR Green I dye and 2 Units of Taq polymerase. Assays
were carried out using the following conditions: 1 cycle of
10 min of 95C, followed by 30 cycles of 10 s of 95C, 15
at 52C and 20 s of 72C. Amplicon dissociation curves
were recorded at the end of the PCR cycles. External
standard curves were constructed using the three AtIPCS
cDNAs and relevant gene-specific primer pairs and used to
determine the number of transcripts for each gene.
Results
AtIPCS1-3 complement an AUR1 auxotrophic mutant
yeast and confer aureobasidin A resistance
Interrogation of the Arabidopsis genome database with the
predicted protein sequence of the protozoan IPC synthase
from Leishmania major (LmIPCS) (Denny et al. 2006)
identified opening reading frames encoding three highly
related sequence orthologues—Arabidopsis IPC synthase 1
(AtIPCS1–At3g54020.1), AtIPCS2 (At2g37940.1) and
AtIPCS3 (At2g29525.1)—demonstrating 26, 29 and 31%
identity to the protozoan protein. Subsequently, AtIPCS2
has been isolated, characterised and designated ERH1
(Wang et al. 2008). The open reading frames of AtIPCS1-
3, when cloned into an URA3 selectable expression vector
to create pRS426 AtIPCS1-3, restored the growth of the
AUR1 auxotrophic mutant YPH499-HIS-GAL-AUR1, as
did the ectopic expression of S. cerevisiae AUR1p (AUR1)
(Fig. 1a). These data indicated that AtIPCS1, 2 and 3 are
functional orthologues of fungal AUR1p, a protein that
forms at least part of an IPC synthase (Nagiec et al. 1997).
By diffusion assay (Nagiec et al. 1997, 2003) the effi-
cacy of two different classes of inhibitor were assayed
Plant Mol Biol (2010) 73:399–407 401
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against YPH499-HIS-GAL-AUR1 pRS426 AtIPCS1, 2 and
3. The transgenic yeast were resistant to aureobasidin
A (AbA, a fungal IPC synthase inhibitor) at 100 lM
(Fig. 1b), a concentration shown to inhibit the growth of
LmIPCS complemented yeast (Denny et al. 2006), but
remained sensitive to myriocin (which inhibits the first step
in sphingolipid biosynthesis—serine palmitoyltransferase,
SPT). Indeed, yeast complemented with the plant enzymes
appeared to be more sensitive to the SPT inhibitor than the
AUR1 control, a similar observation had previously been
made with regard to the LmIPCS complemented yeast
(Denny et al. 2006). The in vitro assay for AtIPCS1-3
described below (Fig. 2a) confirmed that the Arabidopsis
enzymes are AbA insensitive. In contrast, the IPCS activity
from Golden butterwax bean extracts has been shown to be
acutely sensitive to this inhibitor (Bromley et al. 2003).
The reasons for this difference in AbA sensitivity are
unclear and no data are currently available, for the bean
sequence, to help elucidate this discrepancy.
AtIPCS1-3 are functional IPC synthases
In vitro assay of microsomes prepared from YPH499-HIS-
GAL-AUR1 pRS426 AtIPCS1-3 demonstrated that the
three plant enzymes are active IPC synthases (Fig. 2a).
However, their turnover appeared low when compared to
an S. cerevisiae AUR1 control. This was also noted by
Wang et al. (2008) and was unaffected by the use of NBD
C6-phytoceramide rather than C6-ceramide as acceptor
substrate. In support of the data shown above (Fig. 1b),
AtIPCS1-3 activity was insensitive to the addition of AbA
at a concentration (5 lM) that completely inhibited the
Fig. 1 AtIPCS1-3
complements a yeast AUR1
auxotrophic mutant and confers
aureobasidin A resistance.
a YPH499-HIS-GAL-AUR1
auxotropic yeast transformed
with pRS246MET25 either
empty or bearing AUR1 or
AtIPCS1-3 and grown under
permissive (SGR) or non-
permissive conditions (SD).
b 100lM aureobasdin A (AbA)
in DMSO, 1 mM myriocin
(Myr) in DMSO and DMSO
alone spotted in 2 and 3 ll
quantities onto YPH499–HIS–
GAL–AUR1 complemented
with AUR1 or AtIPCS1-3 on
non-permissive SD plates.
pRS426—YPH499–HIS–GAL–
AUR1 pRS426MET25; AUR–
YPH499–HIS–GAL–AUR1
pRS426 ScAUR1; AtIPCS1-3–
YPH499–HIS–GAL–AUR1
pRS426 AtIPCS1-3. Grown on
either permissive (non-glucose
containing) SGR -HIS -URA or
non-permissive (glucose
containing) SD–HIS–URA
402 Plant Mol Biol (2010) 73:399–407
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yeast enzyme (Fig. 2a). Thereafter this inhibitor was
applied to the reaction mix for assay of AtIPCS1-3 at
5 lM.
In the experiment (Fig. 2a) above the plant (and yeast)
enzymes are assayed in the presence of exogenous soybean
PI. To ascertain the effect of adding this exogenous donor
substrate samples were assayed with and without PI in the
reaction mix (Fig. 2b). All samples showed a similar level
of activity in the absence of donor substrate but, surpris-
ingly, only AtIPCS2 demonstrated any significant increase
in turnover on the addition of PI. This indicated that the
AtIPCS1 and 3 are unable to utilize substrate from this
source effectively. Similar results were obtained utilizing
bovine PI which has previously been demonstrated to be
effectively utilized by the protozoan orthologues from both
L. major and Trypanosoma brucei but not by S. cerevisiae
AUR1p (Mina et al. 2009). Despite this, these data confirm
AtIPCS1-3 as functional orthologues of AUR1p, forming at
least part of an IPC synthase.
The plant IPC synthases form a new class
of sphingolipid synthase
The key motifs, D3 and D4, of the sphingolipid synthase
family are conserved in the plant IPC synthases (Wang
et al. 2008). However, unlike their protozoan and mam-
malian counterparts they lack a D1 domain (Huitema et al.
2004). In this they resemble the fungal IPC synthases and it
may be hypothesized that D1 is involved in the binding of
ceramide, a substrate for the protozoan and mammalian
enzymes, whereas another unidentified region is involved
in binding the phytoceramide substrate to the plant and
fungal IPC synthases. Despite the conservation of some of
these motifs the plant sequences are divergent with respect
to primary sequence and so, until recently, remained
cryptic within the genome databases (Wang et al. 2008).
This divergence was illustrated by phylogenetic analysis of
predicted SM and IPC synthase sequences which demon-
strated that the plant enzymes, the three orthologues
identified in the Oryza sativa (rice) database are included,
form a new clade of sphingolipid synthases (Fig. 3).
Expression profiling of AtIPCS1-3
Estimates of the relative abundance of transcripts can be
made from their representation within the EST databases.
For the three AtIPCS genes described a similar number of
AtIPCS1 and AtIPCS3 transcripts are present, whilst the
largest number is for AtIPCS2 (Table 1; data derived from
TAIR BLAST version 2.2.8). However, these data do not
give any information regarding the tissue location of the
transcripts and are therefore of limited use when investi-
gating the expression of gene families. Tissue-specific
transcript abundance data can be obtained from multiple
microarray experiments using Genevestigator (Grennan
2006). Only AtIPCS2 is represented on the Affymetrix
arrays that are used to derive these data and this shows that
the gene is expressed in cauline leaves, roots and rosette
leaves at similar levels and these are approximately twice
the expression levels seen in stems, flowers and siliques
(Table 2).
Given the limitations of these data sets, in order to
establish a complete expression profile for each AtIPCS
isoform, real time quantitative RT-PCR was performed on
RNA isolated from various Arabidopsis tissues (Fig. 4).
AtIPCS2 was the most highly expressed of the three iso-
forms in all tissues. In agreement with the Genevestigator
data, the highest levels of AtIPCS2 transcript were seen in
root, rosette leaves and cauline leaves and these were five
to ten fold greater than the levels of transcripts in siliques,
Fig. 2 AtIPCS1-3 encode functional IPC synthases. In vitro assay of
microsomal extracts from YPH499-HIS-GAL-AUR1 pRS246 AtI-
PCS1-3 and YPH499-HIS-GAL-AUR1 pRS246 AUR1. Assay in
the presence of phosphatidylinositol (PI) with (?) or without (-) the
specific fungal inhibitor aureobasidin A (AbA). In contrast to the
S. cerevisiae IPC synthase (AUR1), the plant activity encoded by
AtIPCS1-3 is insensitive to AbA at 5 lM. Markers of NDB C6-
ceramide and NBD C6-IPC, and the origin (O) indicated. Assay with
(?) or without (-) donor substrate PI in the presence of 5 lM AbA.
Enzyme turnover is only significantly enhanced by the addition PI in
the case of AtIPCS2. Mean of 3 separate experiments, standard error
shown. A.F.U.—Arbitrary Fluorescence Units
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stems and flowers. The patterns of expression determined
by these two methods are in general agreement but the
relative levels differ, this may reflect differences in the
plant material used in the each case. Genevestigator uses a
large number of microarray experiments to generate data
and is therefore robust, however the data represents plant
material grown under different conditions and which may
have been harvested at different times within a develop-
mental stage. The quantitative RT-PCR data presented here
is determined from plants grown and harvested under
identical conditions and therefore represents transcript
levels at defined developmental stages in these tissues.
AtIPCS1 transcripts are expressed at low levels in all
tissues, ranging from 0.05% of AtIPCS2 levels in rosette
leaves to 2.8% of AtIPCS2 levels in stems. While AtIPCS3
transcripts are also present in low levels in cauline leaves,
rosette leaves, roots and stems (ranging from 0.02 to 0.67%
of AtIPCS2 transcripts) they are present at similar levels to
AtIPCS2 transcripts in stem (84% of AtIPCS2 levels) and
flower (74% of AtIPCS2 levels).
The data presented here adds to existing studies by
providing tissue specific expression data for all the
Fig. 3 The plant IPC
synthase defines a new class
of sphingolipid synthases.
Maximum parasimony
analysis of Animalae, Fungi,
Trypanosomatidae and
Plantae sphingolipid synthase
sequences. Bootstrap
scores [60 indicated.
Homo sapiens LPP1 (outgroup)
accession number: O14494;
Arabidopsis thaliana IPCS1-3
accession numbers:
At3g54020.1, At2g37940.1,
At2g29525.1; Oryza sativa
IPCS1-3: NP_001044812,
NP_001055712,
NP_001055096; T. brucei
SLS1-4: Tb09.211.1030,
Tb09.211.1020, Tb09.211.1010,
Tb09.211.1000; T. cruzi
IPCS1&2:
Tc00.1047053506885.124,
Tc00.1047053510729.290;
L. major IPCS: LmjF35.4990;
Aspergillus fumigatus AUR1p:
AAD22750; Candida albicans
AUR1p: AAB67233;
Pneumocystis carinii AUR1p:
CAH17867; Saccharomyces
cerevisiae AUR1p:
NP_012922;
Schizosaccharomyces pombe
AUR1p: Q10142;
Caenorhabditis elegans
SMS1-3: Q9U3D4, AAA82341,
AAK84597; Homo sapiens
SMS1&2: AB154421,
Q8NHU3; Mus musculus
SMS1&2: Q8VCQ6, Q9D4B1
Table 1 EST numbers for AtIPCS genes derived from TAIR BLAST
version 2.2.8
EST
AtIPCS1 32
AtIPCS2 57
AtIPCS3 25
Table 2 Microarray data for AtIPCS2 in the genevestigator database
Root Rosette leaf Cauline leaf Stem Flower Siliques
2383 2135 2509 1167 998 705
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isoforms of AtIPCS which may indicate a specific role for
AtIPCS3 in stems and flowers.
Discussion
The data presented describe the analyses of all three
orthologues of the recently identified Arabidopsis IPC
synthase (Wang et al. 2008). They all represented func-
tional orthologues of S. cerevisiae IPC synthase, AUR1p,
and demonstrated activity in an in vitro assay. However,
unlike the yeast activity the Arabidopsis enzyme is resis-
tant to aureobasidin A, a non-competive inhibitor of the
fungal IPC synthase with an unknown mechanism of action
(Zhong et al. 1999). Conversely, it has previously been
shown that the IPCS activity in Golden butterwax bean
extracts was acutely sensitive to this inhibitor (Bromley
et al. 2003). The reasons for this discrepancy are unclear,
however it is notable that similarly profound differences
in aureobasidin A sensitivity have been observed within
the kinetoplastid parasite IPCS orthologues. Whilst the
L. major enzyme is relatively refractory to the drug, the
T. brucei sphingolipid synthase (TbSLS) is highly sensitive
(Mina et al. 2009). No reason for this can be deduced from
the primary sequence data and it may be envisaged that this
diversity is due to subtle differences in 3-dimensional
enzyme structure.
In the in vitro, microsome-based assay all three Ara-
bidopsis isoforms demonstrated IPC synthase turnover.
However, although the presence of PI (from soybean or
bovine sources) led to a significant increase in turnover
with AtIPCS2, AtIPCS1 and 3 were refractory to the
addition of this donor substrate. This indicated that PI from
these sources was utilized inefficiently by these Arabid-
opsis isoforms. Similarly, it has been noted that mamma-
lian PI is not efficiently utilized by the S. cerevisiae IPC
synthase activity (Mina et al. 2009). Notably, unlike the
yeast phospholipids (Guan and Wenk 2006), plant and
mammalian PIs exhibit varying degrees of polyunsatura-
tion (Thompson and MacDonald 1975, 1976). It may be
hypothesized this polyunstauration may confer structural
constraints and make it less acceptable to the S. cerevisiae
enzyme. However, the lack of reactivity of AtIPCS1 and
with plant derived PI (soybean, C16:0–C18:2) is less easy
to explain. It is possible that the endogenous yeast PI has a
higher affinity for these isoforms and outcompetes the
exogenous substrate. Attempts to minimize the available
quantity of endogenous PI to test this were made by
detergent washing as previously (Mina et al. 2009). How-
ever, this led to apparent inactivation of the enzymes.
Alternatively, significant differences may exist in the
substrate requirements of these Arabidopsis isoforms.
Notably, AtIPCS1 transcript level is low in all plant tissue
and AtIPCS3 in many, including siliques, perhaps reflect-
ing the level of acceptable donor PI in seeds (such as
soybeans, the source of PI in these experiments).
Despite these variances, all the plant IPC synthase
orthologues identified share the motifs predicted to form
the catalytic triad that promotes nucleophilic attack on lipid
phosphate ester bonds which, in the case of IPC synthase,
is thought to lead to the transfer of an inositol phosphate
group from PI to the 1-hydroxyl group of (phyto)ceramide
releasing diacylglycerol as a by-product (Huitema et al.
2004; Neuwald 1997). Therefore it is likely that the
eukaryotic sphingolipid synthases possess a common
mechanism of action, indicating a single evolutionary ori-
gin. In contrast, the prokaryotic SM synthase lacks the
catalytic triad (Luberto et al. 2003) and is likely to have
evolved independently. Phylogenetic analyses show the
plant proteins forming a distinct clade, thereby defining a
new class of eukaryotic sphingolipid synthases.
It has been demonstrated, by RNAi of the first enzyme
in the biosynthetic pathway—serine palmitoyltransferase,
that sphingolipid biosynthesis per se is essential for the
viability of Arabidopsis (Chen et al. 2006). Furthermore,
Fig. 4 Steady-state levels of AtIPCS isoform mRNAs in plant
tissues. The numbers of AtIPCS1-3 transcripts were determined in
total RNA from various tissues, by quantitative RT-PCR using a
standard curve for each transcript. AtIPCS2 (At2g37940.1) is the
most abundant form in roots, leaves and siliques, whereas stems and
flowers have similar numbers of AtIPCS2 and AtIPCS3
(At2g29525.1) transcripts. AtIPCS1 (At3g54020.1) transcript is
uniformly low in all tissues
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recent work has suggested that the plant IPC synthase is
pivotal in pathogen-resistance associated PCD. By analyses
of leaf tissue from an ERH1 (AtIPCS2) insertion mutant
Wang et al. (2008) detected a significant increase in cera-
mide levels, an observation consistent with the fact that
ceramide is a substrate for IPCS. Importantly, ceramide is a
key regulator of PCD (Futerman and Hannun 2004) and the
accumulation of this factor was co-incident with PCD at
the site of powdery mildew infection in Arabidopsis (Wang
et al. 2008). This work is further supported by similar
observations in accelerated-cell-death (acd11 and acd5)
mutants of Arabidopsis in which a sphingosine transfer
protein (ACD11) or a ceramide kinase (ACD5) are affected
(Brodersen et al. 2002; Liang et al. 2003). Given the
prominence of AtIPCS2 as a putative regular of PCD the
differential expression levels of each of the three functional
Arabidopsis orthologues may shed light on this key process
in the whole plant.
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